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The MYC onocogene is frequently overexpressed in human cancer due to its capacity 
to promote cell growth and cell proliferation. MYC overexpression activates the p53 
tumour suppressor pathway, which resists the pro-tumourigeneic program elicited by 
MYC. How MYC overexpression engages p53 is yet to be elucidated, and in this 
study I carried out a large metabolic siRNA screen to determine whether p53 
responds to a specific MYC-driven metabolic pathway. Two clear lipid metabolic 
pathways emerged from the siRNA screen: PPARγ/arachidonate metabolism and de 
novo sphingolipid synthesis. Knockdown or inhibition of PPARγ increased p53 
levels, and PPARγ ligands decreased following MYC overexpression. Knockdown of 
ceramide synthesis depleted p53 levels, and MYC overexpression increased de novo 
ceramide synthesis. This demonstrated that MYC-driven ceramide synthesis 
positively regulates p53, and highlights the role of cell metabolism in the tumour 


































Cell metabolism describes how a cell uses nutrients and energy. Understanding cell 
metabolism is an important area of cancer research because cancer cells change cell 
metabolism to favour their expansion and survival. The MYC gene is often mutated 
in cancer and is described as an oncogene because it promotes tumour formation. 
Genes that protect against tumour formation are also frequently mutated in cancer, 
and these genes are called tumour suppressor genes. The TP53 tumour suppressor 
gene responds to cell stress and is commonly mutated in cells that have deregulated 
MYC. It is known the p53 is activated by MYC, and this study investigated whether 
p53 responds to an unidentified MYC-driven stress. From studying cell metabolism 
we revealed that synthesis of a set of lipids driven by MYC was required for p53 
activation. Several metabolic pathways were also identified that when blocked 
strongly increased cell stress, specifically in cells with increased MYC. These results 
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1 Chapter 1- Introduction 
1.1 The Oncogene MYC 
 
The identification of the MYC gene (named for ‘myelocytomatosis’) in the early 
1960s paved the way for the discovery of retroviruses, viral oncogenes, and the 
exploitation of these tools to study the basis of cancer (Tansey, 2014). Among these 
pioneering experiments was the isolation of V-MYC, the viral homolog of C-MYC, as 
the transforming gene of MC29 avian leukemia virus (Sheiness et al. 1978; 
Vennstrom et al. 1982). Infection of fowl with MC29 caused hematopoietic 
neoplasia, specifically transforming myeloid cells into diffuse growths 
(myelocytomatosis) or solid tumours (myelocytomas) (Ivanov et al. 1964; Mladenov, 
1967). The effort to characterise and understand the biology of MYC is ongoing, and 
its relevance today is highlighted by MYC appearing at an average rate of almost 
three publications per day in recent years (Tansey, 2014).  
 
MYC is frequently deregulated in a wide variety of human cancers (figure 1.1), 
implicating MYC as an important gene to study in cancer research. MYC 
deregulation is predominantly driven by its constitutive overexpression; however 
changes in MYC mRNA and protein stability have also been described (reviewed in 
Kalkat et al. 2017). Constitutive overexpression of MYC is most commonly caused 
by gene amplification (figure 1.1), which arises through genome doubling or tandem 
duplications (Burrell et al. 2013). Overexpression of MYC also occurs through 
chromosomal translocation or increased enhancer activity. Burkitt’s lymphoma is 
driven by chromosomal translocation of C-MYC from chromosome 8 to 
chromosome 14, where C-MYC is under the control of the immunoglobulin 
promoter (a lineage-specific enhancer) (Dalla-Favera et al. 1982). Acquisition of 
increased enhancer activity at the endogenous locus, through single nucleotide 
polymorphisms (Wright et al. 2010) or histone acetylation (Shi et al. 2013), 
upregulates MYC expression.  
 
In the absence of MYC amplification or translocation, abberant signal transduction 
causes MYC deregulation. First, mutations that alter RAS/ phosphatidylinositol-4,5-
bisphosphate 3-kinase (RAS/PI3K) signalling pathways increase MYC protein 
stability (Sears et al. 2000). The phosphatase and tensin homolog (PTEN) tumour 
suppressor gene, which negatively regulates PI3K, is lost in multiple tumours types 
(Li et al. 1997). Loss of PTEN increases serine/threonine kinase 1 (AKT)-dependent 
phosphorylation of glycogen synthase kinase (GSK3), which inactivates GSK3 and 
inhibits its ability to negatively regulate MYC protein stability. Second, mutations 
that cause abberant β-catenin signalling are estimated to occur in over 90% of 
colorectal cancers (Shi et al. 2017), and increase the expression of MYC (He et al. 
1998). Loss of adenomatosis polyposis coli (APC) upstream of β-catenin is the 
predominant mutation in the β-catenin pathway, occurring in 85% of cases (Shi et al. 





























































































































































































































































downstream of MYC, were present in over 65% of T-cell acute lymphoblastic 
leukeamias (Weng et al. 2004). These studies highlight the frequency, and the 
variety of ways in which, MYC is deregulated in human cancer.  
 
The human MYC family comprises three members, C-MYC, N-MYC, and L-MYC, 
which all have described roles in human cancer (Nau et al. 1985, 1986, Little et al. 
1983). All family members are basic-helix-loop-helix leucine zipper proteins 
(bHLH-ZIP) that regulate gene transcription (reviewed in Adhikary and Eilers, 
2005). MYC proteins function only as heterodimers in vivo, and formation of a 
MYC-MAX complex is required for binding of MYC to the DNA sequence 
CAGGTG (E-box) (Amati et al. 1993). MYC-MAX hetermodimers bind E-box 
sequences, and recruit co-regulatory factors including TRRAP, TIP60, and GCN5 to 
activate transcription (Bouchard et al. 2001; Frank et al. 2003; McMahon et al. 
2000). In the absence of MYC, heterodimerisation of MAD-MAX or MNT-MAX at 
E-box sequences represses gene transcription through recruitment of histone 
deacetylase complexes (Ayer et al. 1993). MYC-MAX complexes also have 
transrepression capacity when tethered to a core promoter element, the initiator (Inr), 
by the transcription factor MIZ1. When unbound, MIZ1 transcriptionally activates its 
target genes, however MYC-MAX binding forms a transrepressor complex that 
recruits DNA (cytosine-5)-methyltransferase 3α (Seone et al. 2001; Staller et al. 
2001; Brenner et al. 2005). MAD-MAX or MNT-MAX heterodimers are 
predominant in resting or differentiated cells, whereas MYC-MAX complexes are 
often predominant in proliferating cells (Ayer and Eisenman, 1993). Independently 
of MAX, MYC can activate transcription of its target genes by binding to other 
transcription factors such as YY1 or transcription factor IIIB (TFIIIB) (Vernon and 
Gaston, 2000; Gomez-Roman et al. 2003).  
 
1.2 MYC target genes 
 
Mammalian MYC binds to thousands of promoters, indicating that MYC target 
genes cover a significant proportion of the human genome (Lin et al. 2012; Nie et al. 
2012). Two recent papers have put forward an ‘amplifier model’ to describe the 
transcriptional program driven by MYC. The amplifier model suggests MYC binds 
and amplifies most genes that are ‘on’ in a given cell type (Lin et al. 2012; Nie et al. 
2012). Others argue that this model is oversimplified, and fails to recognise 
important genes that are transrepressed or differentially regulated by MYC (Tansey, 
2014; Stine et al. 2015). Indeed, two comprehensive studies on specific 
transcriptional targets of MYC have recently been published (Sabo et al. 2014; Walz 
et al. 2014). The current literature on how MYC alters the transcriptional program in 
favour of cellular expansion, through regulation of genes involved in cell 
proliferation, cell growth, cell metabolism, and cell differentiation, will be discussed 
in the subsequent sections.  
 




The role of MYC in regulating cell proliferation, and how this becomes deregulated 
when MYC is overexpressed, has been extensively studied. Early studies of MYC 
documented that its mRNA and protein levels increased in response to mitogenic 
stimuli, and this correlated with increased cell proliferation (Kelly et al. 1983; Dean 
et al. 1986; Reed et al. 1986). The ability of MYC to respond to mitogenic stimuli 
was shown to be dependent on the RAS/RAF/MEK/ERK cascade; however exactly 
how this cascade results in MYC activation is yet to be elucidated (Kerkhoff et al. 
1998). MYC overexpression alone was sufficient to induce cell cycle progression in 
quiescent cells using a conditional MYC (MYCER) model (Eilers et al. 1991). 
Concomitantly, MYC downregulation with antisense oligonucleotides prevented S-
phase entry in human lymphoid and myeloid cells (Heikkila et al. 1987; Wickstrom 
et al. 1988). These studies emphasise the importance of MYC in driving cell 
proliferation. 
 
In line with the capacity of MYC to drive cell proliferation, cell cycle related genes 
were some of the first-discovered MYC target genes, including cyclins, CDKs 
(cyclin-dependent kinases), and CKI (cyclin-dependent kinase inhibitor) proteins 
(reviewed in Meyer and Penn, 2008). MYC overexpression was shown to regulate 37 
out of 87 genes classified as belonging to the ‘cell cycle pathway’ in the KEGG 
(Kyoto Encyclopedia of Genes and Genomes) (Yap et al. 2011). The need for MYC 
to regulate multiple cell cycle genes at multiple stages may be due in part to 
redundancy between most cyclins and CDKs. Only cyclins A2 and B1, and CDK1 
carry no redundancy, and these are therefore considered the ‘basic core elements’ of 
the cell cycle machinery (Murphy et al. 1997; reviewed in Bretones et al. 2015). An 
overview of MYC stimulation of cell cycle progression is depicted in figure 1.2.  
 
Of the ‘basic core elements’, MYC regulation of cyclin A (mRNA and protein) was 
documented in Rat1 fibroblasts with conditional or constitutive MYC expression 
(Jansen-Durr et al. 1993; Barret et al. 1995; Hoang et al. 1994) and MYC binding to 
the cyclin B1 promoter was documented in lung cancer cells and Hela cells (Seo et 
al. 2008; Menssen et al. 2002). Furthermore, enforced expression of MYC and loss of 
p53 were shown to be synergistic lesions that enhanced induction of cyclin B1 
(mRNA and protein) in Rat1 cells and 32D myeloid cells (Yin et al. 2001). MYC 
binding to the CDK1 promoter has been described; however MYC alone was not 
sufficient to induce gene expression. Instead, MYC-driven cell proliferation was 
associated with increased CDK2, CDK4, and CDK6 activities that regulate S-phase 
entry (Mateyak et al. 1999; Hermeking et al. 2000).  
 
In addition to transactivation of cell cycle genes, MYC also represses CKIs 
p21CIP1/WAF1 (p21) and p27. MYC repression of p21 was shown to be via MIZ-1, 
which normally transcriptionally activates p21 to inhibit cell cycle progression 
(Staller et al. 2001). MYC-MIZ1 interaction has been studied by introducing a single 
point mutation in MYC that prevents its interaction with MIZ1. The importance of 
MYC-MIZ1 interaction is highlighted by loss of this interaction attenuating MYC-
driven tumourigenesis in vivo (Van Riggelen et al. 2010b). MYC repression of p27 
requires multiple parallel mechanisms, including transcriptional repression (Yang et 






Figure 1.2. MYC regulation of the cell cycle (adapted from Bretones et al. 
2015) 
The figure shows MYC regulation of cyclins, CDKs (cyclin-dependent kinases) 
and CKIs (cyclin-dependent kinase inhibitors) at multiple stages of the cell cycle. 
To progress through G1, MYC activates cyclin D, CDK4, and CDK6 that complex 
to phosphorylate RB (Retinoblastoma). Release of RB frees E2F to activate 
transcription of its target genes required for S-phase. MYC also negatively 
regulates CKIs p21 and p27 to facilitate progression into S-phase. At S-phase, 
MYC activates cyclin A, which complexes with CDK1 and CDK2 to promote 
DNA replication. Cyclin A is continously expressed throughout G2. In the final 
phase, MYC activates cyclin B to complex with CDK1 and drive the cell through 
mitosis. CKIs from the INK4 family (inhibitors of CDK4) restrict reentry into G1, 
and these proteins (p16 and p15) are repressed by MYC.   
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and CDKs that outcompete p27 levels (Pérez-Roger et al. 1997; Bouchard et al. 
1999) and induction of SCFSKP2 ubiquitin ligase components that ubiquitinate p27 
(Bretones et al. 2011; Montagnoli et al. 1999). Protein levels of p27 are frequently 
downregulated in human cancer, and low p27 levels correlate with poor prognosis 
(Chu et al. 2008).  These studies implicate MYC as a key transrepressor of tumour 
suppressor proteins.  
 
After successful S-phase entry, MYC transcriptionally regulates the ORC (Origin 
recognition complex) genes ORC1, ORC2, ORC4, and ORC5, and the MCM 
(minichromosome maintenance) genes MCM3, MCM4, MCM5 and MCM6, which 
are required for DNA replication, initiation, and elongation (Zeller et al. 2006). 
MYC also regulates a plethora of metabolic pathways (discussed in detail below) 
required for the biosynthesis of nucleotides (that are needed for DNA replication) 
(Liu et al. 2008). MYC regulation of the cell cycle at multiple stages implicates 
MYC as a ‘master regulator’ of cell proliferation. MYC regulation of other cell 
processes, such as activation of human telomerase (Wang et al. 1998), is likely to 
contribute to the ability of deregulated MYC to sustain proliferation and drive 
tumourigenesis.   
 
1.2.2 The role of MYC in cell growth 
 
Prior to S phase entry, normal cells first accumulate a critical biomass through 
macromolecular synthesis, which involves an accompanying increase in cell size 
(cell growth) (Pardee, 1974). This idea was pioneered in yeast where the ‘start point’ 
was described as a cell growth-regulated checkpoint for S-phase entry (Hartwell et 
al. 1970). Ribosome biogenesis and mitochondrial biogenesis are two processes that 
are essential to cell growth, and both of these processes are regulated by MYC (see 
subsections below).  
 
The development of models with inducible MYC deletion was an essential 
breakthrough for in vivo studies because germline deletion of MYC was found to be 
embryonic lethal (Charron et al. 1992). Deletion of MYC in T lymphocytes prevented 
cell growth and proliferation in response to T cell receptor (TCR) stimulation by 
staphylococcal enterotoxin B (Wang et al. 2011). Analysis of general signaling 
pathways mediated by TCR and cytokines showed them to be largely intact, 
indicating the deletion of MYC specifically impairs activation-induced T cell growth 
and proliferation. Similar results to the T lymphocyte study were also documented in 
a model of intestinal cancer. Deletion of MYC in APC-deficient adult murine 
intestines inhibited colonic crypt cell growth and proliferation (Sansom et al. 2007), 
indicating MYC mediates much of the pathology associated with APC deletion. 
Importantly, these models of MYC deletion impacted on cell growth and cell 
proliferation; however models that uncouple these two processes have been 
documented. 
 
A conditional MYC overexpression allele in B-lymphocytes demonstrated that cell 
proliferation was dependent on both MYC and foetal calf serum (FCS), while cell 
growth was regulated by MYC without FCS (Schuhmacher et al. 2001). This 
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demonstrated for the first time that MYC-driven cell growth was separable from cell 
proliferation, which required additional FCS-derived cellular cues. A distinct role for 
MYC regulation of cell growth has also been described in vivo using adenoviral gene 
transfer into liver cells (Kim et al. 2000).  
 
1.2.2.1 The role of MYC in ribosome biogenesis  
 
MYC was first hypothetically linked to ribosome biogenesis during MYC 
overexpression experiments, as increased protein synthesis would be required to 
support observed increases in cell proliferation and cell growth (Schuhmacher et al. 
1999; Iritani and Eisenman, 1999). Second, overexpression experiments in 
Drosophila Melenogaster with the MYC homolog Dm resulted in increased nuclear, 
nucleolar, and overall cell size (Pierce et al. 2004). Third, expression of MYC in B-
lymphocytes of transgenic mice increased overall cell size and protein synthesis 
(Schuhmacher et al. 2001).  
 
Ribosome biogenesis is a highly coordinated process involving the transcription of 
ribosomal RNA (rRNA), processing of rRNA, incorporation of rRNA into pre-40S 
and pre-60S subunits, then maturation and assembly of ribosomal subunits into 
mature ribosomes in the cytoplasm (figure 1.3; reviewed in Van Riggelen et al. 
2010a). MYC directly activates all three nuclear RNA polymerases I, II, and III 
(RNA pol I, II and III) (Gomez-Roman et al. 2003; Grandori et al. 2005; Arabi et al. 
2005). Activation of RNA pol I and RNA pol II is required for rRNA transcription 
and processing, and activation of RNA pol III is required for transcription of 5S 
rRNA and transfer RNAs (tRNAs). Boon et al. (2001) documented that expression of 
MYC enhanced approximately 80% of ribosomal protein genes, as well as key genes 
involved in rRNA processing and assembly, nucleolin (NCL) and nucleophosmin 
(NPM1). MYC also directly activated six ribosomal protein genes in vivo (Kim et al. 
2000), and transcriptionally activated eukaryotic initiation factors (eIFs) eIF4E, and 
eIF2α, which are required for translation initiation (Rosenwald et al. 1993).  
 
The requirement for MYC regulation of ribosomal genes to initiate tumourigenesis 
has been explored in vivo (Barna et al. 2008). Ribosomal hemizygote mice were used 
as a genetic tool to reverse increased protein synthesis in Eµ-Myc (Myc driven by the 
immunoglobulin heavy chain enhancer) transgenic mice to normal levels (Adams et 
al. 1985). Loss of one allele of Rpl24 or Rpl38 decreased incidence of lymphoma by 
20% and delayed tumour onset by over 100 days. In this context the oncogenic 
potential of MYC was suppressed by loss of translational control. Haploinsufficiency 
of MYC was found to prolong mouse lifespan and was associated with decreased 
ribosome biogenesis (Hofmann et al. 2015).  
 
In humans, increased levels of individual ribosomal proteins have been found in 
breast (Henry et al. 1993), prostate (Vaarala et al. 1998), uterine cervix (Cheng et al. 
2002), oesophagus (Wang et al. 2001), and liver carcinomas (Kim et al. 2004). 
Combined activation of all three RNA polymerases and specific activation of many 
ribosomal protein genes indicates that this is a major MYC-driven program 
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Figure 1.3. MYC regulation of ribosome biogenesis (adapted from Van 
Riggelen et al. 2010) 
MYC activates all three RNA polymerases I, II, and III, which allows regulation 
of the four stages of ribosome biogenesis: transcription, rRNA processing, 
assembly, and translation initiation. Activation of RNA pol I and RNA pol II is 
required for rRNA processing to form the small ribosomal subunit (RPS) and large 
ribosomal subunit (RPL). RNA pol II synthesises nucleolin (NCL) and 
nucleophosmin (NPM1) that are involved in rRNA processing and export. 
Activation of RNA pol III is required for assembly of small and large ribosomal 
subunits into pre-40S and pre-60S subunits respectively. RNA pol III also encodes 





1.2.2.2 The role of MYC in mitochondrial biogenesis  
 
Early studies on MYC identified several mitochondrial MYC target genes, including 
SURF-1, a serum-regulated complex IV assembly factor. SURF-1 lacks an E-box 
site, and MYC binding at the SURF-1 promoter is dependent on the transcription 
factor YY1 and its cognate binding site (Vernon and Gaston, 2000). Global analysis 
of the MYC transcriptome by chromatin immunoprecipitation (ChIP) analysis has 
highlighted MYC as a master regulator of mitochondrial biogenesis (Kim et al. 2008; 
Seitz et al. 2011). The genes identified as MYC targets can be broadly categorised 
into those involved in mitochondrial transcription, mitochondrial translation, protein 
import, and complex assembly (reviewed in Morrish and Hockenbury, 2014).  
Knockdown of several mitochondrial MYC target genes was synthetically lethal in 
MYC overexpressing cells, indicating that pharmacological inhibition of these genes 
may selectively kill MYC-driven tumour cells in human cancer (Sheth et al. 2014; 
Carroll et al. 2015). 
 
Mitochondria are considered the ‘powerhouses’ of the cell, since they produce ATP 
by highly efficient oxidative phosphorylation and serve as a hub for multiple 
metabolic pathways. Mitochondrial mass also directly influences overall 
transcription rate in the cell (Wonsey et al. 2002; O'Donnell et al. 2006; Li et al. 
2005). Despite clear evidence that MYC transcriptionally regulates mitochondrial 
biogenesis, understanding of the biological significance of this is far from 
understood. Studies of mitochondrial fusion and fission have implicated a role for 
MYC in controlling mitochondrial dynamics, in addition to structure and function 
(Graves et al. 2012). Deficiency in mitochondrial mass and morphology with loss of 
MYC function has been described in T cells and fibroblasts (Li et al. 2005). 
 
1.2.3 The role of MYC in cell metabolism 
 
To maintain cellular homeostasis and produce all of the precursors required for 
macromolecular synthesis and cell expansion, metabolic pathways must balance 
anabolism, ATP generation, and redox stability. This balance is sensed and 
maintained on two levels, transcriptionally and homeostatically. In recent years, 
metabolic reprogramming has been recognised as a cancer hallmark, with oncogene-
driven metabolic adaptation being clonally selected for during tumourigenesis 
(reviewed in Ward and Thompson, 2012). MYC affects and regulates multiple 
metabolic pathways, including glycolysis, glutaminolysis, nucleotide biosynthesis, 
and lipid biosynthesis (reviewed in Stine et al. 2015; see subsections below).  
 
1.2.3.1 The role of MYC in glycolysis 
 
Increased aerobic glycolysis (increased conversion of glucose to lactate in the 
presence of oxygen) was one of the first described metabolic phenotypes associated 
with cancer (Warburg, 1956). MYC-transformed cells exhibit increased glucose 
uptake and increased expression of almost all glycolytic enzymes, including the 
glucose transporter GLUT1 (Osthus et al. 2000). MYC activates lactate 
dehydrogenase-A (LDHA), which converts pyruvate to lactate, and LDHA 
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knockdown reduces MYC-driven cell growth (Shim et al. 1997). Furthermore, 
abrogation of lactate export, by inhibiting the activity of the MYC target MCT1 (a 
monocarboxylate transporter), was shown to reduce cell growth and tumourigenesis 
in vivo (Doherty et al. 2014; Brahimi-Horn et al. 2011).  
 
Aside from lactate generation, glucose supplies carbon to key anabolic pathways, 
including phospholipid synthesis, the pentose phosphate pathway (PPP), amino-acid 
synthesis, and one-carbon metabolism (folate and methionine cycles). Following the 
conversion of glucose into glucose-6-phosphate (G6P) by hexokinase, G6P can be 
used to synthesise phosphatidic acid, from which other phospholipid species and 
triacylglycerol are built upon (reviewed in Vance, 2002). Alternatively, G6P can 
enter the PPP to generate ribose-5-phosphate for nucleotide biosynthesis, and the 
reducing cofactor NADPH from NADP+. Finally, G6P can continue down the 
glycolytic pathway (see below). MYC deregulation in lymphocytes increased flux 
through glycolysis and the pentose phosphate pathway, and this was abrogated in 
MYC deficient cells (Wang et al. 2011). Expression of MYC increased 13C labeling 
of ribose and purine nucleotides (Morrish et al. 2009).  
 
Further down the glycolytic pathway, fructose 1,6-bisphosphate may be used to 
synthesise dihydroxyacetone-phosphate (DHAP) or glyceraldehyde 3-phosphate. 
DHAP is used to generate the glycerol head group of phospholipids (Eljamil, 2015). 
Glyceraldehyde 3-phosphate can be used to synthesise 3-phosphogylcerate in the 
glycolytic pathway. 3-phosphoglycerate can enter the serine synthesis pathway (SSP) 
which supports multiple pathways, including folate and methionine metabolism, 
nucleotide synthesis, and glutathione synthesis. These pathways have been described 
as essential for cancer cell proliferation (reviewed in Locasale, 2013). Serine 
conversion to glycine by serine hydroxymethyl transferase (SHMT) donates one-
carbon to tetrahydrofolate (THF) to yield 5,10-methylene-tetrahydrofolate (me-
THF). MYC induction increased the expression of approximately half of the genes 
involved in folate metabolism (Morrish et al. 2008), and SHMT2 was one of few 
genes shown to partially rescue the slow growth phenotype of MYC null fibroblasts 
(Nikiforov et al. 2002). Lewis et al. demonstrated that SHMT2 contributed to 
mitochondrial NADPH and glycine pools, and that this was the predominant method 
of NADPH regeneration in the cells studied (Lewis et al. 2014).  
 
In addition to the SSP, cells can take in exogenous serine and glycine, and Eµ-Myc 
mice showed significantly extended survival with dietary serine and glycine 
restriction (Maddocks et al. 2017).  Activation of Myc was shown to increase SSP 
enzyme expression; however the reduced survival of Eµ-Myc mice indicates 
exogenous serine uptake is essential in Myc-driven tumours. Eµ-Myc tumours 
showed depleted GSH/GSSG ratios, and genetic modification that reduced reactive 
oxygen species (ROS) increased survival time. Another study in colorectal cancer 
cells showed that serine was utilised for de novo synthesis of ATP, which was 
required to convert methionine to S-Adenosyl methionine (SAM) for methylation 
reactions (Maddocks et al. 2016). These studies highlight the relevance of one-
carbon metabolism to cancer and MYC biology, and indicate that dietary restriction 




1.2.3.2 The role of MYC in glutaminolysis 
 
Glutaminolysis is the direction of glutamine into the TCA cycle. Glutaminolysis is a 
key support mechanism in cells that divert most of their glycolytic intermediates into 
anabolic pathways and lactate, instead of diverting pyruvate into the TCA cycle (Jin 
et al. 2016). MYC activates the glutamine transporter SLC1A5, and enhance 
mitochondrial glutaminase expression through the suppression of miR23a/b (Wise et 
al. 2008; Gao et al. 2009). Metabolic stable heavy-isotope tracer studies confirmed 
that glutaminolysis is increased by MYC (Murphy et al. 2013). Glutamine is also an 
essential amine donor for purine and pyrimidine nucleotide biosynthesis, and the 
dependency of MYC overexpressing cells on glutamine is highlighted by these cells 
becoming dependent upon glutamine (Yuneva et al. 2007).  
 
1.2.3.3 The role of MYC in nucleotide biosynthesis 
 
Genes involved in nucleotide biosynthesis were among the first discovered MYC-
target genes, and ChIP experiments in multiple systems showed that MYC binds and 
activates eleven nucleotide biosynthesis enzymes. Nucleotides are required for RNA 
synthesis and DNA synthesis, and knockdown of IMPDH2 (inosine-5'-
monophosphate dehydrogenase 2) triggered S-phase arrest (Liu et al. 2008). 
Concomitantly, knockdown of MYC in several cell lines decreased expression of 
genes involved in nucleotide biosynthesis and triggered proliferative arrest. Ectopic 
expression of MYC target genes TS (thymidylate synthase), IMPDH2, or PRPS2 
(phosphoribosyl pyrophosphate synthetase 2) relieved the proliferative arrest cause 
by MYC knockdown (Mannava et al. 2008). PRPS2 is the rate-limiting step in purine 
nucleotide synthesis, and its knockdown was synthetically lethal in MYC 
overexpressing cells. Further, PRPS2 loss prolonged the survival of transgenic mice 
with MYC-driven lymphoma, and induced complete tumour remission in 30% of 
mice (Cunningham et al. 2014). These studies highlight the key role of MYC in 
regulating nucleotide biosynthesis, and the relevance of nucleotide metabolism to 
MYC-driven cancer.  
 
1.2.3.4 The role of MYC in lipid synthesis 
 
The importance of lipid metabolism in dividing cells is a rapidly emerging area of 
cell metabolism. Lipids have numerous biological functions as both signalling 
molecules and as membrane structural components that alter membrane permeability 
and curvature (reviewed in Eljamil, 2015). The relevance of lipid composition to cell 
division was recently revealed in a study that compared synchronised Hela cells at 
cytokinesis to cells at S-phase (Atilla-Gokcumen et al. 2014). From the numerous 
lipid species analysed, 11 species increased at least 4-fold during S-phase, of which 8 
belonged to the sphingolipid subclass. The study went on to screen a custom RNAi 
library targeting 244 lipid biosynthetic enzymes and individual knockdown of 23 
genes (involved in sphingolipid, sterol, glycerolipid, and fatty acid metabolism) 
caused cytokinesis failure. Knockdown of the top 3 screen hits caused delayed 
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metaphase and showed unusual membrane blebbing, highlighting that lipid 
composition is crucial for normal cell division.  
 
Fatty acids (FAs) are the precursors to lipids, and MYC targets include ATP citrate 
lyase (ACLY), acetyl CoA carboxylase alpha (ACACA), and fatty acid synthase 
(FAS). These genes are all involved in the de novo synthesis of saturated FAs (SFAs) 
up to the length of palmitate (16 carbons) in the cytosol. MYC also activates 
stearoyl-CoA desaturase (SCD), which is the rate-limiting step of monounsaturated 
FA (MUFA) synthesis (Zeller et al. 2003; Loven et al. 2012). Elongation and 
desaturation of FAs ≥16 carbons in length predominantly occurs in the endoplasmic 
reticulum (ER). Elongation is catalysed in a series of four enzymatic reactions: 
condensation, reduction, dehydration, and reduction (reviewed in Sassa and Kihara, 
2014). Malonyl-CoA donates 2 carbon units with each turn of the cycle (figure 1.4). 
FAs from cytosolic or microsomal synthesis may be stored as neutral lipids, 
metabolised into sphingolipids or phospholipids, or catabolised by fatty acid 
oxidation (FAO, otherwise known as β-oxidation) to generate ATP. Peroxisome 
proliferator-activated receptors (PPARs) are a unique family of transcription factors 
that sense and interpret changes in FAs to modulate lipid homeostasis (reviewed in 
Varga et al. 2011).  
 
MYC overexpression was recently shown to remodel the lipidome. Eberlin et al. 
(2014) documented distinct lipid signatures in MYC- or RAS-induced lymphoma, 
and predicted that this was dominated by MYC-driven lipid changes. Hall et al. 
(2016) also documented a distinct lipid shift in KRAS-driven lung adenocarcinoma 
with reversible activation of Myc. Myc activation increased relative levels of 
phosphatidylinositols and arachidonate-containing phospholipids that can serve as 
signalling precursors; and these changes were reversed by Myc inactivation. Hall et 
al. went on to show that inhibition of COX/5-LOX pathways (eicosanoid pathways 
downstream of arachidonic acid) reduced tumour burden in vivo due to reduced cell 
proliferation.   
 
Several studies have also linked MYC-driven tumours to increased fatty acid 
oxidation (FAO). FAO intermediates were markedly increased in a MYC-driven 
model of triple negative breast cancer (TNBC). Pharmacologic inhibition of FAO in 
vivo and in a TNBC patient-derived xenograft reduced tumour size (Camarda et al. 
2016). Similar results were seen with a MYC-driven Burkitt’s lymphoma model by 
inhibiting FA import into mitochondria (Pacilli et al. 2013). Conversely, while 
MYC-driven tumours increase FAO, knockout of Myc in rat fibroblasts was also 
shown to increase FAO (Edmunds et al. 2014). Further studies to understand the 
effects of MYC on lipid metabolism in different contexts are needed.  
 
1.2.4 The role of MYC in cell differentiation 
 
MYC is a key regulator of cell differentiation, and its ability to induce 
dedifferentiation and maintain this stem-like state has been described in multiple 
(although not all) systems (reviewed in Soucek and Evan, 2010). In vivo, Myc 




Figure 1.4. Microsomal fatty acid elongation cycle (adapted from Sassa 
and Kihara, 2014) 
The microsomal fatty elongation cycle involves 4 enzymatic steps. The first step 
involves condensation of a fatty acyl CoA (≥16 carbons in length) with malonyl-
CoA, which is the 2 carbon donor for the elongation reaction. ELOVL enzymes 
1-7 catalyse this step with differing specificities for chain length and desaturation. 
The 3-ketoacyl-CoA is reduced to form a 3-hydroacyl-CoA, dehydrated to trans-2-
enoyl-CoA, and reduced again to an acyl-CoA with 2 additional carbon units. The 
fatty acyl-CoA may be further elongated, or directed for sphingolipid or 
glycerolipid synthesis if it is to be used for anabolic pathways. ELOVL=fatty acid elongase, 















































































(Finch et al. 2009). Myc activation and co-expression of Bcl-xl in pancreatic islet β 
cells induced dedifferentiation in two independent studies (Pelengaris et al. 2002; 
Finch et al. 2006). A recent study of regeneration in adult echinoderms found Myc 
overexpression was required for proper dedifferentiation of radial glial cells at the 
site of injury (Mashanov et al. 2015). These studies indicate the relevance of MYC 
induced dedifferentiation in multiple biological contexts.  
 
MYC maintains self-renewal properties and represses differentiation by regulating 
miRNAs (Lin et al. 2009). Myc activation in keratinocytes disrupted differentiation 
and caused papillomatosis that rapidly regressed following Myc deactivation. 
Concomitantly, loss of MYC induces differentiation in multiple systems (Knoepfler 
et al. 2002; Shachaf et al. 2004; Sansom et al. 2007). Several studies have shown 
opposing effects of MYC on differentiation, indicating that in some contexts MYC 
can promote differentiation (Gandarillas and Watt, 1997; Arnold and Watt, 2001). 
The majority of evidence implicates MYC as a key regulator of dedifferentiation 
however, and this is clearly demonstrated by the discovery that MYC is one of the 
four factors that when combined can reprogram differentiated cells to the induced 
pluripotent stem (iPS) cell state (Takashi and Yamanaka, 2006). 
 
1.3 p53 - Guarding against MYC deregulation 
 
The cellular impact of deregulation of oncogenes such as MYC is restrained in the 
cell by activation of tumour suppressor genes, in a response often termed ‘oncogene-
induced tumour suppression’. Tumour suppressor genes implement tumour 
suppressive pathways to resist tumourigenesis. These pathways include cell cycle 
checkpoints, apoptosis, senescence, DNA repair, metabolism, and redox balance 
(reviewed in Levine and Puzio-Kuter, 2010). 	
 
For tumourigenesis to occur, a cell must acquire several mutations in oncogenes and 
tumour suppressor genes (reviewed in Vogelstein and Kinzler, 1993). This step-wise 
progression of pathogenesis is clearly demonstrated in colorectal cancer where a 
specific series of mutations are documented to accumulate over 20-40 years before 
malignant transformation occurs (figure 1.5; reviewed in Fearon and Vogelstein, 
1990). Somatic mutation of the p53 tumour suppressor gene (TP53) is the most 
common lesion detected in human cancer and affects a broad range of human cancer 
types (figure 1.6). Germline mutations in TP53 predispose a person to early-onset 
cancers, including breast carcinomas, sarcomas, brain tumors, and adrenal cortical 
carcinomas (Li et al. 1988; Olivier et al. 2003). The predisposition to these cancers is 
defined by Li-Fraumeni syndrome (Olivier et al. 2003).  
 
The majority of TP53 mutations are missense mutations in the DNA-binding domain 
(Petitjean et al. 2007). Outside this region missense mutations are less common and 
the majority of mutations are nonsense of frameshift. Mutations in the DNA-binding 
domain are are at residues that make contact with the DNA (e.g. R248) or support 
the structure of the DNA-binding surface (e.g. R249) (Joerger et al. 2007), indicating 
the importance of p53 transcriptional targets in resisting tumourigenesis. To 
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Figure 1.5. A step-wise model of colorectal tumourigenesis (adapted from 
Rajagopalan et al. 2003) 
The development of colorectal cancer is documented to occur over a period of 
20-40 years due to the sequential accumulation of specific mutations.  Initiation of 
this process is predominantly caused by inactivation of the APC (adenomatous 
polyposis coli) tumour supressor gene. Mutation of oncogene KRAS often 
preceeds large polyp formation, and 10-20% of these polyps progress to cancer by 
aquiring an additional mutation such as loss of the p53 pathway. 	
Normal  
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determine the functional effect of missense mutations (in a yeast-based functional 
assay), Kato et al. (2007) tested 2314 missense mutants for their activity at 8 
different p53 response elements. All hotspot mutants showed decreased 
transcriptional activity at p53 response elements, fitting with a tradiotional tumour 
suppressor model whereby mutation of a tumor suppressor gene reults in loss of 
protein function. However, a small group of mutants showed partial or enhanced 
activity at p53 response elements, the latter of which indicates a gain of function 
mutation. Further studies in vivo using knockin of hotspot mutants R175h and R273h 
(Lang et al. 2004; Olive et al. 2004) showed increased metastasis compared to Tp53 
knockout mice. This confirmed that TP53 gain of function mutants did indeed have 
relevance in vivo. Mutant p53 proteins can also exert dominant negative effects on 
wild-type p53 (Petitjean et al. 2007). This is because p53 tetramer formation is 
required for DNA-binding in all four DNA quarter-sites (McLure and Lee, 1998). 
Research is ongoing to determine the relevance of these rare mutants in human 
cancer (reviewed in Olivier et al. 2010).  
 
MYC expression stabilises and activates p53, although TP53 is not a direct 
transcriptional target of MYC (Hermeking and Eick, 1994; Lindström and Wiman, 
2003). p53 is stabilised and activated by a series of post-translational modifications, 
including phosphorylations, acetylations, methylations, ubiquitinations, and 
sumoylations (figure 1.7; reviewed in Lavin and Gueven, 2006). Several 
modifications in the N-terminal domain stabilise p53 by releasing it from its 
interacting protein MDM2 (mouse double minute 2). MDM2 is a ubiquitin ligase that 
ubiquitinates p53 prior to its proteosomal degradation. MDM2 is also modified 
during stress conditions to facilitate p53 stabilisation. Several ribosomal proteins, 
including RPL5, RPL11, and RPL23, bind and block MDM2 activity in response 
ribosomal stress (reviewed in Zhang and Lu, 2009). p14ARF (mouse p19ARF) is also an 
important negative regulator of MDM2, and MYC expression induces the expression 
of CDKN2A by an unknown mechanism (Zindy et al. 1998).  
 
p14ARF is a tumour suppressor protein encoded at the INK4A locus. The INK4A locus 
also encodes p16INK4A (also a tumour suppressor protein), and the two proteins are 
translated by alternative reading frames (hence the acronym ARF). Deletion of 
CDKN2A from TP53 knockout mice accelerated tumour formation (Weber et al. 
2000), indicating a tumour suppressive function(s) of p14ARF that is p53-
independent. Several studies have highlighted the importance of the p14ARF-MDM2-
p53 axis in resisting tumourigenesis (Pomerantz et al. 1998; Zhang et al. 1998; 
Kamijo et al. 1998; Stott et al. 1998). 
 
p53 modulates several tumour suppressive pathways, and the choice of response 
activated by p53 may be driven by levels of stress and affinity for target gene 
binding (Vousden, 2000). In this model, low levels of stress (such as transient 
nutrient depletion) induce levels of p53 that activate high affinity growth arrest 
genes. In contrast, high levels of stress (such as acute DNA damage) would be 
sufficient to induce low affinity pro-apoptotic genes as well (Inga et al. 2002). This 






Figure 1.7. Post-translational modifications that stabilise and activate p53 
(adapted from Lavin and Gueven, 2006) 
Proteins that phosphorylate, acetylate, methylate or sumoylate p53 at a range of 
different sites across the protein are depicted in the upper portion of this 
schematic. Where modification occurs at the same or adjacent sites this is shown, 
for example, at K381, K382 methylation and acetylation. Sites of ubiquitination 
are represented by pentagons under the schematic. The transactivation, SH3, DNA 
binding, tetramerisation and regulatory domains of p53 are outlined. Proteins that 
interact with these domains are depicted at the bottom of the figure, for example 
MDM2 interacts with the N-terminal transactivtion domain. ATM=ATM serine/threonine 
kinase, ATR=ATR serine/threonine kinase, DNA-PK=protein kinase, DNA-activated, SMG1=SMG1, nonsense mediated 
mRNA decay associated PI3K related kinase, MTOR=mechanistic target of rapamycin kinase, CHK2=checkpoint kinase 2, 
P38K=P38 mitogen-activated protein kinases, GSK3B=glycogen synthase kinase 3 beta, CAK=cyclin-dependent kinase 
activating kinase, HIPK2=homeodomain-interacting protein kinase 2, JNK=c-Jun N-terminal kinase, p300=E1A binding 
protein p300, PCAF=p300/CBP-associated factor,  PKC=protein kinase C, CHK1=checkpoint kinase 1, SUMO1=small 
ubiquitin-related modifier 1 precursor, PKR= protein kinase RNA-activated, CK2=casein kinase 2, CREB=cyclic-AMP 
response element binding protein , CBP=CREB-binding protein, COP9=COP9 signalosome, ING1B=inhibitor of growth 
1B, FAK=focal adhesion kinase, MDM2=mouse double minute 2 homolog, PIN1=peptidyl-prolyl cis-trans isomerase 
NIMA-interacting 1, RPA=replication protein A, TAFII31=transcription initiation factor IID, SIN3=SIN3 transcription 
regulator, WOX1=WUSCHEL-related homeobox 1, IκBα=nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha, BLM=bloom syndrome recq like helicase, BRCA1=breast and ovarian cancer susceptibility protein 1, 
CSB=CS complementation group B protein, PARC=cullin-9, PTEN=phosphatase and tensin homolog, RAD51=RAD51 
recombinase, TOPOI=DNA Topoisomerase I, TOPOII=DNA Topoisomerase II, WRN=werner syndrome recq like helicase. 
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 stage of tumour development (such as in colorectal cancer, figure 1.5) when the high 
stress associated with oncogene burden would otherwise trigger apoptosis. The role 
of p53 and other tumour suppressor genes in guarding against MYC deregulation is 
discussed in the following subsections.  
 
1.3.1 The role of p53 in cell cycle checkpoints 
 
Cell cycle arrest in response to cellular stresses such as DNA damage is triggered by 
p53 at multiple checkpoints (Giono and Manfredi, 2006). Cell cycle arrest in 
response to exogenous MYC activation occured specifically at the G2 checkpoint 
(Felsher et al. 2000). Arrest at G2 was dependent on p53 and its downstream effector 
p21, as loss of either gene permitted proliferation when MYC was activated. Arrest in 
G2 rather than G1/S may be because MYC is capable of overriding cell cycle 
inhibitors at the G1/S checkpoint (Felsher and Bishop, 1999).  Finch et al. also 
described an Arf/p53-dependent proliferative checkpoint in response to Myc 
activation in vivo (Finch et al. 2006).  
 
1.3.2 The role of p53 in apoptosis 
 
p53 is a master regulator of apoptosis, stimulating both death receptor signaling and 
mitochondrial perturbation (Vousden, 2000). In response to stress p53 
transcriptionally activates multiple genes involved in apoptosis, including BAX, 
TP53I3, TNFRSF10B, FAS, TP53AIP1, PERP, and BH3-only proteins NOXA and 
PUMA (reviewed in Riley et al. 2008). p53 also has transcription-independent 
functions that promote apoptosis such as localising to the mitochondria and inducing 
mitochondrial outer membrane permeabilisation (Mihara et al. 2003; Green and 
Kroemer, 2009).  
 
Constitutive expression of MYC leads to increased apoptosis in multiple biological 
systems, highlighting apoptosis as a key tumour suppressive mechanism in resisting 
MYC deregulation (Askew et al. 1991; Evan et al. 1992). Further, MYC 
deregulation was shown to sensitise cells to multiple apoptotic triggers such as serum 
withdrawal (Evan et al. 1992), glutamine withdrawal (Yuneva et al. 2007), and 
treatment with death receptor ligands such as TNF (Klefstrom et al. 1994) or TRAIL 
(Lutz et al. 1998). While p53 clearly activates apoptosis in response to multiple 
cellular stresses, the precise role of p53 in MYC-induced apoptosis is less clear. 
Hermeking and Eick (1994) showed that loss of TP53 in vitro attenuates MYC-
induced apoptosis and drives cell cycle entry, indicating that p53 mediates MYC-
induced apoptosis in this system. Several other studies show that loss of TP53 in vivo 
accelerates MYC-driven tumourigenesis; however this was due to enhanced 
proliferation not reduced apoptosis (Elson et al. 1995; Hsu et al. 1995; Finch et al. 
2006). These in vivo studies indicate that p53 does not mediate MYC-induced 
apoptosis, and that loss of TP53 does not engage an alternative apoptotic response 
despite accelerating proliferation. The synergistic importance of MYC 




A homeostatic metabolic model may better describe MYC-induced apoptosis. MYC-
induced apoptosis is linked to the status of pro-apoptotic and anti-apoptotic BCL-2 
members, which have clear metabolic roles in the mitochondria. Anti-apoptotic 
BCL-2 members BCL-2 and BCL-XL protect against apoptosis associated damage 
such as reactive oxygen species (ROS), mitochondrial membrane potential decline, 
and impaired nucleotide exchange and respiratory control (Gottlieb et al. 2000, 2002, 
Vander Heiden et al. 1997, 1999, 2001; Hockenbery et al. 1993).  Concomitantly, 
expression of BCL-2 or BCL-XL was shown to block MYC-induced apoptosis 
(Fanidi et al. 1992). Pro-apoptotic BCL-2 family members BAX or BAK-1 are 
required for MYC-induced apoptosis (Brunelle et al. 2004; Dansen et al. 2006; 
Eischen et al. 2001), and the pro-apoptotic function of BAX may require the 
mitochondrial ATPase (Matsuyama et al., 1998). The requirement for BCL-2 family 
members to modulate MYC-induced apoptosis, and the function of BCL-2 family 
members in mitochondrial nucleotide metabolism led us to uncover a metabolic basis 




Only recently was MYC overexpression shown to induce cell senescence under some 
circumstances. This tumour suppressive mechanism may be important in regressing 
MYC-driven tumours. Senescence was first observed during the propagation of 
human cells in culture, with the cells eventually arresting whilst retaining viability 
and metabolic activity (Hayflick and Moorhead, 1961). A decade later it was shown 
that replicative senescence was induced by telomere shortening (Olovnikov, 1970; 
Watson, 1972). Later it was shown that senescence was induced independently of 
telomere shortening by cell stresses such as oncogene activation or tumour 
suppressor gene loss (Serrano et al. 1997; Chen et al. 2005). In addition to growth 
arrest, senescent cells were shown to share several distinct biomarkers, including 
morphological transformation, activation of tumour suppressor networks, induction 
of senescence-associated β-galactosidase activity, appearance of senescence-
associated heterochromatic foci, and release of a senescence-associated secretary 
phenotype (SASP) (Kuilman et al. 2010).  
 
MYC overexpression alone does not induce senescence; however perturbation of two 
genes, Werner gene (WRN) or cyclin dependent kinase 2 (CDK2), induced 
senescence. MYC was shown to transcriptionally activate WRN, a conserved RecQ 
helicase, and loss of WRN led to genomic instability and induction of senescence 
(Grandori et al. 2003). This indicated that WRN activation by MYC may promote 
tumourigenesis through evasion of senescence. Further mechanistic insight into 
MYC-induced senescence was documented in two papers (Campagner et al. 2010; 
Hydbring et al. 2010). Campagner et al. showed that prolonged expression of MYC 
in CDK2 knockout cells induced senescence, and this was dependent on p16, p21, 
p27 and retinoblastoma (RB). Overexpression of MYC causes evasion of senescence 
by oncogenic KRAS, and Hydbring et al. showed that this was dependent on CDK2-
mediated phosphorylation of MYC at Serine 62. Importantly, knockdown of CDK2 
forced senescence in the presence of two oncogenes. Identification of this 
mechanism has significant implications for MYC-driven tumours, as 
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pharmacological inhibition of CDK2 could regress tumours through induction of 
senescence.  
 
1.3.4 Metabolism and redox balance 
 
The function of p53 in permanently halting pro-tumourigenic cells (through initiation 
of cell cycle arrest or apoptosis) has been well documented. More recently, p53 was 
shown to promote cell survival through regulation of metabolic pathways (reviewed 
in Kruiswijk et al. 2015). p53-driven metabolic changes include inhibition of 
glycolysis, gluconeogenesis, the pentose phosphate pathway (Jiang et al. 2011), and 
inhibition of the expression of NADPH-producing malic enzymes (Jiang et al. 2013) 
to block anabolism (in contrast to MYC).  p53 also promotes oxidative 
phosphorylation (OXPHOS) (Matoba et al. 2006), and FAO (Assaily et al. 2011) to 
support ATP generation (figure 1.8). In support of p53 responding to cell stress, p53 
directly responds to nutrient deprivation conditions (Liu et al. 2014a; Heoferlin et al. 
2013; Shiraki et al. 2014).  
 
Glycolysis and gluconeogenesis (the production of glucose from non-carbohydrate 
carbon sources) essentially generate similar intermediates, and p53 directly and 
indirectly inhibited multiple enzymes in both pathways. p53 transcriptionally 
repressed glucose transporters GLUT1 and GLUT4, and indirectly inhibited GLUT3, 
thus preventing glucose uptake (Zhang et al. 2013; Kawauchi et al. 2008). p53-
induced activity of TIGAR (TP53-inducible glycolysis and apoptosis regulator) 
inhibited phosphofructokinase 1 (PFK1), the rate-limiting step in glycolysis, through 
reduction in levels of its allosteric regulator fructose 2,6-bisphosphate. TIGAR 
expression reduced levels of reactive oxygen species, and TIGAR knockdown 
sensitised cells to p53-induced apotosis (Bensaad et al. 2006). Bensaad et al. 
concluded that inhibition of PFK1 diverted glycolytic carbon through the pentose 
phosphate pathway. As the pentose phosphate pathway generates NADPH and 
ribose-5-phosphate this would restore redox homeostasis and may also support the 
DNA repair activity of p53 (through increased nucleotide biosynthesis). In 
contradiction, p53 inhibited the first step of the pentose phosphate pathway G6PDH 
(glucose-6-phosphate dehydrogenase) (Jiang et al. 2011) and expression of malic 
enzymes (Jiang et al. 2013), both of which generate NADPH.  More research is 
needed to determine cellular contexts in which p53 promotes or restricts diversion of 
glycolytic carbon into the pentose phosphate pathway, as demonstrated by the 
contradictory results of these two studies.  
 
In opposition to the terminal conversion of pyruvate to lactate, p53 increased the 
activity of pyruvate dehydrogenase (PD), which converts pyruvate to acetyl-CoA in 
the mitochondrial matrix (Contractor and Harris, 2012; Zhang et al. 2011).  Flux 
through the TCA cycle generates important reducing agents (NADH and FADH2) for 
OXPHOS. p53 activated synthesis of cytochrome C oxidase 2 (SCO2), which 
positively regulates mitochondrial cytochrome C oxidase (COX) assembly, and 
therefore electron transport chain homeostasis (Matoba et al. 2006). OXPHOS is by 
far the most efficient way of producing ATP; however a byproduct of OXPHOS is 




Figure 1.8. p53 regulation of metabolic pathways (adapted from Kruiswijk 
et al. 2015) 
p53 limits the glycolytic rate by inhibiting glucose transporters GLUT1, GLUT3, 
and GLUT4, and glycolytic enzymes HK2, PFK1, and PGM. p53 inhibits 
gluconeogenesis through activation of SIRT1, which inhibits FOXO1 target genes 
G6PC and PCK1. p53 promotes OXPHOS indirectly by activating PDH and 
GLS2 to direct carbon into the TCA cycle, and directly by stimulating AIF and 
SCO2. p53 promotes FA uptake and β-oxidation by stimulating MCD, LPIN1, and 
PANK1. GLUT=glucose transporter type; HK2=hexokinase 2; PFK1=phosphofructokinase 1; PGM=phosphoglycerate 
mutase;  SIRT1=sirtuin 1; FOXO1=forkhead box protein O1; G6PC=glucose-6-phosphatase; PCK1=phosphoenolpyruvate 
carboxykinase; OXPHOS=oxidative phosphorylation; PDH=pyruvate dehydrogenase; GLS2=glutaminase 2; 
AIF=apoptosis-inducing factor; SCO2=synthesis of cytochrome c oxidase 2; CPT1C=carnitine palmitoyltransferase 1C 
MCD=malonyl-coenzyme A decarboxylase; LPIN1=lipin; PANK1=pantothenate kinase 1, TIGAR=TP53-inducible 












































































accommodate for this problem by activating glutaminase 2  i(GLS2). Hu et al. 
(2010) reported that p53 transcriptionally activated GLS2, increased levels of 
glutamate and α-ketoglutarate (via glutaminolysis), mitochondrial respiration rate 
and, importantly, glutathione levels. Glutamate is a key precursor of glutathione 
synthesis and glutathione is an important antioxidant, such that depletion in total 
reactive oxygen species was reported (Hu et al. 2010). Inability to cope with 
increased superoxide radical species generated by OXPHOS may be part of the 
reason that cancer cells activate aerobic glycolysis to promote cytosolic ATP 
generation.  
 
Several p53-driven metabolic changes counter metabolic changes stimulated by 
MYC deregulation or cancer cells in general, including p53-mediated inhibition of 
glycolysis and promotion of OXPHOS. However, other metabolic changes are not as 
clear, such as restoration of redox homeostasis, which may favour tumourigenesis. 
Further, p53 has been shown to promote FAO through direct activation of carnitine 
palmitoyl transferase 1 (essential for FA import into the mitochondria) and 
pantothenate kinase 1 (essential for CoA synthesis)(see figure 1.8). As discussed 
earlier 1.2.3.4, MYC deregulation promotes FAO and inhibition of FAO is 
detrimental to MYC-driven tumours in vivo. More research is needed to fully explore 
the role of tumour suppressor genes in metabolic reprogramming, particularly in the 
context of oncogene activation.  
 
1.4 Cooperation between MYC deregulation and p53 loss 
 
Several lines of evidence have indicated that disabling p53 confers a selective 
advantage to MYC-driven cancer. As discussed above, MYC deregulation strongly 
activates the p53 pathway, which resists cell cycle progression (Hermeking and Eick, 
1994; Lindström and Wiman, 2003). In vivo, a common ‘second-hit’ following MYC 
deregulation is loss of p53. Eµ-Myc transgenic mice developed B-cell lymphomas 
that exhibited loss of either TP53 (28% of cases) or CDKN2A (24% of cases) 
(Eischen et al. 1999). TP53 is also commonly mutated in Burkitt’s lymphoma cell 
lines (Farrell et al. 1991; Wiman et al. 1991). The selection for TP53 loss following 
MYC deregulation suggests that this lesion offers a potent tumourigeneic advantage.  
 
Enforced expression of MYC and loss of TP53 were synergistic lesions that enhanced 
induction of cyclin B1 (mRNA and protein) in Rat1 cells and 3D myeloid cells (Yin 
et al. 2001). In vivo, mice with genetically enforced expression of Myc and 
disruption of Tp53 showed accelerated development of malignant lymphomas. 
Moreover accelerated malignancy was a consequence of enhanced proliferation, not 
reduced apoptosis (Hsu et al. 1995). These studies indicate that TP53 loss relieves 
proliferative arrest following MYC deregulation. 
 
Finch et al. offered further insight into the cooperation of genetic lesions with MYC 
deregulation using a switchable model of Myc expression in pancreatic islet β-cells 
(Finch et al. 2006; figure 1.9). Myc activation drove low levels of proliferation due to 




Figure 1.9. Activation of Myc in β cells of pancreatic islets alone or plus  
Bcl-xl overexpression, Arf loss, or P53 loss (Finch et al. 2006) 
Myc was activated in β cells of pancreatic islets (MycERTAM) of mice for 3 days. 
MycERTAM alone was compared to MycERTAM; Bcl-xl (Bcl-xl overexpression), 
MycERTAM; Arf-/- (Arf loss), and MycERTAM; P53-/- (P53 loss). Apoptosis was 
measured by TUNEL (grey with eosin counter stain; A-D). BrDU was adminitered 
3.5 hr before sacrifice and S phase cells were identified with anti-BrDU (green),  
anti-insulin (red) and Hoescht (blue) counterstain (I-L). Staining with anti-insulin 
(I-L) or anti-ERα (M-O) followed by excess secondary antibody allowed 





increased by Myc activation, and this could be rescued by overexpression of 
antiapoptotic protein Bcl-xl. Loss of Arf relieved cell cycle inhibition allowing 
increased proliferation, and also potently increased apoptotic rate. This suggests that 
apoptosis is homeostatically regulated because if you relieve the proliferative brake 
you increase apoptosis. Loss of Tp53 increased proliferation without affecting 
apoptosis, indicating that p53 loss counters stresses associated with increased 
proliferation in some way. Due to the broad metabolic remodelling driven by MYC, 
and the ability of p53 to modulate and resist metabolic transformation, it is likely that 
loss of p53 gives MYC expressing cells a metabolic advantage. Further, as TP53 is a 
tumour suppressor gene described to respond to metabolic changes (as discussed 
above) it is likely that p53 directly responds to metabolic changes driven by MYC 
deregulation. 
 
Understanding the cooperation between MYC deregulation and TP53 loss is 
therapeutically important because tumours with these genetic lesions are particularly 
aggressive. In vivo, Myc-driven Tp53 null B-cell tumours were described as large, 
invasive, and irregular (Finch et al. 2006). In humans Hill et al. (2015) compared 
medulloblastoma biopsies at diagnosis and relapse and found combined MYC 
amplifications and p53 pathway defects commonly emerged at relapse. All patients 
in the group died of rapidly progressive disease post-relapse, indicating that 
combined MYC amplifications and p53 pathway defects may also drive aggressive 
tumourigenesis in humans.   
1.5 Hypothesis 
 
MYC expression drives an anabolic program that promotes cell growth and 
proliferation (section 1.2). In response to MYC overexpression, the p53 tumour 
suppressor pathway is activated via an unknown mechanism (section 1.3). Given that 
p53 has been documented to restrict anabolism and respond to a variety of nutrient 





Tp53 mutations commonly occur following MYC deregulation in vivo and result in a 
more aggressive tumour phenotype (section 1.4).  The contrasting effects of MYC 
(section 1.2.3) and p53 (section 1.3.4) on cell metabolism indicate that loss of TP53 
may favourably remodel the metabolism of MYC deregulated cells. I therefore 
hypothesize this to be the case.  
1.6 Thesis questions 
1. Does p53 respond to a MYC-driven metabolic pathway? 
2. What metabolic changes are driven by MYC overexpression?  
a. Does loss of p53 function impact MYC-driven metabolic changes? 
3. What lipid changes are driven by MYC overexpression? 




2 Chapter 2- Materials and Methods 
 
 
All solutions and compounds referred to here and in the following sections were 
obtained from Sigma unless otherwise stated. The composition of routinely used 
solutions are listed in Table 2.1. 
 
Table 2.1 Routinely used solutions 
 
Substance Composition 
PBS Phosphate-buffered saline tablets 
PBS-Tween (PBS-T) PBS + 0.5 % TWEEN20 
TBS-Tween (TBS-T) 10mM Tris (pH 7.5), 154mM NaCl, 0.5% Tween  
PBS/BSA In 1 litre: 10 Dulbeccos tablets, 0.1 g NaN3, 20 g BSA 
Cell lysis buffer 20mM Tris, 100mM NaCl, 5mM MgCl2, 0.5%IGEPAL 
10 X running buffer 25 mM Tris, 192 mM glycine, 0.1% SDS  
10 X transfer buffer 25 mM Tris, 192 mM glycine 
 
 
2.1 Cell culture and treatments 
 
2.1.1 Cell culture  
 
MRC5 human fibroblasts were obtained from the European Collection of 
Authenticated Cell Cultures (ECACC) via Public Health England. All cells were 
immortalized by transduction of retroviral hTERT, followed by either retroviral 
vector pM6P-blast (kind gift of F. Randow, MRC Laboratory of Molecular Biology, 
Cambridge UK) or pM6P-blast-MycERT2. From this point onwards, MRC5 pM6P-
blast cells will be referred to as ‘Vec cells’ and MRC5 pM6P-blast-MycERT2 cells as 
‘Myc cells’. Myc cells were activated by 4-hydroxytamoxifen (200 ng/ml) for 48 hr 
(unless otherwise stated), and 4-hydroxytamoxifen was present in all Vec cell 
samples. HEK293ET cells were a kind gift of F. Randow, MRC Laboratory of 
Molecular Biology, Cambridge UK. Cells were routinely maintained in DMEM high 
glucose, no pyruvate +10% FBS (referred to as standard media).  
 
2.2 Transfection of plasmid DNA 
 
2.2.1 Polyethylenimine (PEI) transfection 
 
To produce virus, HEK293ET cells were seeded in 75 cm2 flasks the day before 
transfection. For each flask, 10 µg midi prepped plasmid DNA, pMD2G, and 
pGAGPol were combined with 40 µl PEI (1 mg/ml) and 450 µl standard DMEM. 
Medium was changed 24 hr post-transfection, and incubated for a further 24 hr for 
viral production. MRC5 cells were seeded in 75 cm2 flasks the day before infection 
at a suitable cell density to reach confluence after 48 hr. For each MRC5 flask, 1 ml 
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viral media was combined with 9 mL standard DMEM and 10 µl polybrene (5 mg/ml 
stock). Successful infection was indicated by a GFP control, and cells were selected 
in an appropriate antibiotic (puromycin or blasticidin) for at least one week before 
harvesting.  
 
2.3 RNA interference 
 
2.3.1 siRNA (short interfering RNA) library design, transfection, and 
analysis 
 
2.3.1.1 siRNA library design 
 
A large metabolic siRNA library was designed in collaboration with Flora Dix and 
Juan-Carlos Acosta using the custom-design DHARMACON ON-TARGETplus 
siRNA tool. A total of 553 test siRNAs were selected to cover a broad range of 
metabolic pathways and transcription factors (Table 2.2). The siRNA library spanned 
seven 96-well plates in triplicate, with four wells on a plate targeting the same gene. 
Each well comprised a SMARTpool- a mixture of four siRNAs targeting the same 
gene provided as a single reagent. All siRNAs listed here and in the following 
sections were obtained from DHARMACON. Unless otherwise stated siRNAs were 
SMARTpools.  
 
Table 2.2 siRNA library overview 
 
Pathway targeted Number of genes 
Glucose metabolism  59 
Nucleotide biosynthesis 22 
Amino acid biosynthesis 16 
Transporters 17 
Transcription factors 18 




2.3.1.2 siRNA transfection 
 
Dharmacon SMARTpool siRNA mix (30 nM) was delivered by ‘reverse 
transfection’, meaning that the siRNA was plated first, followed by the transfection 
reagent, followed by the cells. DHARMAFECT1 transfection reagent 
(DHARMACON) was diluted 1:175 in null DMEM media, and then 17.5 µl of the 
solution was added per well. MRC5 cells (Vec or Myc) were seeded at 2000 
cells/well in 100 ul standard DMEM. The day after transfection assays were carried 
out as described below.  
 




In addition to siRNA SMARTpools, two controls were included in the screen to 
measure the range of p53 levels. siTP53 was used as described above to demonstrate 
p53 antibody specificity. Actinomycin D (50 ng/ml), which was previously shown to 
activate p53 (Choong et al. 2009), was added to media 24 hr before fixation to 
determine maximum p53 levels.  
 
2.3.1.4 siRNA analysis 
 
Following immunofluorescent staining (described below), plates were acquired with 
the ImageXpress Micro XLS Widefield High-Content Analysis System (Molecular 
Devices LLC, CA). Normalisation and Z score calculations were carried out using 
the web cellHTS2 software package. Plates identified as having poor 
immunofluorescent staining were omitted from the study, and it was found necessary 
to carry out an additional replicate of Myc plates. A median Z score cut off of greater 
than 1.5 for positive hits, and less than -2 for negative hits was set as the threshold of 
significance. The Functional Annotation tool on The Database for Annotation, 
Visualization and Integrated Discovery (DAVID) was used to assign the top 5 
functional annotations, as determined by lowest p-value (Huang et al. 2009).  
 
2.3.2 shRNA design and production 
 
2.3.2.1 Lentiviral shRNA design and production 
 
shRNA constructs were designed and cDNA cloned into the lentiviral GIPZ vector 
(Dharmacon) by Andrea Quintanilla. Following transfection of plasmid DNA, 
MRC5 cells Vec and Myc were selected in puromycin (1 µg/µl) for one week before 
successful shRNA knockdown was verified by qRT-PCR. Details of shRNA 
constructs can be found in Table 2.3.  
 
Table 2.3 Lentiviral shRNA reference numbers 
 
Target gene Supplier Reference numbers 
CERS4 (1-3) Dharmacon 274306, 348840, 348844 
SPTLC2 (1-3) Dharmacon 249662, 67791, 379817 
GBA (1-3) Dharmacon 83141, 340366, 340339 
SLC7A11 (1-3) Dharmacon 196769, 251161, 392255 
 
2.3.2.2 Retroviral shRNA design and production 
 
shRNA constructs were designed and cDNA cloned into the pSUPER-retro vector by 
Andrea Quintanilla. Following viral transduction, MRC5 cells Vec and Myc were 
selected in puromycin (1 µg/µl) for one week before successful shRNA knockdown 
was verified by qRT-PCR. Details of shRNA constructs can be found in Table 2.4.  
 
Table 2.4 Retroviral shRNA sequences 
 
Target gene Target sequence 
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SPTLC2 (1) UCAAACAGAUACCGGUUAA 
SPTLC2 (2) AGUCUGAGGAUGUGCGCAA 
CERS4 (1) GUGCCAACCUGCUGCGCAU 
DEGS2 (1) GCAAGGAGAUACUGGCCAA 
DEGS2 (2) GGGUGAAGGUGCUCUGGGA 
DEGS2 (3) GUUCUGGGCCUACGCCUUU 
DEGS2 (4) GCAGCGACUUCGAGUGGGU 
 
2.3.3 Retroviral overexpression constructs 
 
Overexpression constructs were designed by Andrea Quintanilla, and cDNA of the 
target gene was cloned into pMSCV as a Xho1-EcoR1 fragment. Following 
transfection of plasmid DNA, MRC5 cells Vec and Myc were selected in puromycin 
(1 µg/µl) for one week before successful overexpression was verified. 
 
2.3.4 Genetic suppressor elements 
 
A genetic suppressor element encoding dominant negative mutant p53 peptide was 
transfected into Vec and Myc cells as described previously (Gallagher et al. 1997). 
Loss of p53 function was validated by inability to increase p21 levels in response to 
MYC activation.  
 
2.4 Quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) 
 
2.4.1 RNA extraction 
 
Cells were scraped in PBS, centrifuged at 6000 rpm, and pellets frozen at -80 °C. 
RNA was extracted using RNeasy Plus Mini Kit (QIAGEN) following 
manufacturer’s instructions. RNA was eluted in 30-50 µl molecular biology grade 
RNAse-free ddH2O depending on the size of the original cell pellet. RNA 
concentration was quantified using a Nanodrop 2000C (Thermo Scientific). 
 
2.4.2 Complementary DNA (cDNA) synthesis 
 
An intermediate stock of 50 ng/µl was made up to a final volume of 25 µl for each 
RNA extract. For each reaction, 20 µl of the intermediate stock was combined with 8 
µl 5 X QUANTA qScript RT Supermix and 12 µl H20. cDNA synthesis was carried 
out on a SureCycler 8800 PCR machine (Agilent technologies). Program: 25 °C	 5	




qRT-PCR primers were designed using the Primer3web (version 4.0.0) online tool 
(Table 2.5) (Untergasser et al. 2012; Koressaar and Remm, 2007). Primers were 
designed to span exon/exon boundaries to ensure only mRNA was amplified. A 
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primer master mix was prepared. Per sample the master mix contained: 25 µl 2X 
SYBR Select Master Mix (Applied Biosystems), 0.5 µl forward primer (10 µM), 0.5 
µl reverse primer (10 µM), and 20 µl H20. Primers are listed in table 2.5. 
Intermediate tubes representing pooled technical triplicates were prepared, each 
containing 47 µl of the relevant primer master mix, and 3 µl cDNA. From the 
intermediate tubes, 15 µl of sample was plated in triplicate onto MicroAmp Fast 
optical 96w reaction plates (Thermo Scientific). qRT-PCR was performed on a 
StepOnePlus Real-Time PCR System using the Stepone software (version 2.3). The 
routine program used was: hold 95 °C 10 min → 40 cycles (95 °C 15 sec → 60 °C 30 
sec → 72 °C 15 sec) → melt curve 95 °C 15 sec, 60 °C 1 min, 95 °C 15 sec. RNAse-
free ddH2O alone was used as a control, and no contamination was detected.  A 
threshold was established in the linear phase of the amplification plot, and the log Ct 
(the number of cycles to reach the threshold) for each sample was used for 
quantification.  
 
Table 2.5 Primer sequences 
 
Gene ID Forward Reverse 
ACTIN CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT 
CDKN1A CCTGTCACTGTCTTGTACCCT GCGTTTGGAGTGGTAGAAATCT 
CERS4 ATCAGACCAGGAGGCAAGTG GGCCTCACAGAACTTCTTGGT 
GBA TTGCAGGGCTAACCTAGTGC GGCTTGGGACATTCCTCTCT 
SLC7A11 TGCTGGGCTGATTTTATCTTCG GAAAGGGCAACCATGAAGAGG 
SPTLC2 GCTCTACATGCCTGCCAAAA AATTGGGGTGGCAGGAAATC 
DEGS2 ACGACTTCCCCAGCATCC AATCCCAGAGCACCTTCACC 
TP53 (1) GCGCACAGAGGAAGAGAATC AGAGGAGCTGGTGTTGTTGG 
TP53 (2) TGGCTCTGACTGTACCACCA CCAGTGTGATGATGGTGAGG 
TP53 (3) CACATGACGGAGGTTGTGAG ACACGCAAATTTCCTTCCAC 
P14ARF CCCTCGTGCTGATGCTACTG ACCTGGTCTTCTAGGAAGCGG 
P16INK4A CGGTCGGAGGCCGATCCAG GCGCCGTGGAGCAGCAGCAGCT 
 
2.5 Immunofluorescence and microscopy 
 
2.5.1 Immunofluorescence  
 
2.5.1.1 Antibodies and controls 
 
Antibodies used for immunofluorescence are listed with dilutions in Table 2.6.  
 
Table 2.6 Antibodies for immunofluorescence 
 
Name Supplier Dilution Reactivity 
Primary 
p53 DO7 Leica- NCL-L-p53-DO7 1:100 Mouse 
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p21 Sigma- P1484 1:100 Mouse 
Secondary 
Alexa-Fluor-488 Mouse IgG1 ThermoFisherScientific 1:1000 Mouse 
Alexa-Fluor-568 Mouse IgG1 ThermoFisherScientific 1:1000 Mouse 
Alexa-Fluor-488 Rabbit IgG1 ThermoFisherScientific 1:1000 Rabbit 
 
2.5.2 Staining protocols 
 
At the experimental end point, cells were fixed in situ with 4% PFA/PBS for 30 min. 
Three PBS washes were carried out prior to every stage of the staining protocol 
(excluding addition of the primary antibody), and all staining was carried out at room 
temperature. Following fixation, cells were permeablised with 0.2% triton/PBS for 
10 min, then incubated in blocking solution (BSA/PBS) for 30 min. Primary 
antibody was added for 30 min, secondary antibody for 1 hr, and DAPI for 10 min. 
For DAPI cell count assays, staining protocols were the same but primary and 





Plates were acquired with the ImageXpress Micro XLS Widefield High-Content 
Analysis System (Molecular Devices LLC, CA). For threshold-based acquisition, a 
4x4 grid was set at the center of each well and the adaptive acquisition setting was 
used to count a total of 2000 cells/well. A threshold for secondary antibody 
immunofluorescent intensity was set, and the percentage of cells that scored above 
the threshold was calculated (using DAPI count as the total cell count for that well).  
 
2.6 Western blotting 
 
2.6.1 Cell lysis 
 
Cell pellets were washed in PBS then lysed in an appropriate volume of cell lysis 
buffer (50-200 µl).  Pellets that contained high numbers of apoptotic cells were 
sonicated at a moderate frequency for 30 sec. Following a 5 min incubation on ice, 
cells were centrifuged at 13,000 rpm for 5 min. The supernatant was removed and 
quantified using the Bradford Assay.  
 
2.6.2 SDS-PAGE electrophoresis 
 
Lysates were normalised to an equivalent protein concentration to allow 25 µg 
protein to be loaded per well. To each sample, 0.95 volumes of 2 x Lamelli Sample 
Buffer and 0.05 volumes of β-mercaptoethanol	were	added.	Samples	were	heated	
to	 95°C	 for	 5	 min,	 and	 centrifuged	 before	 loading	 onto	 10%	 precast	
polyacrylamide	 gels	 (BIO-RAD).	 Gels	were	 run	 in	 1X	 running	 buffer	 (1:9;	 10X	






2.6.3 SDS-PAGE gel transfer 
 
To prepare for the transfer, 6 sheets of chromatography paper (Whatman) were 
equilibrated in 1X transfer buffer (1:1:8; 10X transfer buffer:MeOH:ddH20), and the 
transfer membrane (Immobilon-P, pore size 0.45 µm) was primed with methanol for 
1 min. The sheets of paper were then placed either side of the gels and membrane to 
‘sandwich’ them together. The gels were electroblotted for 1 hr in 1X transfer buffer 
at 100V. Ice packs were used to keep the gels cool.  
 
2.6.4 Antibody probing 
 
Membranes were washed 3 times in TBST, then blocked for 30 min with 2% milk in 
TBST. Antibodies were diluted with 2% milk in TBST, as indicated in Table 2.7.  
Antibodies were routinely incubated at 4	 °C	 overnight,	 with	 the	 exception	 of	 β-
Actin,	which	was	incubated	at	room	temperature	for	1	hr.		
	
Table 2.7 Antibodies for western blotting 
	
Name Supplier Dilution Reactivity 
Primary 
p53 DO7 Leica- NCL-L-p53-DO7 1:1000 Mouse 
Actin ProteinTech- 60008-1-Ig 1:20,000 Mouse 
c-Myc (Y-69) Abcam- ab32072 1:5000 Rabbit 
ORMDL2 Abcam- ab10762 1:1000 Rabbit 
p21 Sigma- P1484 1:1000 Mouse 
CAD Cell signalling- 11933 1:500 Rabbit 
PP2A C Cell signalling- 2038 1:1000 Rabbit 
PP1A Santa Cruz- scc-6140 1:200 Goat 
GRP75 Abcam- ab2799 1:500 Mouse 
PPARγ Cell signalling- C26H12 1:1000 Rabbit 
Secondary 
Anti-Goat-HRP Santa Cruz- sc2020  1:1000 Goat 
Anti-Mouse-HRP Cell signalling- 7076S 1:20,000 Mouse 
Anti-Rabbit-HRP Cell signalling 1:1000 Rabbit 
 
2.7 Small molecule inhibitors 
 
All drugs stocks were stored at -20 °C,	and	fresh	dilutions	in	standard	media	were	
prepared	immediately	before	treatment. A summary of the inhibitors tested can 
be found in Table 2.8.  
 




Name Supplier Catalogue number 
6-aminonicatinamide Cayman Chemical 329-89-5 
ATM/ATR kinase inhibitor Calbiochem 905973-89-9 
C-20 ceramide Cayman Chemical 10724 
C-24 ceramide Cayman Chemical 62535 
C-6 ceramide Avanti Polar 
Lipids 
860506 
Conduritol B epoxide (CBE) Cayman Chemical 15216 
Ceramide from bovine spinal cord Sigma Aldrich 22244 
Ceranib 1 Tocris Bioscience 4448 
CYM50260 Tocris Bioscience 4677 
CYM50308 Cayman Chemical 14667 
CYM5442 Cayman Chemical 16925 
Fatty Acids Unsaturated Kit Sigma Aldrich UN10-1KT 
Supelco 
Fuminosin B1 (FB1) Tocris Bioscience 3103 
JTE-013 Cayman Chemical 10009458 
Miglustat hydrochloride (MH) Tocris Bioscience 3117 
Myriocin (MYR) Cayman Chemical 63150 
NVP-231 Calbiochem 219493 
Okadaic acid Abcam Ab120375 
PKC ζ pseudosubstrate Tocris Bioscience 1791 
Rapamycin Enzo BML-A275 
Rosiglitazone Cayman Chemical 71740 
SEW2871 Abcam ab120983 
Sphingosine kinase inhibitor 1 (SKI-1) Abcam ab142209 
Sphingosine-1-phosphate (S1P) Cayman Chemical 62570 
T0070907 Cayman Chemical 10026 
Torin 1 Tocris Bioscience 4247 
VPC 23019 Cayman Chemical 13240 
W146 (trifluoroacetate salt) Cayman Chemical 10009109 
 
2.8 Liquid Chromatography Mass Spectrometry (LC-MS) 
 
2.8.1 Isotope labeling 
 
Heavy isotopes were dissolved to an appropriate concentration in DMEM, no 
glucose, no glutamine, no phenol red. Media was supplemented with metabolites to 
match their concentration in standard DMEM. Where possible 100% of the media 
was labeled; however in the cases of glycine, serine, and choline a 2/3 label was used 
due to the presence of these metabolites in the media. To label the cells, media was 
aspirated and replaced with the heavy-isotope labeled media for a given pulse time. 




Table 2.9 Heavy-isotopes 
Name Supplier Catalogue number 
L-Asparagine-amide-15N 
monohydrate 
Sigma Aldrich 605166 
L-Asparagine-13C4 Cambridge Isotope Laboratories CLM-8699 
Choline chloride-15N Sigma Aldrich 609269 
L-Cystine-15N2 Cambridge Isotope Laboratories NLM-3818 
Ethanolamine-15N Cambridge Isotope Laboratories NLM-8722-PK 
D-Glucose-13C6 Cambridge Isotope Laboratories CLM-1396-5 
D-Glucose-13C6 Sigma Aldrich 389374 
L-Glutamine-13C5 Sigma Aldrich 605166 
L-Glutamine-amide-15N Sigma Aldrich 490024 
Glycine-2-13C Sigma Aldrich 279439 
Glycine-15N Sigma Aldrich 299294 
Palmitic acid-d31 Sigma Aldrich 366897 
Sodium Pyruvate-13C3 Sigma Aldrich 490717 
D-Ribose-13C5 Cambridge Isotope Laboratories CLM-3652 
L-Serine-13C2 Sigma Aldrich 605174  
L-Serine-15N Cambridge Isotope Laboratories NLM-2036 
 
 
2.8.2 Extraction of metabolites 
 
Individual wells of a 6-well plate were washed with ice-cold PBS then extracted in 
0.5 ml extraction buffer (50% methanol, 30% acetonitrile, 20% water at -20 °C	 or	
lower).	Extracts	were	centrifuged	at	maximum	speed	and	stored	at	-80	°C.		
	
2.8.3 Extraction of metabolites from RNA or DNA 
 
To determine metabolite content specifically in RNA or DNA cells were first scraped 
in PBS, centrifuged at 6000 rpm, and pellets frozen at -80 °C. RNA was extracted 
using RNeasy Plus Mini Kit (QIAGEN) or DNA was extracted using DNeasy blood 
and tissue kit (QIAGEN) following the manufacturer’s instructions. RNA or DNA 
was eluted in 30-50 µl molecular biology grade RNAse-free ddH2O depending on the 
size of the original cell pellet. RNA or DNA concentration was quantified using a 
Nanodrop 2000C (Thermo Scientific) to ensure the extraction worked. Elulted RNA 
or DNA was extracted in 0.5 mL extraction buffer (50% methanol, 30% acetonitrile, 
20% water at -20 °C	or	lower).	Extracts	were	centrifuged	at	maximum	speed	and	
stored	at	-80	°C.		
 
2.8.4 Extraction of lipids 
	
The lipid extraction method was adapted from Bligh and Dyer (Bligh and Dyer, 
1959) as recommended by Terry K. Smith (University of St. Andrews). Individual 
plates (10 cm) were washed and scraped in ice-cold PBS. Cells were centrifuged at 
800 g for 10 min. Pellets were suspended in 100 ul PBS and transferred to a glass test 
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tube. A total of 375 ul 1:2 (v/v) chloroform:methanol was added to each tube and 
vortexed. Suspensions were agitated vigorously for 30 min at 4 °C. Suspensions 
were made biphasic by adding 125 ul chloroform, vortexing, 125 ul water, vortexing, 
and centrifuging at 1000 rpm for 5 min. The lower phase (chloroform phase) was 
then transferred to a glass vial and dryed under nitrogen. Lipid extracts were stored 
at 4 °C, and resuspended in 2:1:1 (v/v) isopropanol:acetonitrile:water prior to 
analysis.  
 
2.8.5 Metabolomic LC-MS methods 
 
LC-MS was carried out using a Thermo Ultimate 3000 HPLC inline with a 
QExactive mass spectrometer. A 32 min gradient was developed over a 100 mm x 
4.6 mm ZIC-pHILIC column (Merck-Millipore) from 10% buffer A (20 mM 
ammonium carbonate), 90% buffer B (acetonitrile) to 95% buffer A, 5% buffer B. 10 
µl of metabolite extract was applied to the column equilibrated in 5% buffer A, 95% 
buffer B.  
 
Samples were acquired in positive-negative switching mode and standard ESI source 
and spectrometer settings were applied (typical scan range 75-1050). Metabolites 
were identified by either standard metabolite matching to m/z and retention time, or 
by fragmentation fingerprint pattern.  
 
2.8.6 Lipidomic LC-MS methods 
 
LC-MS was routinely carried out using a Thermo Ultimate 3000 HPLC inline with a 
QExactive mass spectrometer or an Orbitrap Fusion Lumos Tribrid Mass 
Spectrometer where stated. A 10 min gradient was developed over a Phenomex C18 
column from 80% buffer A (60:40 acetonitrile:water plus 10 mM ammonium 
formate, 20% buffer B (90:10 isopropanol:acetonitrile plus 10 mM ammonium 
formate) to 3% buffer A, 97% buffer B. The gradient was then held at this 
composition for 2 min.  
 
All samples were acquired twice, once in positive MS2 mode, once in negative MS2 
mode. The standard scan range in positive mode was 300-1000 Da, and 500-1200 Da 
in negative mode. The QExactive mass spectrometer was routinely used for data 
acquisition and identification of lipids. Metabolites were identified by either standard 
metabolite matching to m/z and retention time, or by high collision energy (HCD) 
fragmentation fingerprint. The identification of this fingerprint was partially 
automated with the perl script LipidSlider.pl. The Orbitrap Fusion Lumos Tribrid 
Mass Spectrometer was used to acquire a single dataset to test its capacity to detect 
lipid species. Sensitive mass analysis of HCD and CID (collision-induced 
dissociation) fragments allowed complete fatty acid identification of 
glycerophospholipids, and multistage ion activation (MSn) allowed complete fatty 








The perl script LipidSlider.pl was designed and written in collaboration with Jimi 
Wills to address an unmet need for free software to identify lipid subclass by MS2 
fingerprint. The software reads MS2 data in mgf format, and scans for sets of 3 ions 
(the subclass fingerprint) that are listed in the configuration file. The selected ions 
were chosen to detect glycerophospholipid and sphingolipid species. For 
glycerophospholipid species that have more than one fatty acid residue, the software 
identifies the lipid subclass and then the summed carbons and double bonds are 
calculated for a given lipid. As ceramide species have a sphingosine backbone that 
forms the subclass fingerprint, and one fatty acid residue, a generic composition 
solver was used to calculate the fatty acid residue, thus resolving the complete lipid 
composition. An estimation of the false discovery rate is printed after completion of 




The ThermoScientific Software LipidSearch was tested alongside the Orbitrap 
Fusion Lumos Tribrid Mass Spectrometer for its ability to identify sphingolipid, 
glycerolipid, and glycerophospholipid species by ms2 and ms3 fingerprint. The 
corresponding dataset is indicated in the figure legend.  
 
2.8.7.3 assayR 
assayR was developed in collaboration with Jimi Wills and Andrew Finch to address 
an unmet need for free software that allows targeted analysis of heavy isotope 
labeled metabolites (unpublished data). The metabolites to be processed in the 
targeted analysis are entered in the form of a configuration file that contains 
metabolite name, m/z value, retention time window, peak intensity threshold, and 
possible isotopes. Possible isotopes of the elements hydrogen, nitrogen, and carbon 
are considered, and a maximum number of isotopes is assigned to each metabolite. 
The final output consists of a csv file, extracted ion chromatograms of all 
metabolites, histograms of percent isotope labeling, and histograms of absolute peak 
area. assayR allows for rapid processing of complex labeling experiments, and this 




X13CMS software was used to analyse heavy-isotope tracer experiments in an 
untargeted manner (Huang et al. 2014). X13CMS is implemented in R, and 
compares unlabeled and heavy-isotope labeled samples between two biological 
conditions. The output from the isoDiffreport from X13CMS highlights ions that are 
differentially labeled between the two biological conditions. These ions were then 
further analysed for peak integrity using assayR, and assigned metabolite IDs by 








Calculations of significance between pairs of means were routinely carried out with 
Microsoft Excel using the two-tailed Student’s t-test. T-tests were carried out on a 
representative dataset, or where possible on biological triplicates, as indicated in the 
figure legends. A p-value of ≤ 0.05 was considered to be statistically significant.  
 




Large lipid datasets were quantile normalised using the function 
‘normalize.quantiles’ in the R package ‘preprocessCore’ (R Core Team, 2013; 




Statistical analysis of large lipid datasets was carried out using the one-way analysis 
of variance (ANOVA) function in R (R Core Team, 2013). This method was selected 
due to ANOVA applying the F-test to calculate statistical significance between all 




Normalised peak areas were clustered using the GUI program Cluster3 (de Hoon et 
al. 2004). Cluster3 was used to log transform the data, before centering samples and 
peak areas on the median value. The data then underwent hierarchical clustering 
using the average linkage, and the output was visualized with Java TreeView 
(Saldanha, 2004).  
 
2.9.2.4 Network clustering analysis 
 
Spearman correlation values were calculated in R from normalised lipid peak areas 
and used to set edge weights. Mixture modeling was used to filter out edge weights 
with low significance (below a threshold of 0.5). The network was visualised using 
Cytoscape open source software (Shannon et al. 2003), and lipids were clustered 
using the Molecular Complex Detection (MCODE) plugin (Bader and Hogue, 2003). 
Clusters were separated by force directed layout and Fisher’s exact test (Fisher, 
1922) was carried out to determine whether the separation was statistically 
significant. Log2 values of normalised lipid peak areas were assigned to the relevant 
node within the network, and a thicker node border was used to indicate statistical 






3 Chapter 3- Metabolic mediators of p53 accumulation 
 
The aim of this study was to investigate fundamental mechanisms of MYC-driven 
tumour suppression that are selected against in cancer cell lines. MRC5 human 
fibroblast cells were used as the experimental system for this project due to their 
intact genetic background and normal ploidy. This means that tumour suppressor 
pathways have not already been selected against and can therefore be assessed. To 
investigate the role of metabolic pathways in regulating MYC-driven p53 
accumulation, a large metabolic loss of function siRNA screen was carried out using 
high-content microscopy. Functional annotation of screen hits was then carried out to 
identify metabolic pathways that regulate MYC-driven p53 accumulation. This 
chapter outlines the results and initial validation of the metabolic loss of function 
screen.  
3.1 Primary siRNA screen 
 
MRC5 cells were transduced with pM6P-blast (Vec) or pM6P-blast-MYCERT2 
(Myc). Activation of MYC with 4OHT increased p53 levels over a 48 hr timecourse 
(figure 3.1A) as described previously (Hermeking and Eick, 1994; Lindström and 
Wiman, 2003). Accumulation of p53 also led to increased levels of its downstream 
target p21, indicating that the accumulation of p53 was sufficient to increase its 
activity (figure 3.1B).  These results show that MRC5 cells transduced with 
conditional MYC are a suitable system to investigate how MYC activates the p53 
tumour suppressor pathway.  
 
To determine whether MYC activates p53 via a metabolic mechanism, a large 
metabolic loss of function siRNA screen was carried out to identify metabolic 
enzymes, transporters, or transcription factors that altered MYC-driven p53 
accumulation. The siRNA library consisted of over 550 siRNA targets that covered a 
broad range of metabolic pathways, including glucose metabolism, nucleotide 
biosynthesis, amino acid biosynthesis, and lipid biosynthesis; as well as transporters 
and transcription factors  (table 3.1). Screen conditions were optimised in 96-well 
plates using a p53 immunofluorescent readout to calculate percent p53 positive cells 
per well  (figure 3.2). Cells transfected with non-target siRNA (siNT) were treated 
with vehicle or 4-hydroxytamoxifen (4OHT) to activate MYC. MYC deregulated cells 
(Myc +4OHT) increased percent p53 positive cells to ~40% compared to MYC 
control cells (Myc -4OHT) which had ~4% p53 positive cells. This indicated that 
MYC deregulation increased p53 accumulation, as described previously (Hermeking 
and Eick, 1997). Vec control cells had <1% p53 positive cells regardless of treatment 
with 4OHT. Two controls for the screen were used that strongly decreased or 
increased percent p53 positive cells compared to 40% p53 positive cells in MYC 
deregulated cells. Cells transfected with siTP53 had <1% p53 positive cells across all 
cell types and treatments, validating p53 antibody specificity. Actinomycin D was 
previouslydescribed to inhibit RNA synthesis (Perry et al. 1970) and activate p53 
(Choong et al. 2009). Vec and Myc cells treated with actinomycin D (24 hr) had 




Figure 3.1. Validation of experimental system 
(A) Western blot validates that levels of p53 protein increase over a 48 hr time 
course of MYC activation with 4OHT (n=1).  (B) Western blot shows that 48 hr 
MYC activation with 4OHT increases p53 activity, as measured by increased p21 
levels (a downstream target of p53) (n=3). This indicates that increased levels of 
p53 are sufficient to increase p53 activity.  
A 
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Table 3.1. siRNA library overview 
The table shows an overview of siRNA targets within the siRNA library. The 
siRNA library was designed in collaboration with Flora Dix and Juan-Carlos 
Acosta. 
Pathway targeted Number of genes 
Glucose metabolism  59 
Nucleotide biosynthesis 22 
Amino acid biosynthesis 16 
Transporters 17 
Transcription factors 18 






Figure 3.2. Immunofluorescent setup of the primary siRNA screen 
Immunofluorescent images show the setup conditions for a large metabolic 
siRNA screen to follow. Immunofluroescence shows DAPI (blue) and p53-FITC 
(green). Setup conditions are siNT (non-target siRNA), siTP53 as the positive 
control, and AD (actinomycin D, 24 hr treatment at 50 ng/ml) as the negative 
control. The siRNA conditions were tested +/- 4OHT treatment.  















indicated that the siRNA screen could identify metabolic pathways that positively or 
negatively regulated p53 levels in response to MYC deregulation.  
 
Following acquisition, percent p53 positive cells for each siRNA pool was calculated 
and the full dataset was analysed using the web-based platform webcellHTS2. Screen 
replicates (consisting of seven 96-well plates in quadruplicate) were batch 
normalised (figure 3.3A and B). Normalised median values were aligned at a value 
of zero, and these values were used to show good separation of controls in each plate 
and across the replicate (figure 3.2C and D). To identify screen hits, a Z score 
distribution was plotted (figure 3.3E). Sixteen siRNAs that decreased p53 
accumulation with a Z score greater than 1.5 were considered positive screen hits 
(table 3.2). Twenty siRNAs that increased p53 accumulation with a Z score less than 
-2 were considered negative screen hits (table 3.3). A lower Z score threshold was set 
for positive hits because these were the metabolic pathways responsible for 
positively regulating p53, therefore the effect of their knockdown may be more 
subtle. In contrast, it was likely that knockdown of several metabolic enzymes would 
induce stress and strongly exacerbate p53 accumulation. 
 
The 36 siRNA screen hits were assigned functional annotations using the functional 
annotation tool on The Database for Annotation, Visualization and Integrated 
Discovery (DAVID; Huang et al. 2009). Of the broad range of metabolic pathways 
included in the siRNA library (table 3.1), the top 5 functional annotations were lipid 
metabolism, metabolic pathways, lipid biosynthesis, sphingolipid biosynthetic 
process, and fatty acid biosynthetic process (as determined by lowest p-value; table 
3.4). The large number of screen hits that clustered in fatty acid and sphingolipid 
synthesis indicated that these pathways were key in regulating the p53 response to 
MYC deregulation. Interestingly, a recent genome-wide siRNA screen in 
Caenorhabditis elegans (C.elegans) looking for targets that blocked the 
mitochondrial stress response revealed 6 hits in the sphingolipid biosynthesis 
pathway (Liu et al. 2014b). As the C.elegans screen was genome-wide it implicated 
the broader relevance of our metabolic siRNA screen in a cellular response to 
mitochondrial stress (see subsection below).  
 
Positive siRNA screen hits (i.e that reduced MYC-driven p53 accumulation) were 
validated using 4 individual siRNAs per gene (figure 3.4). Ceramide synthase 4 
(CERS4) was added to the validation screen as it is the enzymatic step between two 
other screen hits serine palmitoyltransferase long chain base subunit 2 (SPTLC2) and 
dihydroceramide desaturase 2 (DEGS2) in the de novo sphingolipid synthesis 
pathway. CERS was also one of six sphingolipid hits in the C.elegans screen (Liu et 
al. 2014b). CERS4 was validated specifically (there are 6 CERS subtypes) as it was a 
strong hit in a parallel tumour suppressor screen carried out on the same metabolic 
siRNA library (Dix et al. unpublished data). A gene was considered a strong hit if 2 
or more of the 4 siRNAs decreased the percent p53 positive cells in siNT by 30 
percent. The strongest hits were sphingolipid enzymes SPTLC2 and DEGS2 (CERS4 
was validated with 1 of the 4 siRNAs), TCA cycle enzyme oxoglutarate 




Figure 3.3. Primary metabolic siRNA screen  
siRNA screen data was analysed using the web based program webcellHTS2. (A) 
Histogram shows the distribution of raw values across the 7 plates tested. (B) 
Histogram shows the median values of each plate normalised to zero. The median 
values are indicated by the black line on both histograms. (C) Figure shows the 
separation of normalised values for each plate. (D) Figure shows the separation of 
positive (siP53) and negative (AD, actinomycin D) controls. No overlap between 
controls and a Z score factor close to 1 is indicative of a strong screen. (E) Z score 
distribution shows most test siRNAs clustering on the median, with potential 
siRNA hits deviating from the median (dashed red line) with the positive and 
negative controls. A Z score threshold cut off of ≥1.5 was set for positive hits, and 
≤-2 for negative hits was set, and these siRNAs were considered for further 
validation. Data represents a single replicate out of the four replicates included in 
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Gene ID Gene symbol Median Z score Plate replicates Hits Hit error 
4609 MYC 4.5 1 1 NA 
441531 PGAM4 2.5 3 3 0.30 
57521 RPTOR 2.5 3 2 0.43 
23657 SLC7A11 2.2 3 3 0.18 
9517 SPTLC2 2.2 3 2 0.17 
4191 MDH2 2.1 1 1 NA 
3991 LIPE 2.0 1 1 NA 
8877 SPHK1 1.8 3 2 0.16 
2629 GBA 1.8 2 1 NA 
5105 PCK1 1.6 3 1 0.25 
4967 OGDH 1.6 3 1 1.13 
23761 PISD 1.5 3 1 0.26 
123099 DEGS2 1.5 4 1 0.23 
5297 PI4KA 1.5 3 1 0.45 
22934 RPIA 1.5 3 1 0.60 
150763 GPAT2 1.5 2 1 NA 
Table 3.2. Metabolic siRNA positive screen hits 
The table indicates the gene ID and gene symbol for siRNA screen positive hits. 
The knockdown of these genes decreased p53 accumulation in response to MYC 




Gene ID Gene symbol Median Z score Plate replicates Hits Hit error 
7372 UMPS -7.7 3 3 1.40 
229 ALDOB -5.0 4 4 0.57 
5468 PPARG -4.8 3 3 0.57 
29095 ORMDL2 -4.6 3 3 0.68 
247 ALOX15B -4.1 4 4 1.09 
33 ACADL -3.7 3 2 0.91 
7528 YY1 -3.6 3 3 0.28 
581 BAX -3.4 3 3 0.41 
51046 ST8SIA3 -3.4 3 3 0.44 
55825 PECR -3.4 3 3 0.17 
5319 PLA2G1B -3.2 3 3 0.56 
79993 ELOVL7 -3.1 1 1 NA 
8612 PPAP2C -3.1 3 3 0.13 
57171 DOLPP1 -2.9 4 3 0.90 
100137049 PLA2G4B -2.8 3 3 0.64 
79717 PPCS -2.7 2 1 NA 
239 ALOX12 -2.7 4 4 0.33 
9023 CH25H -2.6 4 3 0.41 
1737 DLAT -2.5 4 4 0.36 
64834 ELOVL1 -2.0 1 1 NA 
Table 3.3. Metabolic siRNA screen negative hits 
The table indicates the gene ID and gene symbol for siRNA screen positive hits. 
The knockdown of these genes increased p53 accumulation in response to MYC 




Functional annotation Gene count p-value 
Lipid metabolism 15 2.6E-15 
Metabolic pathways 21 4.2E-09 
Lipid biosynthesis 7 1.9E-07 
Sphingolipid biosynthetic process 5 2.6E-06 
Fatty acid biosynthetic process 5 3.5E-06 
Table 3.4. Functional annotation of metabolic siRNA screen hits 
The table indicates the top 5 functional annotations, as determined by lowest p-
value, assigned by the functional annotation tool on The Database for Annotation, 
Visualization and Integrated Discovery (Huang et al. 2009).  The number of genes 
classified into each functional category, and the p-value, is indicated. The p-value 
is calculated using a modified Fisher Exact test to measure the gene-enrichment in 
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Figure 3.4. Validation of metabolic siRNA screen positive hits 
Four individual siRNAs per gene were tested for their effect on percentage p53 
positive cells. Percent p53 positive cells was calculated using an 
immunofluorescent p53 readout (p53-FITC), divided by total cell number (DAPI). 
siRNAs were considered to have a significant effect, as indicated by *, if they 
decreased percent p53 positive cells in the non-target (NT) pool by 30 percent. A 




phosphoglycerate mutase 4 (PGAM4), and regulatory associated protein of MTOR 
(RPTOR).  
 
The identification of RPTOR, which is part of the mammalian target of rapamycin 
complex 1 (MTORC1), increased our confidence of the screen hits. MTOR is a 
master regulator of protein synthesis and collaborates with MYC to phosphorylate 
eukaryotic translation initiation factor 4E binding protein-1 (4EBP1) (Pourdehnad et 
al. 2013). Moreover, Pourdehnad et al. went on to show that MTOR-dependent 
phosphorylation of 4EBP1 is required for MYC-dependent tumour initiation and 
maintenance. Knockdown of RPTOR in this loss of function siRNA screen would 
likely inhibit MYC-driven cell growth, thereby decreasing metabolic stress, and 
potentially decreasing the homeostatic activation of p53. Pharmacological inhibitors 
of MTOR, Rapamycin and Torin 1, both significantly reduced p53 accumulation 
compared to the vehicle control (figure 3.5). This supported the contribution of 
MTOR activity to MYC-driven p53 accumulation.  
 
Seven of the negative siRNA screen hits (i.e that increased MYC-driven p53 
accumulation) were validated using 4 individual siRNAs per gene (figure 3.6). Ying-
Yang 1 (YY1) was the strongest negative hit. As discussed above, one of the ways 
that MYC promotes mitochondrial biogenesis is by activating SURF-1 (a complex 
IV assembly factor), and this is dependent on a functional YY1 binding site (Vernon 
and Gaston, 2000). Knockdown of YY1 in this screen may exacerbate metabolic 
stress due to dysfunctional mitochondrial homeostasis, and thus increase p53 
accumulation. However, knockdown of YY1 also significantly increased the 
percentage of p53 positive cells in Vec cells (figure 3.7), suggesting that increased 
stress caused by YY1 knockdown is not a MYC-specific stress response. Other 
validated negative siRNA screen hits included the FA responsive transcription factor 
peroxisome proliferator-activated receptor gamma (PPARG), arachidonate 15-
lipoxygenase, type B (ALOX15B), and peroxisomal trans-2-enoyl-CoA reductase 
(PECR), which is involved in FA elongation through FAO (Varga et al. 2011; Das et 
al. 2000). Interestingly, several of these hits are involved in arachidonate 
metabolism, which was previously described to be remodelled by MYC 
overexpression (Hall et al. 2016). Further analysis of MYC-driven changes in FA 
metabolism is outlined in chapter 4.  
 
3.2 Validation of sphingolipid biosynthesis enzymes 
 
The de novo sphingolipid synthesis pathway begins with the rate-limiting step, the 
condensation of an acyl-CoA (predominantly palmitoyl-CoA) and serine by SPT to 
form 3-ketosphinganine (reviewed in Eljamil et al. 2015). 3-ketosphinganine is then 
reduced in an NADPH-dependent reaction to sphinganine. Synthesis of dihydro-
ceramide is catalysed by CERS, which adds an acyl-CoA that forms the FA residue 
of the lipid. In the last enzymatic step, DEGS desaturates dihydroceramide to 
ceramide in an NADPH-dependent reaction. As three consecutive de novo 





















Figure 3.5. Pharmacological inhibition of mTOR 
Cells were treated with mTOR inhibitors Rapamycin (1 nM) or Torin 1 (50 nM) at 
the same time as Myc activation with 4OHT for 48 hr. Error bars are the standard 
error (n=3).  *** indicates a p-value ≤0.001 (T-test). Statistics were carried out on 
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* * * * * * * * 
Figure 3.6. Validation of metabolic siRNA screen negative hits 
Four individual siRNAs per gene were tested for their effect on percentage p53 
positive cells. Percent p53 positive cells was calculated using an 
immunofluorescent p53 readout (p53-FITC), divided by total cell number (DAPI). 
siRNAs were considered to have a significant effect, as indicated by *, if they 
increased percent p53 positive cells in the non-target (NT) pool by 30 percent. A 





















Figure 3.7. siRNA knockdown of YY1 
Cells transfected with siNT were compared to those transfected with siYY1 for 
percent p53 positive cells as measured using a p53 immunofluorescent antibody. 
Error bars are the standard error (n=3). ** indicates a p-value <0.01 (T-test). 






 genes were required for MYC-driven p53 accumulation, these genes were further 
characterised. 
 
siRNA knockdown of SPTLC2, CERS4, and DEGS2, was respectively shown to 
significantly reduce p53 accumulation by immunofluorescent staining (figure 3.8A-
C). Reduction of p53 levels was also demonstrated by western blot, whereby siRNA 
knockdown of SPTLC2 or DEGS2 reduced p53 levels to a similar extent as shown by 
immunofluorescent staining (figure 3.8D). Knockdown of each of the sphingolipid 
target genes was validated by qRT-PCR, and the decrease in mRNA expression was 
greater than 50 percent in all cases compared to siNT (figure 3.9A). Relative mRNA 
expression of TP53 was measured to determine whether increased transcription could 
account for increased p53 protein levels. As described previously (Hermeking and 
Eick, 1997), mRNA expression increased only 3-fold (figure 3.9B), indicating that 
MYC-driven p53 accumulation is primarily regulated at the protein level. In keeping 
with this, siRNA knockdown of SPTLC2, CERS4, or DEGS2 did not significantly 
change TP53 or CDKN2A (p14ARF) mRNA expression (figure 3.9C and D 
respectively).  
 
Lentiviral shRNA constructs targeting SPTLC2, CERS4, GBA, and SLC7A11 were 
each transfected into Vec or Myc cells to test their effect on p53 accumulation. Three 
constructs were tested for each of the genes by qRT-PCR to select the construct with 
the strongest knockdown of mRNA expression (figure 3.10A). The strongest 
construct for each gene was tested for its effect on p53 accumulation; however none 
of the constructs affected p53 accumulation compared to empty vector alone (figure 
3.10B). This was surprising for SPTLC2, CERS4, and SLC7A11 as all three of these 
genes were validated by siRNA. As GBA was not validated the lack of effect on p53 
accumulation as a result of its knockdown was not unexpected. To determine 
whether there was a problem with lentiviral shRNA knockdown, retroviral shRNA 
constructs (regulated by different promoters) targeting SPTLC2, CERS4, and DEGS2 
were tested for their effect on MYC-driven p53 accumulation. By western blot, 
shSPTLC2 depleted p53 levels to a similar extent as was seen by siRNA knockdown 
of SPTLC2; however shDEGS2 did not affect p53 levels (figure 3.11A). By western 
blot, shCERS4 depleted p53 similarly to shSPTLC2 (figure 3.11B). Thus data 
obtained with retroviral shRNA transduction supported our initial siRNA 
observations. 
 
One possibility was that de novo ceramide synthesis enzymes were not regulating 
p53 stability but were affecting MYC overexpression. To test this, levels of the MYC 
target gene carbamoyl-phosphate synthetase 2 (CAD) were measured by western blot 
in cells transfected with control or shSPTLC2 (Grandori and Eisenman, 1997). MYC-
deregulated cells increased CAD protein levels to a detectable level, and this 
persisted in MYC deregulated cells with SPTLC2 knockdown, despite p53 levels 
decreasing (figure 3.11C). This indicated knockdown of de novo ceramide synthesis 
enzymes regulated p53 accumulation in response to MYC overexpression, not 































































































Figure 3.8.  siRNA knockdown of de novo sphingolipid synthesis- effect on protein 
level 
(A) Histogram compares percent p53 positive cells in the non-target pool (siNT) 
to siSPTLC2, siCERS4, and siDEGS2. Percent p53 positive cells was calculated 
using an immunofluorescent p53 readout (p53-FITC), divided by total cell number 
(DAPI). * indicates a p-value ≤0.05 (T-test) for a single representative dataset; 
however this pattern of results was obtained in triplicate. (B) As in (A), however 
histogram shows the ratio of percent p53 positive cells. * indicates a p-value 
≤0.05 (T-test) across 3 biological replicates. (C) Immunofluorescent images show 
the effect of siRNA knocdown of sphingolipid synthesis enzymes SPTLC2, 
CERS4, and DEGS2 on p53 accumulation, as quantified in (A) and (B). 
Immunofluroescence shows DAPI (blue) and p53-FITC (green). (D) Western blot 
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Figure 3.9.  siRNA knockdown of de novo sphingolipid synthesis- effect on mRNA 
expression 
(A) Histogram of qRT-PCR data indicates the knockdown efficiency of 
siSPTLC2, siCERS4, and siDEGS2 for their respective genes, as indicated by the 
relative mRNA expression (β-actin). * indicates a p-value ≤0.05 (T-test) for a 
single representative dataset. ND indicates that mRNA was not detected in the 
sample set. (B) Histogram of qRT-PCR data indicates the relative mRNA 
expression (β-actin) of TP53. ns= not significant (T-test). (C) Histogram of qRT-












































































































































































Figure 3.10. Lentiviral shRNA knockdown of metabolic siRNA screen hits 
(A) Histogram of qRT-PCR data indicates the knockdown efficiency of 3 shRNA 
constructs against SPTLC2, CERS4, GBA, and SLC7A11 (n=1). Values are the 
relative mRNA expression (β-actin). (B) Construct number 2 for each of the 
constructs tested in (A) was further analysed for the effect of the knockdown on 
p53 accumulation. Histogram compares the percent p53 positive cells in the 
empty vector (e.v) to shRNA knockdown of SPTLC2, CERS4, GBA, and 
SLC7A11 (n=3). Percent p53 positive cells was calculated using an 
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Figure 3.11. Retroviral shRNA knockdown of of de novo sphingolipid synthesis- 
effect on protein level 
(A) Western blot compares p53 accumulation in the empty vector (e.v) to 
shDEGS2 and shSPTLC2 (n=1). (B) Western blot compares p53 accumulation in 
the empty vector (e.v) to shCERS4 (n=3). (C) Western blot compares CAD 


























































































































Knockdown of each of the target genes was validated by qRT-PCR. Relative mRNA 
expression was reduced by over half using shSPTLC2 construct 2, and this was 
selected as the strongest construct (figure 3.12A). DEGS2 mRNA was reduced to 
undetectable levels in all four shRNA constructs (figure 3.12A). CERS4 mRNA was 
reduced by over 80 percent in the single construct tested (figure 3.12B). The effect of 
shCERS4 on TP53 and CDKN2A mRNA expression was also tested and showed no 
significant differences (figure 3.12C and D respectively). This suggested that 
shRNA-mediated knockdown of SPTLC2 and CERS4 blocked MYC-driven p53 
accumulation at the protein level, as opposed to blocking TP53 transcription.   
 
SPT is the first and rate-limiting enzyme in de novo ceramide synthesis, which 
synthesises the sphingosine backbone (reviewed in Eljamil et al. 2015). Three main 
SPT subunits have been identified in human tissues, of which SPTLC2 and SPTLC3 
contain pyridoxal-binding motifs required for catalytic activity (Hornemann et al. 
2006, 2007). SPTLC1 in complex with either SPTLC2 or SPTLC3 associates with a 
third small subunit SPTSSB. Overexpression of SPT subunits was hypothesised to 
potentially increase de novo ceramide synthesis, and thereby increase p53 
accumulation; however retroviral overexpression constructs of SPTLC1, SPTLC2 or 
SPTSSB did not alter p53 accumulation compared to the empty vector control (figure 
3.13). However, overexpression of each of the target genes was not validated by 
mRNA expression or by western blot.  
 
ORMDL2 was identified as the fourth strongest hit during the loss of function 
siRNA screen. ORMDL proteins are negative regulators of de novo ceramide 
synthesis, and knockdown of ORMDL2 therefore increased p53 accumulation (table 
3.3). Mammalian ORMDL proteins are orthologues of the yeast Orm proteins (Orm 
1/2), which negatively regulate SPT in response to changes in cellular ceramide 
levels (Breslow et al. 2010; Han et al. 2010; Liu et al. 2012). Overexpression of 
ORMDL2 was hypothesised to decrease SPT activity, reduce de novo sphingolipid 
synthesis, and reduce p53 accumulation. Overexpression of ORMDL2 was validated 
by western blot (figure 3.14). Surprisingly, ORMDL2 overexpression increased p53 
and p21 levels in MYC deregulated cells, and also increased p21 levels in Vec 
control cells (rather than decreased as expected). As ORMDL2 knockdown and 
overexpression both increased p53 levels it is likely that ORMDL proteins have other 
cellular roles independent of SPT regulation.   
 
Retroviral overexpression of CERS4 moderately increased p53 accumulation 
compared to the empty vector (figure 3.15A). Interestingly, CERS4 overexpression 
strongly increased TP53 mRNA expression both in Vec control and Myc cells (>15-
fold and >50-fold respectively; figure 3.15B). This indicates that overexpression of 
CERS4 engages an alternative p53 response involving the transcriptional activation 
of p53 to that driven by MYC deregulation. Overexpression of CERS4 was validated 
by LC-MS using a 2,3-13C-serine heavy isotope label to trace de novo ceramide 
synthesis (figure 3.15C). Uptake of the M+2 label into ceramide with FA chain 
lengths 18:0, 20:0, and 22:0 was increased in Vec and Myc cells that overexpressed 
CERS4 compared to the empty vector. Synthesis of ceramide 18:1, 20:0 was the most 





Figure 3.12. Retroviral shRNA knockdown of of de novo sphingolipid synthesis- 
effect on mRNA expression 
Histograms show qRT-PCR data. Values are the relative mRNA expression (β-
actin). (A) Histogram indicates the knockdown efficiency of 2 shRNA constructs 
against SPTLC2, and 4 constructs against DEGS2. (B) Histogram indicates the 
knockdown efficiency of shCERS4. Error bars are the standard error (n=3). * 
indicates a p-value≤0.05 comparing e.v with shCERS4. Statistics were carried out 
on a single dataset. (C) Histogram compares the mRNA expression of TP53 in e.v 
to shCERS4. Error bars are the standard error (n=3). (D) Histogram compares the 




































































































































































































Figure 3.13.  Stable overexpression of serine palmitoyl transferase subunits 
Histogram compares the percent p53 positive cells in the empty vector (e.v) to 
retroviral overexpression of  serine palmitoyl transferase subunits SPTLC1, 
SPTLC2, and SPTSSB. Percent p53 positive cells was calculated using an 





















































Figure 3.14.  Stable overexpression of ORMDL2 
Western blot shows overexpression of ORMDL2 (ORMDL2+), and the effect this 


































Figure 3.15.  Stable overexpression of ceramide synthase 4 
(A) Histogram compares the percent p53 positive cells in the empty vector (e.v) 
to retroviral overexpression of CERS4. Percent p53 positive cells was calculated 
using an immunofluorescent p53 readout (p53-FITC), divided by total cell 
number (DAPI). (B) Histogram of qRT-PCR data indicates the relative mRNA 
expression (β-actin) of TP53. The ratio of Vec/e.v is compared to all other 
conditions. (C) The histogram shows percent change in M+2 labeling (from a 48 
hr 2,3-C13-serine pulse) between e.v and CERS4+. The x-axis indicates the 
ceramide FA (fatty acid) chain length of a ceramide with a 18:1 sphingosine 
backbone. An increase in M+2 labeling validates CERS4 overexpression and 



























































































































10% in Vec cells and 20% in Myc cells. This validated CERS4 overexpression, and 
indicated the specificity of this enzyme for C18 to C22 FA chain lengths, as 
previously described (Sassa and Kihara, 2014).  
 
3.3 Mitochondrial and endoplasmic reticulum stress 
 
As mentioned above, at the same time as the primary metabolic siRNA screen was 
carried out in this study, Liu et al. (2014b) reported a genome-wide siRNA screen 
with overlapping hits in sphingolipid metabolism (figure 3.16). Liu et al. used 
antimycin A treatment to disrupt mitochondrial function, and looked for siRNAs that 
disrupted activation of mitochondrial chaperone genes hsp-6 and hsp-60 in C.elegans 
(GRP75 in humans). Due to the similarity in screen hits it is highly plausible that 
MYC deregulation and sphingolipid remodelling may induce mitochondrial stress. 
MYC deregulation increased GRP75 positive cells by immunofluorescent staining 
(figure 3.17A and B). Induction of GRP75 following MYC deregulation was 
observed more clearly by western blot where GRP75 levels clearly increased (figure 
3.17C). This may indicate the sphingolipid remodelling at the mitochondrion 
contributes to p53 accumulation.  
 
As de novo sphingolipid synthesis occurs at the endoplasmic reticulum (ER), the 
effect of MYC deregulation on ER chaperone gene GRP78 was also tested by 
western blot. MYC deregulation had no clear effect on GRP78 levels, probably 




Based upon a large metabolic loss of function siRNA screen, this chapter outlines the 
identification of two key clusters of metabolic enzymes that regulate the p53 
response to MYC deregulation. Knockdown of enzymes involved in sphingolipid 
synthesis, particularly de novo ceramide synthesis, decreased p53 accumulation. This 
was with the exception of ORMDL2 whose knockdown increased p53 accumulation; 
however ORMDL2 is described to negatively regulate SPT and therefore validates 
this cluster of sphingolipid hits (Breslow et al. 2010). Knockdown of a second 
cluster of enzymes involved in FA biosynthesis, particularly arachidonic acid 
synthesis, increased p53 accumulation. This indicates that reduction of arachidonate 
metabolism may be metabolically stressful in MYC deregulated cells, as described 
previously (Hall et al. 2016).  
 
Several hits in both functional clusters were validated using individual siRNAs 
targeting each gene, as opposed to siRNA pools. De novo ceramide synthesis 
enzymes SPTLC2, CERS4, and DEGS2, as well as FA synthesis enzymes ALOX15B 
and PECR, were validated in this manner. FA-responsive transcription factor PPARγ 
was also validated, indicating that PPARγ may be a key sensor of MYC-driven FA 
















Liu et al. screen hits 
p53 screen hits 
#	 Gene product	 Homo sapiens gene	 C.elegans gene	
1	 Serine palmitoyl transferase	 SPTLC2	 sptl-1, sptl-3	
2	 ORMDL sphingolipid biosynthesis regulator	 ORMDL2	 -	
3	 Ceramide synthase	 CERS4*	 hyl-2, hyl-1, lagr-1	
4	 Dihydroceramide desaturase	 DEGS2	 -	
5	 Sphingomyelinase	 -	 asm-3	
6	 Ceramidase	 -	  	
7	 Ceramide kinase	 -	  	
8	 Sphingosine kinase	 SPHK1	 sphk-1	
9	 Glucosylceramidase	 GBA	 -	
- gene not identified as a hit in this screen 
* gene not identified in the primary siRNA screening process but later validated as a screen hit  
Figure 3.16.  Diagram of sphingolipid hits and corresponding genes that 
overlapped between the primary siRNA screen and a genome wide siRNA screen 
in C.elegans 
Diagram compares sphingolipid hits from the primary siRNA screen and a 
genome-wide siRNA screen published by Liu et al. (2014b). Liu et al. used 
antimycin A treatment (a mitochondrial complex III inhibitor) to induce 
mitochondrial stress, and looked for hits whose knockdown blocked induction of 
mitochondrial chaperone genes in C.elegans. Sphingolipid enzymes identified as 
hits in either screen are indicated by a coloured dot (see key), and the number 
corresponds to the gene product indicated in the table below the diagram.  


















Figure 3.17. Mitochondrial stress response	
(A) The immunofluorescent images show levels of mitochondrial chaperone 
protein GRP75 following MYC activation and/or treatment with antimycin A, 
which inhibits mitochondrial complex III and thereby induces mitochondrial 
stress. (B) The histogram quantifies levels of GRP75 protein in the images from 
A. Error bars are the standard error (n=3). (C) The western blot shows levels of  
GRP75 and endoplasmic reticulum chaperone protein GRP78 in response to MYC 
activation. MYC-target gene CAD verifies MYC activation.  
Vec Myc Vec Myc 






























less clear. Knockdown of PGAM4, OGDH, and malate dehydrogenase 2 (MDH2) 
were validated to decrease p53 accumulation, while knockdown of ALDOB 
increased p53 accumulation. These enzymes are likely to be important for acetyl-
CoA synthesis.  
 
Stable shRNA knockdown of SPTLC2, CERS4, and DEGS2, was tested to give 
further insight into the role of de novo ceramide synthesis in regulating p53. 
Knockdown of SPTLC2 was initially successful (as measured by reduced mRNA 
expression), and reduced p53 protein levels without affecting protein levels of MYC-
target gene CAD (Grandori and Eisenman, 1997). This indicated that MYC-driven 
ceramide synthesis was regulating p53 accumulation, as opposed to reducing MYC 
overexpression.  
 
Following several passages, shRNA knockdown of SPTLC2 no longer reduced p53 
protein levels, indicating that SPTLC2 was either compensated for or selected 
against. SPTLC2 and SPTLC3 have different acyl-CoA specificities for palmitoyl-
CoA (C16-CoA) or mysristoyl (C14-CoA) and lauryl-CoA (C12-CoA) respectively 
(Hornemann et al. 2009). Ceramides with 18:1 backbones (derived from C16-CoA) 
are predominantly synthesised in mammalian cells (Hanada et al. 2000); however it 
is not clear whether SPTLC3 may compensate for SPTLC2 following its knockdown. 
It is possible that SPTLC3 can initially compensate for SPTLC2, but is eventually 
selected against. Concomitantly, Ruangsiriluk et al. (2012) documented no decrease 
in ceramides following silencing of SPTLC2 or SPTLC3, while silencing all three 
SPT enzymes reduced ceramide levels. This could explain why overexpression of 
SPTLC1, SPTLC2 or SPTSSB alone had no affect on p53 accumulation.  
 
Retroviral shRNA knockdown of CERS4 reduced CERS4 mRNA expression, and 
MYC deregulated cells had reduced levels of p53 protein. CERS adds a fatty acyl-
CoA to the sphinganine backbone, and six CERS enzymes confer different chain 
length specificities. CERS1 uses C18-CoA (Venkataraman et al. 2002), CERS2 uses 
C22-C24-CoAs (Laviad et al. 2008), CERS3 uses ≥C26-CoAs (Mizutani et al. 
2006), CERS4 uses C18-C22-CoAs (Riebeling et al. 2003), and CERS5 and CERS6 
mainly use C16-CoAs (Mizutani et al. 2005). In keeping with this, overexpression of 
CERS4 only increased the synthesis of ceramides with C18-C22 FA residues. 
Knockdown of CERS4 reproducibly reduced p53 protein levels, indicating CERS4 
knockdown may be tolerable due to the small group of ceramides it catalyses, while 
still sufficient to affect p53 accumulation.  
 
Stable shRNA knockdown of DEGS2 strongly reduced DEGS2 mRNA expression 
but had no effect on p53 protein level. Ruangsiriluk et al. (2012) reported that 
silencing DEGS1 is sufficient to reduce ceramides to a similar extent as that of 
silencing all three SPT enzymes. This demonstrates that DEGS1 is the predominant 
desaturase enzyme in mammalian cells; however it is unclear why siRNA 
knockdown of DEGS2 was not also compensated for by DEGS1, or why DEGS1 




Knockdown of SPTLC2, CERS4 or DEGS2 decreased p53 protein, but did not affect 
TP53 mRNA expression. This indicates that de novo ceramide synthesis positively 
regulates p53 accumulation at the protein level. The following chapters investigate 
whether p53 protein is stabilised in response to MYC-driven lipid and fatty acid 





























4 Chapter 4- MYC-driven metabolite changes 
	
This chapter presents data focused upon untargeted and targeted metabolite analyses 
to interrogate MYC-driven changes in metabolic pathways with particular focus 
upon MYC-driven fatty acid (FA) changes. Understanding the effect of MYC 
activation on FA synthesis was of particular importance due to the functional 
annotation of one of the two major screen clusters in this pathway. Further, as 
ceramides (components of the other major cluster) are synthesised from two fatty 
acyl-CoAs, FA synthesis also feeds directly into this cluster. Finally, this chapter 
investigates the effect of p53 loss on MYC-driven metabolite changes (using a p53 
dominant negative construct), to address the hypothesis that loss of p53 gives MYC 
activated cells a metabolic advantage.  
 
4.1 Untargeted analysis of MYC-driven metabolic flux 
 
Stable heavy isotope labelling was used as a tool to measure flux through metabolic 
pathways (reviewed in Chokkathukalam et al. 2014). Cells were pulsed with U-13C-
glucose or a dual 15N-amide-glutamine and 13C5-glutamine isotope label for 6 hr 
before metabolite extraction. X13CMS software was used to compare Vec and Myc 
cells and identify significant changes (p≤0.05) in percent labelling of metabolites 
driven by MYC activation (summarised in figure 4.1). X13CMS software was used 
for the analysis because it compares percent labelling of ions between two biological 
conditions in an untargeted manner, allowing for identification of flux through 
pathways not typically included in targeted analyses (Huang et al. 2014). MYC 
activation moderately increased labelling of lactate (1.4 fold-change) from U-13C-
glucose, and targeted analysis of glycolysis revealed an increase in label 
incorporation into pyruvate (1.3 fold-change) in Myc cells (table 4.1). This indicated 
that MYC drives glycolysis, although perhaps not to the extent suggested previously 
from MYC target genes (Osthus et al. 2000).  
 
Further targeted analysis following U-13C-glucose labelling showed that MYC 
activation significantly increased labelling of the serine synthesis pathway (SSP), as 
determined by increased label incorporation into serine and glycine (4.2 and 6 fold-
change respectively). Untargeted analysis of 15N-amide-glutamine incorporation 
revealed MYC activation strongly increased synthesis of nucleotides, nucleosides, 
and nucleobases; and further targeted analysis identified nucleotide-based lipid 
precursors, CDP-ethanolamine, CDP-choline, and UDP-glucose, to also be 
significantly labelled in Myc cells (table 4.2; p≤ 0.05). CDP-choline and CDP-
ethanolamine are used to synthesise glycerolipids, fitting with the broader 
classification of siRNA screen hits in lipid biosynthesis. UDP-glucose is used to 	  
synthesise glycosphingolipids and is also important for protein glycosylation. 
Nucleotides ATP and UTP, as well as UDP-glucose, were also identified as hits from 
the U-13C-glucose untargeted analysis, strengthening these hits due to the overlap 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4.1. Untargeted analysis of U-13C-glucose incorporation 
Table summarises isotope tracer analysis following a 6 hr U-13C-glucose pulse. 
X13CMS software was used to identify ions with 13C incorporation, then the 
percent label incorporation in Vec and Myc samples was compared to identify 
significant changes. X13CMS hits that significantly increased or decreased in 
Myc are indicated in the first panel of the table. Predominant isotopologue, ratio 
of Vec to Myc percent label, and pvalue (T-test) are also indicated. Significant hits 
were taken for further processing to verify peak integrity. Peak area was then 
extracted and normalised to total ion count (TIC). The normalised results are 
indicated in the second panel of the table. The third panel ‘Normalised pathway 
analysis hit’ shows metabolites that were not pulled out by X13CMS, but were in 
the same pathway as a metabolite that was a hit. The panel indicates that these 
metabolites had a p-value ≤0.05 following normalisation.  
X13CMS hits 
Increased in Myc 
Metabolites Predominant isotopologue Ratio p-value 
Lactic acid M+3 1.5 0.002 
Acetyl-alanine M+5 2.0 ≤0.001 
Glutamic acid M+2 1.5 0.001 
Acetyl-glutamic acid M+2 11.7 ≤0.001 
Acety-methionine M+2 1.2 ≤0.001 
Uridine triphosphate  M+5 1.2 0.001 
Adenosine triphosphate  M+6 1.2 ≤0.001 
Uridine disphosphate-glucose M+11 1.1 ≤0.001 
Decreased in Myc 
Acetyl-aspartyl-glutamic acid M+11 10.57 ≤0.001 
Normalised X13CMS hits 
Increased in Myc 
Metabolites Predominant isotopologue Ratio p-value 
Lactic acid M+3 1.4 0.010 
Acetyl-alanine M+5 1.9 ≤0.001 
Glutamic acid M+2 1.5 0.004 
Acetyl-glutamic acid M+2 3.0 ≤0.001 
Acetyl-methionine M+2 1.2 ≤0.001 
Uridine triphosphate  M+5 1.1 ≤0.001 
Adenosine triphosphate  M+6 1.2 ≤0.001 
Uridine disphosphate-glucose M+11 1.1 ≤0.001 
Decreased in Myc 
Acetyl-aspartyl-glutamic acid M+11 5.62 ≤0.001 
Normalised pathway analysis hits 
Increased in Myc 
Metabolites Predominant isotopologue Ratio p-value 
Pyruvic acid M+3 1.3 ≤0.001 
Alanine M+3 1.5 ≤0.001 
Glycine M+2 6.0 ≤0.001 
Serine M+3 4.2 ≤0.001 
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Table 4.2. Untargeted analysis of 15N-amide-glutamine incorporation 
Table summarises isotope tracer analysis following a 6 hr 15N-amide-glutamine 
pulse. X13CMS software was used to identify ions with 15N incorporation, then 
the percent label incorporation in Vec and Myc samples was compared to identify 
significant changes. X13CMS hits that significantly increased or decreased in 
Myc are indicated in the first panel of the table. Predominant isotopologue, ratio 
of Vec to Myc percent label, and pvalue (T-test) are also indicated. Where the ratio 
reads Inf, this indicates that the percent label in Vec was below the threshold of 
detection giving an infinite ratio. Significant hits were taken for further processing 
to verify peak integrity. Peak area was then extracted and normalised to total ion 
count (TIC). The normalised results are indicated in the second panel of the table. 
The third panel ‘Normalised pathway analysis hit’ shows metabolites that were 
not pulled out by X13CMS, but were in the same pathway as a metabolite that 
was a hit. The panel indicates that these metabolites had a p-value ≤0.05 following 
normalisation.  
	 X13CMS hits 
Metabolites Predominant isotopologue Ratio p-value 
Uracil M+1 Inf. (0 in control) 
Orotic acid M+1 Inf. (0 in control) 
Cys-Gly M+1 Inf. (0 in control) 
Inosine M+1 Inf. (0 in control) 
Uridine monophosphate M+1 Inf. (0 in control) 
Uridine diphosphate M+1 Inf. (0 in control) 
Uridine diphosphate-acetyl-glucosamine M+1 1.2 0.033 
Normalised X13CMS hits 
Metabolites Predominant isotopologue Ratio p-value 
Uracil M+1 29.5 ≤0.001 
Orotic acid M+1 2.1 0.005 
Cys-Gly M+1 Inf. (0 in control) 
Inosine M+1 Inf. (0 in control) 
Uridine monophosphate M+1 Inf. (0 in control) 
Uridine diphosphate M+1 3.3 ≤0.001 
Uridine diphosphate-acetyl-glucosamine M+1 1.2 ≤0.001 
Normalised pathway analysis hits 
Metabolites Predominant isotopologue Ratio p-value 
Uridine triphosphate M+1 1.5 ≤0.001 
Cytidine diphosphate M+1 Inf. (0 in control) 
Cytidine M+1 10.9 ≤0.001 
Cytidine diphosphate-choline M+1 Inf. (0 in control) 
Uridine disphosphate-glucose M+1 2.3 ≤0.001 
Cytidine diphosphate-ethanolamine M+1 10.2 ≤0.001 
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Incorporation of 13C5-glutamine into the TCA cycle was observed in Vec and Myc 
cells (figure 4.2); however untargeted analysis of this label did not reveal any 
significant differences between the two cell types. This was unexpected as MYC 
activation clearly increased incorporation of glutamine-derived amide into nucleotide 
biosynthesis  (see above), which also generates glutamate. One possibility is that 
increased glutamate synthesised during nitrogen donation is rapidly metabolised into 
downstream pathways that were not detected by X13CMS (such as glutathione 
metabolism).   
 
Several studies of MYC target genes have indicated enzymes involved in nucleotide 
biosynthesis are required for MYC-driven cell proliferation (Liu et al. 2008; 
Mannava et al. 2008; Cunningham et al. 2014), and these isotope tracer experiments 
clearly demonstrate that MYC drives a demand for nucleotide biosynthesis that is 
met by glucose-derived carbon (through the pentose phosphate pathway) and 
glutamine-derived amine donation. Importantly these experiments also revealed that 
MYC activated cells increase synthesis of nucleotide-based lipid precursors, which 
may be indicative of increased lipid synthesis in MYC activated cells.  
 
4.2 MYC-driven fatty acid changes 
 
Several de novo FA biosynthesis enzymes have been identified as MYC target genes 
(Zeller et al. 2003; Loven et al. 2012), however as shown above no FAs were 
significantly labelled by a 6 hr U-13C-glucose pulse (table 4.1). This was likely 
because a large proportion of glucose-derived carbon was used in early glycolytic 
pathways (such as the pentose phosphate pathway and serine synthesis pathway) 
rather than being converted into pyruvate (for FA synthesis) further down glycolysis. 
To determine the effect of MYC activation on de novo FA synthesis, Vec or Myc 
cells were pulsed with 13C3-pyruvate over a timecourse of 2, 4, or 8 hr (figure 4.3). 
All metabolites were then normalised to a 100 percent pyruvate label at timepoint 2 
hr, which allowed visualisation of percent label incorporation as a ‘pulse chase’ style 
experiment. 13C3-pyruvate was added at a concentration of 1 mM to cells otherwise 
cultured in pyruvate-free medium. Labelled pyruvate was rapidly taken up into Vec 
or Myc cells at 2 hr and the percentage of labelled pyruvate decreased over the 
timecourse in both cell types, indicating rapid consumption and depletion of the 
labelled pyruvate. This transient labelling pattern was observed for lactate, citrate, 
and α-ketoglutarate, demonstrating flux of the label into downstream pathways. 
 
MYC activated cells increased synthesis of lactate compared to control cells, in 
keeping with activation of the MYC target gene LDHA, and the untargeted U-13C-
glucose pulse described above (Shim et al. 1997). Synthesis of citrate was 
consistently increased in MYC activated cells across the timecourse, in contrast to  
synthesis of α-ketoglutarate, which was only significantly increased at 2 hr. At 2 hr 
there was no significant difference in palmitate (FA 16:0) or lignocerate (FA 24:0) 
synthesis between control and MYC activated cells. However, at 4 hr MYC activated 
cells significantly increased palmitate synthesis, and subsequently at 8 hr MYC 
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Figure 4.2. 13C5-glutamine labelling of the TCA cycle 
Schematic shows the percent labelling of Vec or Myc cells from a 6 hr 13C5-
glutamine pulse. Purple spots indicate the incorporation of labelled carbons (M+4 
or M+5) into newly synthesised metabolites. Data is plotted relative to a 100% 










































































































































































































































































































































































































































































































































































that MYC-drives de novo FA synthesis in preference to directing carbon into the 
TCA cycle. Further, MYC-activated cells particularly increased synthesis of 
lignocerate, which occurs from shuttling palmitate to the endoplasmic reticulum 
where it is elongated by elongase enzymes (ELOVLs). MYC-driven synthesis of 
lignocerate fits with the specificity of screen hit ELOVL1 for FA of chain lengths 
C22-C26 (Ohno et al. 2010).  
 
Total levels of FAs were also analysed to determine the effect of MYC activation on 
FA remodelling. MYC activation significantly depleted levels of palmitate and 
lignocerate (figure 4.3), and this was true for the majority of saturated fatty acids 
(SFA), monounsaturated fatty acids (MUFAs), and polyunsaturated fatty acids 
(PUFAs) (figure 4.4A-C), such that median FA content almost halved (figure 4.5A). 
This indicates that MYC drives the synthesis of FAs and their remodelling into 
downstream pathways. In keeping with increased FA synthesis, MYC-activated cells 
also showed increased levels of 4-phospho-pantothenate, an intermediate in the CoA 
synthesis pathway (figure 4.5B).  
 
FAs are used in the cell for anabolic pathways such as glycerophospholipid or 
sphingolipid synthesis, and for storage through triacylglycerol synthesis, fitting with 
the broader classification of screen hits in ‘lipid metabolism’. FAs can also be 
catabolised by fatty acid oxidation (FAO) to generate ATP; however FAO does not 
typically occur at the same time as de novo FA synthesis (McGarry et al. 1978), 
which was shown above to be increased in MYC activated cells.   
 
Over one third of siRNA screen hits whose knockdown increased MYC-driven p53 
accumulation clustered in arachidonate metabolism, suggesting that arachidonate 
metabolites negatively regulate p53. Levels of arachidonic acid (FA 20:4) and 
arachidonic acid-derived FAs docosapentanoic acid (FA 22:5) and docosahexanoic 
acid (FA 22:6) were all significantly lowered following MYC activation (figure 
4.4C). Docosahexanoic acid treatment was previously shown to result in its 
incorporation into membrane glycerophospholipids (Zerouga et al. 1996), indicating 
that MYC activation may drive remodeling of arachidonate metabolites into 
glycerophospholipid synthesis. This fits with the first results presented in this chapter 
that MYC activation drives the synthesis of phospholipid precursors CDP-choline and 
CDP-ethanolamine (for de novo phosphatidylcholine and phosphatidylethanolamine 
synthesis respectively). Further analysis of MYC-driven lipid synthesis is 
documented in chapter 5. 
 
Whilst the majority of FAs were depleted in MYC activated cells, several longer 
chain FAs and PUFAs were increased (figure 4.4A-C). This indicates that either 
MYC activated cells are not remodeling these FAs downstream, or that the synthesis 
of these FAs is rapid enough to maintain levels of the FA substrate. FAs can be 
classified into several groups relating to their chain length: for example long-chain 
FAs (LCFAs) have chain lengths of C11-C20, very long-chain FAs (VLCFAs) have 
chain lengths >C20, and ultra long-chain FAs have chain lengths ≥C26. In particular, 
MYC activation significantly increased levels of ULC SFAs 26:0 and 28:0 (figure 
















































































































Figure 4.4.  MYC-driven changes in SFAs, MUFAs and PUFAs 
Histograms show the average fold change in SFAs (saturated fatty acids; (A)), 
MUFAs (monounsaturated fatty acids; (B)), and PUFAs (polyunsaturated fatty 
acids; (C)) between Vec and Myc. Error bars are the standard error (n>3). * 
indicates a p-value ≤0.05 comparing the average fold change of Vec with Myc (T-
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Figure 4.5.  MYC-driven changes in total FA content 
(A) Histogram shows the average median FA content of >3 biological replicates. 
(B) Histogram shows the average fold change between Vec and Myc of 5 
biological replicates. Error bars are the standard error (n>3). * indicates a p-value 
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analysed over a timecourse of 72 hr MYC activation, and were shown to increase 
over the timecourse (figure 4.6). In keeping with the functional annotation of siRNA 
screen hits in sphingolipid synthesis, mammalian cells have been shown to 
predominantly utilise FAs with ≥C24 chain lengths for sphingolipid synthesis (Ohno 
et al. 2010).  This may indicate that MYC activated cells increase synthesis of 
ULCFAs for sphingolipid synthesis. The relevance of MYC-driven FA changes to 
sphingolipid synthesis is explored in chapter 5.   
 
4.3 The effect of p53 loss on MYC-driven metabolite changes  
 
In a typical model of tumour suppression, loss of p53 would be expected to trigger 
apoptosis due to increased cell stress associated with relief of proliferative restraints. 
Counterintuitively, several in vivo studies documented that loss of p53 increases the 
proliferative rate of MYC-driven tumours without affecting apoptosis (Elson et al. 
1995; Hsu et al. 1995; Finch et al. 2006). To explain these findings, we hypothesised 
that loss of p53 facilities remodelling of metabolic pathways in MYC activated cells, 
which supports increased proliferation. This fits with studies showing that p53 and 
MYC have contrasting effects on cell metabolism, favouring catabolic or anabolic 
pathways respectively (reviewed in Kruiswijk et al. 2015 and Dang et al. 2013). To 
investigate this hypothesis, Vec and Myc cells were transfected with a genetic 
suppressor element encoding p53 dominant negative peptide (p53DN) or control, and 
the four conditions were compared by targeted LC-MS analysis (Gallagher et al. 
1997).  
 
p53 loss did not affect median FA content alone or in MYC overexpressing cells 
(figure 4.7), and analysis of  twelve common FAs detected in MRC5 cells showed 
similar patterns regardless of p53 status (figure 4.8A). This was with the exception of 
FA 24:1 (nervonic acid), which significantly increased in p53DN cells (~5-fold 
relative to Vec; p≤0.05, suggesting that p53 negatively regulates FA 24:1. Relative 
levels of FA 24:1 in Myc/p53DN cells compared to Myc cells also increased, 
although this was not statistically significant, indicating that MYC may drive the 
utilisation of FA 24:1 in downstream pathways (such as sphingolipid synthesis).  
 
Analysis of glycolytic metabolites showed no significant difference between Myc 
cells and Myc/p53DN cells in the case of glucose 6-phosphate or fructose 6-
phosphate (figure 4.9A and B respectively), however fructose 1,6-bisphosphate and 
glyceraldehyde 3-phosphate significantly increased (figure 4.9C and D respectively; 
p≤0.05). Levels of lactate significantly decreased in Myc/p53DN cells compared to 
Myc cells (figure 4.9F; p≤0.05), and there was also a small decrease in pyruvate   
 (figure 4.9E), indicating that loss of p53 may promote diversion of upstream 
glycolytic intermediates into anabolic pathways.  
 
Myc/p53DN cells significantly increased PPP metabolites ribose 5-phosphate and 
sedoheptulose 7-phosphate (figure 4.9H and I; p≤0.05), but not 6-phosphogluconate 
(figure 4.9G). This could be because the flux through 6-phosphogluconate is very 































Figure 4.6.  A timecourse of MYC-driven changes in  ULCFAs 
Histogram shows the average fold change in ULCFAs (ultra long chain fatty 
acids) across a 72 hr timecourse of MYC activation with 4OHT compared to Vec 
control. Error bars are the standard error (n=3). * indicates a p-value ≤0.05 
comparing Vec with Myc samples at the specified timepoint (T-test). Statistics 









































Figure 4.7.  Total changes in FA content driven by MYC overexpression and p53 
loss 
Histogram shows the median fold change of 12 common fatty acids between Vec 
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Figure 4.8. FA changes driven by MYC overexpression and p53 loss 
(A) Histogram shows the average fold change of 12 common fatty acids between 
Vec and Myc, p53DN, or Myc/p53DN. Peak areas were normalised to median 
metabolite content prior to fold change calculations. Error bars are the standard 
error (n=3). * indicates a p-value ≤0.05 comparing Vec with Myc (red), Vec with 
p53DN (green), Vec with Myc/p53DN (orange), or Myc with Myc/p53DN 
(purple) (T-test). Statistics were carried out on a single representative dataset. (B) 




































































































































































































































































































































































































































































Figure 4.9. Glycolytic and pentose phosphate pathway changes driven by MYC 
overexpression and p53 loss 
Histograms compare the normalised peak area of the specified metabolite between 
Vec, Myc, p53DN and Myc/p53DN. Peak area was normalised to median 
metabolite content. Error bars are the standard error (n=3). * indicates a p-value 
≤0.05 comparing Vec with Myc (red), Vec with p53DN (green), Vec with Myc/
p53DN (orange), Myc with Myc/p53DN (purple), or p53DN with  Myc/p53DN 
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pharmacological inhibition of downstream enzyme 6-phosphogluconate 
dehydrogenase (figure 4.10). The PPP is a key cytosolic generator of NADPH, and 
Myc/p53DN cells significantly increased levels of NADPH compared to Myc cells 
(figure 4.9J; p≤0.05), in keeping with previous studies showing that p53 inhibits 
NADPH synthesis (Jiang et al. 2011 and 2013). Myc/p53DN cells also exhibited 
significantly increased levels of serine and glycine compared to Myc cells (figure 
4.11A and B respectively; p≤0.05). Intermediates of the pentose phosphate pathway 
and the serine synthesis pathway are used for nucleotide biosynthesis, and levels of 
all nucleotide monophosphates (NMPs) (figure 4.12A-E) and nucleotide 
diphosphates (NDPs) (figure 4.13A-D) significantly increased in Myc/p53DN cells 
compared to all other conditions (p≤0.05). Levels of nucleotide triphosphates (NTPs) 
(figure 4.14A-D) did not significantly change between Myc alone and Myc/p53DN 
cells.  
 
To determine whether nucleotides were being utilised by Myc/p53DN for 
biosynthetic purposes, cells were pulsed with 15N-amide-glutamine and then RNA or 
DNA was extracted and digested into mononucleotides prior to metabolite 
extraction. Heavy isotope label incorporation into RNA-derived NMPs (figure 
4.15A) and DNA-derived dNMPs (figure 4.15B) was significantly increased in Myc 
cells compared to control cells, and significantly increased further in Myc/p53DN 
compared to Myc cells (p≤0.01). Label incorporation into nucleotide-based lipid 
precursors from whole cell metabolite extracts was also analysed and shown to 
follow the same pattern (figure 4.16, p≤0.01). These heavy-isotope tracer 
experiments demonstrated that compared to MYC-activated cells alone, Myc/p53DN 
cells increase synthesis of RNA, DNA, and lipid precursors, confirming that p53 loss 




This chapter has demonstrated that MYC activation increases de novo FA synthesis, 
supporting the cluster of siRNA screen hits in this pathway. MYC activation 
increased palmitate synthesis, but particularly drove the synthesis of lignocerate (FA 
24:0), in keeping with the substrate specificity of screen hit ELOVL1. While 
increasing FA synthesis, MYC overexpression significantly depleted median FA 
content, potentially indicating increased utilisation of FAs in downstream pathways. 
Of the screen hits involved in FA biosynthesis, several of these hits clustered in 
arachidonate metabolism, and MYC overexpression decreased all arachidonic acid. In 
contrast to this, MYC overexpression increased synthesis of several ULCFAs (and 
PUFAs), which may have important roles in sphingolipid synthesis (Ohno et al. 
2010).  
 
In addition to remodelling FA metabolism, untargeted heavy-isotope tracer analysis 
revealed that MYC overexpression drives synthesis of nucleotides, nucleobases, 
nucleosides, and nucleotide-based lipid precursors that may support RNA synthesis, 
DNA synthesis, and phospholipid synthesis. Further targeted analysis revealed MYC 





































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.11. Serine and glycine changes driven by MYC overexpression and p53 
loss 
Histograms compare the normalised peak area of the specified metabolite between 
Vec, Myc, p53DN and Myc/p53DN. Peak area was normalised to median 
metabolite content. Error bars are the standard error (n=3). * indicates a p-value 
≤0.05 comparing Vec with Myc (red), Vec with p53DN (green), Vec with Myc/
p53DN (orange), Myc with Myc/p53DN (purple), or p53DN with  Myc/p53DN 







































































































































Figure 4.12. Nucleotide monophosphate 
changes driven by MYC overexpression 
and p53 loss 
Histograms compare the normalised 
peak area of the specified metabolite 
between Vec, Myc, p53DN and Myc/
p53DN. Peak area was normalised to 
median metabolite content. Error bars 
are the standard error (n=3). * indicates 
a p-value ≤0.05 comparing Vec with 
Myc (red), Vec with p53DN (green), 
Vec with Myc/p53DN (orange), Myc 
with Myc/p53DN (purple), or p53DN 
with  Myc/p53DN (black) (T-test). 
Statistics were carried out on a single 
















































































































































































































Figure 4.13. Nucleotide diphosphate changes driven by MYC overexpression and 
p53 loss 
Histograms compare the normalised peak area of the specified metabolite between 
Vec, Myc, p53DN and Myc/p53DN. Peak area was normalised to median 
metabolite content. Error bars are the standard error (n=3). * indicates a p-value 
≤0.05 comparing Vec with Myc (red), Vec with p53DN (green), Vec with Myc/
p53DN (orange), Myc with Myc/p53DN (purple), or p53DN with  Myc/p53DN 




















































































































































































Figure 4.14. Nucleotide triphosphate changes driven by MYC overexpression and 
p53 loss 
Histograms compare the normalised peak area of the specified metabolite between 
Vec, Myc, p53DN and Myc/p53DN. Peak area was normalised to median 
metabolite content. Error bars are the standard error (n=3). * indicates a p-value 
≤0.05 comparing Vec with Myc (red), Vec with p53DN (green), Vec with Myc/
p53DN (orange), Myc with Myc/p53DN (purple), or p53DN with  Myc/p53DN 



































































































































































































































Figure 4.15. Heavy isotope labeling of RNA and DNA synthesis 
Histograms show percent label incorporation from a 12 hr 15N-amide-glutamine 
pulse into RNA or DNA synthesis. (A) RNA was extracted prior to metabolite 
extraction to show the percent label incorporation into RNA synthesis. (B) DNA 
was extracted prior to metabolite extraction to show the percent label 
incorporation into DNA synthesis. Error bars are the standard error (n=3). * 
indicates a p-value ≤0.01 comparing Vec cells  with Myc cells or Myc cells with 
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Figure 4.16. Heavy isotope labeling of nucleotide-based lipid precursors 
Histogram shows percent label incorporation from a 12 hr 15N-amide-glutamine 
pulse into 3 nucleotide-based lipid precursors. The predominant isotopologue 
(displayed) is M+1 for UDP-glucose, and M+2 for CDP-choline and CDP-
ethanolamine. Error bars are the standard error (n=3). * indicates a p-value ≤0.01 
comparing Vec cells  with Myc cells or Myc cells with Myc/p53DN cells (T-test). 

































































































Myc/P53DN /   p
	
99	
pathways, the pentose phosphate pathway (PPP) and the serine synthesis pathway 
(SSP), that have previously been shown to support nucleotide biosynthesis, one-
carbon metabolism, and subsequently tumourigenesis (reviewed in Locasale, 2013). 
MYC overexpression combined with p53 loss significantly accumulated 
intermediates in the PPP, SSP, and in nucleotide biosynthesis compared cells that 
overexpress MYC alone. Further, Myc/p53DN cells increased label incorporation 
into RNA synthesis, DNA synthesis, and synthesis of nucleotide-based lipid 
precursors. These data show that loss of p53 does indeed result in metabolic 
remodeling in MYC-overexpressing cells, which may support increased proliferation 
associated with p53 loss.  
 
The following chapter will build upon these results and outline the effect of MYC 
































5 Chapter 5- MYC-driven lipid changes 
 
By coupling a large metabolic loss of function siRNA screen and metabolic analysis, 
the previous chapters have indicated that cells expressing deregulated MYC may 
remodel sphingolipid and phospholipid metabolism. Chapter 3 outlined the 
functional annotation of siRNA screen hits in lipid metabolism, within which two 
major clusters involved in fatty acid synthesis/arachidonate metabolism and 
sphingolipid biosynthesis were identified. Chapter 4 presented results demonstrating 
that cells expressing deregulated MYC increase de novo fatty acid (FA) synthesis, 
particularly of longer-chain FAs, and remodel FAs (including arachidonic acid) into 
downstream pathways. This chapter investigates the effect of MYC deregulation on 
sphingolipid and phospholipid remodelling with the hypothesis thay MYC 
deregulation changes these pathways.  
 
5.1 MYC-driven changes in sphingolipids 
 
To determine the effect that MYC overexpression has on the cellular compartment of 
sphingolipid species, lipid extractions were carried out on Vec and Myc cells and 
analysed by LC-MS. A correlation network was created to look for distinct clusters 
of sphingolipids that changed following MYC activation. This method was selected 
to allow more subtle changes within the sphingolipid network to be identified due to 
co-clustering of similar species, which may have been missed by carrying out a one-
way ANOVA alone. Of over 50 sphingolipid species analysed, including ceramides, 
dihydroceramides, hexosylceramides and lactosylceramides, 2 distinct clusters 
formed in the correlation network (figure 5.1) whose separation was statistically 
significant (Fisher’s test; p=1.7x10-6). The majority of sphingolipid species 
decreased in response to MYC activation but a cluster of 6 sphingolipid species with 
longer ≥C24 FA residues increased. The sphingolipid species in this cluster included 
ceramides and lactosylceramides, and several individual species were found to 
significantly increase in addition to the cluster as a whole (one-way ANOVA; p 
≤0.05).  
 
The initial results of the correlation network were repeated three times, and 
representative histograms were plotted to show the total levels (figure 5.2A) and the 
fold change between Vec and Myc for 12 common ceramide species (figure 5.2B). 
Ceramides with <C24 FA residues consistently decreased in response to MYC 
activation, while ceramides with ≥C24 FA residues consistently increased. 
Ceramides and lactosylceramides with ≥C24 FA residues have previously been 
described to have important structural and signalling roles at cell membranes (Sassa 

































Figure 5.1. Correlation network of MYC-driven sphingolipid changes 
The correlation network depicts clusters of sphingolipid species that change 
following MYC activation. Lipid peak areas were quantile normalised in R using 
peak areas of >150 lipids from sphingolipid and phospholipid subclasses.  A one-
way ANOVA was carried out on normalised sphingolipid peak areas comparing 
Vec and Myc samples, and FDR-corrected, significant (p≤0.05) sphingolipids 
were highlighted in the correlation network by thicker node borders. Log2 fold 
change between Vec and Myc was represented by node colour, as indicated by the 
key. An asterisk at the end of a lipid name indicates that more than one isomer of 
the lipid was identified across a single chromatographic peak.  
Log2 fold change values were used to calculate spearman correlation values, and 
weak correlations were removed using mixture modeling (threshold ~0.5). 
Correlation values were attributed to edge weights and imported into Cytoscape 
where the MCODE plugin was used to identify clusters of correlation within the 
network. Positive correlations were colour coded as green edges, and negative 
correlations were colour coded as red edges. A force-directed layout was used to 
separate clusters for visualisation. Fisher’s test was carried out to determine if 
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Figure 5.2. MYC-driven changes in sphingolipids 
The histogram shows peak areas of 12 ceramide species normalised to median 
lipid content. Error bars are the standard error (n=3). * indicates statistical 
significance of a single representative dataset (p≤0.05). The same pattern of 
results was observed in 3 biological replicates. (B) The histogram shows the log2 
fold change between Vec and Myc for each ceramide specie detected in (A) to 
















































Ceramide 18:1 FA residue 
A 
B 





5.2 MYC-driven changes in phospholipids 
 
In addition to sphingolipid synthesis, FAs may be utilised in acylglycerols such as 
triacylglycerols (TGs), or for synthesis of phosphatidic acid and other 
glycerophospholipids including phosphatidylethanolamines (PEs) or 
phosphatidylcholines (PCs) (reviewed in Eljamil, 2015). Analysis of TGs showed 
MYC activation significantly increased levels of several TG species (one-way 
ANOVA; p<0.05), to the extent that Vec and Myc samples formed two distinct 
hierarchical clusters (figure 5.3). TGs are an important store of FAs that can be 
released from lipid droplets in times of need. Two enzymes involved in FA storage 
and release were identified as screen hits whose knockdown decreased p53 
accumulation. This could indicate that TG-derived FAs are used for sphingolipid 
synthesis. Glycerol-3-phosphate acyl transferase 2 (GPAT2) condenses a fatty acyl-
CoA with glycerol-3-phosphate to synthesise lysophosphatidic acid (LPA). Lipase E 
(also known as Hormone Sensitive Type) hydrolyses a FA from TG in the second of 
three reactions catalysed by distinct enzymes. As knockdown of both the synthesis 
and release of TGs decreases MYC-driven p53 accumulation, TG remodelling may 
have biological significance in MYC-deregulated cells.  
 
PEs also clustered separately according to MYC status, and all PEs that significantly 
changed were increased compared to Vec (figure 5.4; one-way ANOVA; p≤0.05). Of 
the PCs that significantly changed (one-way ANOVA; p≤0.05), 2 hierarchical 
clusters formed based on those that increased or decreased (figure 5.5). Almost all 
PCs that increased in Myc samples comprised at least one docosahexanoic acid 
(DHA; 22:6) residue. Two PE species that significantly increased in Myc samples 
also comprised a DHA residue, and one of the PE species contained an arachidonic 
acid (AA) residue (one-way ANOVA; p≤0.05). This confirmed that MYC activated 
cells deplete polyunsaturated fatty acids, due their utilisation in glycerophospholipid 
synthesis. DHA treatment has been documented to affect membrane structure and 
function by increasing membrane fluidity, permeability, vesicular fusion, elastic 
compressibility, and flip-flop rate (reviewed in Stillwell and Wassall, 2003). In 
keeping with the changes in sphingolipid synthesis, this may indicate that MYC 
activation specifically drives an accumulation of glycerophospholipid species that 
can alter membrane structure and function.  
 
5.3 MYC-driven changes in lipid synthesis 
 
The previous sub-sections outlined MYC-driven changes in total lipid levels. 
Moving forwards, stable heavy-isotope labelling was used to measure lipid synthesis. 
As serine is condensed with palmitoyl-CoA at the first step of de novo sphingolipid 
synthesis it was hypothesised that stable heavy-isotope labelled serine could be used 
to measure the rate of de novo ceramide synthesis. At the same time as MYC 
activation with 4-hydroxytamoxifen (4OHT), cells were pulsed with 2,3-13C-serine 
for 48 hr prior to lipid extraction and analysis by LC-MS. Incorporation of serine-
derived carbon was approximately doubled in Myc samples compared to Vec 
samples across 6 common ceramide species detected in MRC5 cells (figure 5.6). 
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Figure 5.3. MYC-driven changes in triacylglycerides 
The heat map shows hierarchical clustering on the y-axis, and clustering of 4 
biological replicates of Vec and Myc on the x-axis. Values are the log2 fold 
change calculated on quantile normalised peak areas for each lipid. The heat map 
in the top right hand corner displays the raw peak area for each lipid. A one-way 
ANOVA was carried out on all lipid subclasses identified in figure 1, and lipids 
with a p-value≤0.05 are indicated in bold. Data was acquired using an Orbitrap 
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Figure 5.4. MYC-driven changes in phosphatidylethanolamines 
The heat map shows hierarchical clustering on the y-axis, and clustering of 4 
biological replicates of Vec and Myc on the x-axis. Values are the log2 fold 
change calculated on quantile normalised peak areas for each lipid. A one-way 
ANOVA was carried out on all lipid subclasses identified in figure 1, and lipids 
with a p-value≤0.05 are indicated in bold. Due to space constraints, only 
significant phosphatidylethanolamine species have been displayed in this 
heatmap. Data was acquired using an Orbitrap Fusion Lumos Tribrid Mass 
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Figure 5.5. MYC-driven changes in phosphatidylcholines 
Heat map shows hierarchical clustering on the y-axis, and clustering of 4 
biological replicates of Vec and Myc on the x-axis. Values are the log2 fold 
change calculated on quantile normalised peak areas for each lipid. A one-way 
ANOVA was carried out on all lipid subclasses identified in figure 1, and lipids 
with a p-value≤0.05 are indicated in bold. Due to space constraints, only 
significant phosphatidylcholine species have been displayed in this heatmap. Data 
was acquired using an Orbitrap Fusion Lumos Tribrid Mass Spectrometer, and 
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Figure 5.6. Stable-isotope labeling of de novo ceramide synthesis 
(A) Histogram shows 2,3-13C-serine labeling of the six predominant ceramide 
species in MRC5 cells. *indicates a pvalue≤0.05 (T-test) comparing Vec and Myc 
percent labeling in a single representative biological replicate. (B) Histogram 
shows heavy isotope serine labeling of ceramide (18:1, 24:1). *indicates a p-




























This indicated that MYC drives de novo sphingolipid synthesis at almost twice the 
rate of control cells, in keeping with results from chapter 3 that showed de novo 
sphingolipid enzymes were required for MYC-driven p53 accumulation. 
 
To gain further insight into synthesis of sphingolipids and glycerophospholipids, a 
simultaneous 15N-serine, 15N-ethanolamine, and 15N-choline stable heavy-isotope 
labelling timecourse was carried out. Following 48 hr MYC activation with 4OHT, 
cells were labelled for 2, 4, 8, or 24 hr prior to metabolite or lipid extraction. This 
meant that at 24 hr labelling MYC had been activated for 72 hr. Cellular 
incorporation of serine (as measured by percent labelling of serine; figure 5.7A) and 
ethanolamine (as measured by percent labelling of phosphoethanolamine; figure 
5.7C) was very rapid, meaning Vec and Myc cells were both fully labelled at 2 hr. 
Incorporation of choline (as measured by percent labelling of phosphocholine; figure 
5.7B) occurred gradually over 8 hr and was slightly increased in Myc cells.  
 
MYC deregulated cells showed consistently increased label incorporation across the 
timecourse compared to Vec control cells (figure 5.8), and this trend was significant 
in sphingolipids with longer ≥C22 FA residues (one-way ANOVA; p<0.05). In 
contrast, label incorporation into PEs or PCs showed a similar trend in MYC 
deregulated and control cells (figure 5.9 and 5.10 respectively), indicating that while 
some phospholipid changes were significant they may not be biologically significant 
(one-way ANOVA; p<0.05). These data indicate that MYC deregulated cells strongly 
increase de novo ceramide synthesis, while only moderately affecting phospholipid 
synthesis, in keeping with the major cluster of screen hits in sphingolipid 
biosynthesis. 
 
Sphingolipid and glycerophospholipid metabolism converges at the synthesis of 
sphingomyelins (SMs), which are important plasma membrane components 
(reviewed in Eljamil, 2015). The summed contribution of heavy-isotope from 
ceramide and either PE or PC was calculated to investigate whether MYC drives SM 
synthesis. Synthesis of SMs at 24 hr was similar in Vec and Myc samples, however 
percent labelling of several SM species did significantly change across the 
timecourse (figure 5.11). There was no clear hierarchical clustering of SMs based on 
FA chain length or desaturation. This result is possibly unexpected as MYC 
deregulation clearly increases de novo ceramide synthesis; however it is possible that 
ceramides are being remodelled into other downstream pathways (such as the 
salvage pathway, ceramide phosphate synthesis, or glycosphingolipid synthesis, see 
figure 6.2A).  
 
5.4 Summary   
 
In summary, this chapter has demonstrated that MYC deregulation remodels 
sphingolipid and phospholipid metabolism, which may have important biological 
consequences. Data presented in chapter 3 showed that de novo sphingolipid 
synthesis was required for MYC-driven p53 accumulation, indicating that p53 
somehow responds to this pathway. Concomitantly, this chapter presents data 
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Figure 5.7. Stable-isotope labeling timecourse of sphingolipids and 
glycerophospholipids 
Hisotgrams show percent label incorporation of 15N-serine into serine (A), 15N-
choline into phosphocholine (B), and 15N-ethanolamine into phosphoethanolamine 
(C). Media was pulsed with heavy isotope at time point 0 hr, 48 hr after Myc 
activation, and metabolites were extracted at 0 hr, 2 hr, 4 hr, 8 hr, and 24 hr. Due 
to the presence or absence of natural abundance metabolite in the media, 15N-
serine in the pulse media was at ¾ label, 15N-choline at ⅔ label, and 15N-
ethanolamine at 100% label. The dashed black line on each graph indicates 
















































Figure 5.8. Stable-isotope labeling timecourse of de novo ceramide synthesis 
The heatmap shows hierarchical clustering of ceramide species across a 15N-serine 
labeling time course of 0 hr to 24 hr. Media was pulsed with heavy isotope at time 
point 0 hr, 48 hr after MYC activation, and lipids were extracted at 0 hr, 2 hr, 4 hr, 
8 hr, and 24 hr. Data was acquired using an Orbitrap Fusion Lumos Tribrid Mass 
Spectrometer, and lipids were identified using LipidSearch. Values are fold-
change in average percent label (n=3-4). A one-way ANOVA was carried out on 
all ceramide species, and lipids with a p-value ≤0.05 across the time course are 
indicated in bold. An asterisk at the end of a lipid name indicates that more than 
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Figure 5.9. Stable-isotope labeling timecourse of phosphatidylethanolamine 
synthesis 
The heatmap shows hierarchical clustering of phosphatidylethanolamine (PE) 
species across a 15N-ethanolamine labeling time course of 0 hr to 24 hr. Media 
was pulsed with heavy isotope at time point 0 hr, 48 hr after MYC activation, and 
lipids were extracted at 0 hr, 2 hr, 4 hr, 8 hr, and 24 hr. Data was acquired using an 
Orbitrap Fusion Lumos Tribrid Mass Spectrometer, and lipids were identified 
using LipidSearch. Values are the average percent label for a lipid at a given time 
point (n=3-4). A one-way ANOVA was carried out on all PE species, and lipids 
with a p-value ≤0.05 across the time course are indicated in bold. An asterisk at 
the end of a lipid name indicates that more than one isomer of the lipid was 
identified across a single chromatographic peak. Due to space constraints, only 
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Figure 5.10. Stable-isotope labeling timecourse of phosphatidylcholine synthesis 
The heatmap shows hierarchical clustering of phosphatidylcholine (PC) species 
across a dual 15N-choline and 15N-ethanolamine labeling time course of 0 hr to 24 
hr. Media was pulsed with heavy isotope at time point 0 hr, 48 hr after MYC 
activation, and lipids were extracted at 0 hr, 2 hr, 4 hr, 8 hr, and 24 hr. Data was 
acquired using an Orbitrap Fusion Lumos Tribrid Mass Spectrometer, and lipids 
were identified using LipidSearch. Values are the average percent label for a lipid 
at a given time point (n=3-4). A one-way ANOVA was carried out on all PC 
species, and lipids with a p-value ≤0.05 across the time course are indicated in 
bold. An asterisk at the end of a lipid name indicates that more than one isomer of 
the lipid was identified across a single chromatographic peak. Due to space 
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Figure 5.11. Stable-isotope labeling timecourse of sphingomyelin synthesis 
The heatmap shows hierarchical clustering of sphingomyelin (SM) species across 
a dual 15N-serine, 15N-choline and 15N-ethanolamine labeling time course of 0 hr 
to 24 hr. Media was pulsed with heavy isotope at time point 0 hr, 48 hr after MYC 
activation, and lipids were extracted at 0 hr, 2 hr, 4 hr, 8 hr, and 24 hr. Data was 
acquired using an Orbitrap Fusion Lumos Tribrid Mass Spectrometer, and lipids 
were identified using LipidSearch. SM species can be labeled by  15N derived 
from 15N-serine, as well as 15N derived from either 15N-choline or 15N-
ethanolamine.  Values are the summed (M+1 and M+2) average percent label for a 
lipid at a given time point (n=3-4). A one-way ANOVA was carried out on all SM 
species, and lipids with a p-value ≤0.05 across the time course are indicated in 
bold. An asterisk at the end of a lipid name indicates that more than one isomer of 
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demonstrating that MYC deregulated cells potently drive de novo ceramide synthesis 
at almost twice the rate of control cells. This was demonstrated at 48 hr MYC 
activation (the same time-point used to measure p53 accumulation), and was also 
shown to persist 24 hr beyond this time-point. Whilst MYC-driven ceramide 
synthesis showed no FA chain length specificity, analysis of total levels of 
sphingolipid revealed an accumulation of ceramides with longer ≥C24 FA residues 
following 48hr MYC activation. This is in keeping with results from chapter 4 that 
showed MYC drives an accumulation of longer ≥C26 FAs.  
 
In addition to sphingolipid remodelling, MYC deregulated cells remodelled 
phospholipid species. In particular, PC species that comprised at least one DHA 
residue (FA 22:6) increased, and these lipids clustered separately from lipids with 
other FA chain lengths or desaturation level.  These results differ from lipid 
remodelling in response to MYC overexpression documented by Hall et al. (2016) 
who found increased incorporation of AA, not DHA, into PCs. Several studies have 
demonstrated that treatment with polyunsaturated FAs (such as DHA) has profound 
effects on mitochondrial membrane phospholipid composition and mitochondrial 
function due to incorporation of DHA into phospholipid species (reviewed in Stanley 
et al. 2014). Moreover, treatment with a mixture of DHA and EPA (eicosapentaenoic 
acid, 20:5) was shown to improve mitochondrial tolerance to Ca2+-induced 
mitochondrial permeability transport pore (MPTP) opening (O’Shea et al. 2009). 
This may indicate that MYC deregulated cells promote remodelling of 
polyunsaturated FAs (including DHA) into phospholipids to delay MPTP opening as 
a result of MYC-induced mitochondrial stress. 
 
As presented in chapter 3, the metabolic siRNA screen results presented here clearly 
overlapped with a genome-wide siRNA screen in C.elegans looking for regulators of 
the mitochondrial stress response (Liu et al. 2014b). Multiple sphingolipid 
biosynthesis enzymes were identified in both siRNA screens (figure 3.16). 
Furthermore, MYC deregulated cells were shown to increase levels of mitochondrial 
chaperone gene GRP75, the mammalian equivalent of the readout of the C.elegans 
screen. Together with the data presented in this chapter, these data indicate that p53 
responds to MYC-driven lipid remodelling at the mitochondria.  
 
Finally, MYC deregulation potently accumulated TGs of varying lengths and levels 
of desaturation, which may be hydrolysed during periods of high-energy demand to 
generate precursors for sphingolipid and phospholipid synthesis (reviewed in 
Coleman and Lee, 2004). The following chapter will give further mechanistic insight 
into how MYC-driven remodelling of FAs, phospholipids, and sphingolipids 








6 Chapter 6- Perturbation of p53 accumulation 
	
The previous chapters have demonstrated that MYC activation drives fatty acid and 
lipid remodelling that regulates MYC-driven p53 accumulation. MYC-driven 
synthesis of sphingolipids was required for p53 accumulation, and this chapter 
documents further mechanistic insight into how ceramide positively regulates p53. 
This includes perturbation of downstream sphingolipid pathways and known 
ceramide signalling targets (see subsections below).  
 
While de novo ceramide synthesis positively regulated p53 (meaning knockdown of 
ceramide synthesis enzymes blocked full p53 accumulation), knockdown of FA 
synthesis enzymes or PPARγ increased p53 accumulation. The majority of FA 
synthesis enzymes identified as siRNA screen hits were involved in arachidonate 
metabolism (figure 6.1), including ELOVL7 (fatty acid elongase 7), which shows 
high specificity for linolenic acid (Ohno et al. 2010), the substrate for de novo 
arachidonic acid synthesis; as well as PLA2G1B (phospholipase A2 group IB) and 
PLA2G4B (phospholipase A2 group IVB), which hydrolyses membrane 
glycerophospholipids to release arachidonic acid (Dennis and Norris, 2015). The fact 
that knockdown of de novo synthesis and release pathways of arachidonic acid 
increased MYC-driven p53 accumulation implicates the key role of arachidonate 
metabolism in regulating p53 (as one pathway does not compensate for the other).  
 
Polyunsaturated Fas, including AA and DHA, were previously described to activate 
PPARγ (figure 6.1; Kliewer et al. 1997), which was one of the strongest siRNA 
screen hits. Analysis of FA remodeling driven by MYC deregulation showed that 
AA, DPA, and DHA all significantly decreased compared to extracts from control 
cells (figure 4.4C). We therefore hypothesised that PPARγ negatively regulates p53 
in response to MYC-driven FA remodeling. To investigate this hypothesis this 
chapter documents experiments that perturb PPARγ activity and FA metabolism (see 
subsections below).  
 
6.1 Perturbation of sphingolipid metabolism 
 
In chapter 3 it was demonstrated that knockdown of de novo sphingolipid enzymes 
blocked full p53 accumulation, while overexpression of CERS4 increased p53 
accumulation beyond the level driven by MYC deregulation. Small molecule 
inhibitors that perturbed sphingolipid metabolism were tested for their effect on p53 
accumulation. These inhibitors were selected to cover 5 key sphingolipid pathways: 
de novo synthesis, sphingomyelin hydrolysis, glycosphingolipid, salvage, and 
ceramide phosphate (figure 6.2A). Four of the inhibitors tested are known to block 
the remodeling of ceramide into downstream pathways, and were shown to increase  
 
MYC-driven p53 accumulation in a dose-dependent manner (except perhaps for 
Miglustat hydrochloride) (figure 6.2Bi-iv). The remaining three compounds are 
reported to inhibit ceramide synthesis, and had no clear effect on MYC-driven p53 
accumulation (figure 6.2Ci-iii). Of the compounds tested, ceranib 1 and NVP-231 
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Figure 6.1.  siRNA screen hits in arachidonate metabolism and PPARγ signalling  
The diagram depicts primary siRNA screen hits involved in arachidonate 
metabolism (highlighted in green). PLA2G1B and PLA2G4B enocode 
phospholiase A2s that degrade membrane glycerophospholipids to release 
arachidonic acid. Arachidonic acid may be used to synthesise eicosinoid HETE 
(hydroeicosatetraenoic acid) for leukotriene synthesis by ALOX12 and ALOX15B. 
Arachidonate metabolites were previously described to activate PPARγ (Kliewer 
et al. 1997), as indicated by the dashed line. As knockdown of PPARγ increased 
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Figure 6.2. The effect of sphingolipid pathway inhibitors on p53 accumulation 
(A) The diagram summarises five key sphingolipid pathways: De novo, 
Sphingomyelin hydrolysis, Glycosphingolipid, Salvage, and Ceramide phosphate. 
Dashed arrows indicate multiple enzymatic steps, and arrow head indicates the 
direction of the reaction. Small molecule inhibitors tested for their effect on P53 
stabilisation are indicated in lower case blue (myr= Myriocin, fb1= Fumonisin B1, 
mh= Miglustat hydrochloride,  cbe= Conduritol B Epoxide (CBE), cer1= Ceranib 
1, ski1= Sphingosine Kinase Inhibitor-1 (SKI-1), nvp= NVP-231). Ceranib 1, 
NVP-231, Miglustat, and SKI-1 inhibit ceramide remodeling into downstream 
pathways; while Myriocin, Fumonisin B1, and CBE inhibit ceramide synthesis. 
(B) Histograms shows concentration responsive effects of the indicated drug on 
percent p53 positive cells. Where no error bar is shown n=1. All inhibitors in (B) 
inhibit ceramide remodeling into downstream pathways. (C) Histograms shows 
concentration responsive effects of the indicated drug on percent p53 positive 
cells. Where no error bar is shown n=1, otherwise n=3. All inhibitors in (C) inhibit 
ceramide synthesis. (D) The histogram compares percent p53 positive cells in 
vehicle to treatment with Ceranib 1 or NVP-231. These drugs were selected as 
having the greatest effect on p53 accumulation from the dose response histograms 






had the strongest effect on p53 accumulation, and these compounds are known to 
function by blocking the conversion of ceramide to sphingosine or ceramide to 
ceramide phosphate respectively. The optimal concentration of these inhibitors (as 
determined from the dose-dependent effects on percent p53 positive cells) was 
further tested and shown to significantly increase p53 accumulation (figure 6.2D). 
These results indicate that it was the accumulation of ceramide in general that 
exacerbated MYC-driven p53 accumulation, as opposed to a particular downstream 
pathway. However, further analysis to validate that the compounds inhibit the 
pathway they are documented to is required, for example myriocin (an SPT inhibitor) 
does not recapitulate that results seen with siRNA or shRNA knockdown of SPT 
(Wadsworth et al. 2013).  
 
Sphingosine-1-Phosphate (S1P), which is synthesised from sphingosine downstream 
of ceramide, was previously described to regulate cell growth (Zhang et al. 1991) 
and suppress programmed cell death (Cuvillier et al. 1996) through its interaction 
with G-protein-coupled-receptors (GPCRs). To test whether S1P signaling effects 
MYC-driven p53 accumulation a panel of S1P receptor agonists and antagonists 
were tested across a range of relevant concentrations. Of the 7 small molecules tested 
there was no clear effect on p53 accumulation, indicating that S1P signaling through 
the S1P receptors does not affect the p53 response to MYC overexpression (figure 
6.3).  
 
6.2 Ceramide signalling 
 
Several proteins have been shown to interact with ceramide that may offer 
mechanistic insight into how p53 responds to deregulation of MYC via de novo 
ceramide synthesis. These include protein phosphatases such as protein phosphatase 
1 (PP1) and protein phosphatase 2A (PP2A) (Chalfant et al. 1999, 2004), as well as 
protein kinase C zeta (PKCζ) (Müller et al. 1995; Bourbon et al. 2002). The effect of 
MYC deregulation on PP1A and PP2AC was investigated by western blot (figure 
6.4). MYC deregulation did not clearly affect PP1A levels, but increased levels of 
PP2AC (PP2A catalytic subunit). The effect of protein phosphatase and PKCζ 
knockdown on p53 was analysed by immunofluorescent staining (figure 6.5), and 
knockdown of PP1A subunits PPP1CA or PPP1CC had no effect on p53 
accumulation, while knockdown of PP2A catalytic subunit PPP2AC moderately 
decreased p53 accumulation (p≤0.05). Knockdown of PRKC2 had no effect on p53 
accumulation. These results indicate that PP2A may be involved in regulating p53 in 
response to MYC-driven de novo ceramide synthesis. 
 
Small molecule inhibitors of protein phosphatases and PKCζ were also tested. 
Okadaic acid was previously shown to inhibit PP1 (IC50 = 3 - 15 nM) and PP2A 
(IC50 = 0.1-1 nM) (Mailhes et al. 2003), and was hypothesised to decrease p53 
accumulation similarly to siPPP2AC at lower doses. Okadaic acid significantly 
reduced MYC-driven p53 accumulation at a concentration known to inhibit PP2A (1 
nM; figure 6.6A), and showed a trend towards increasing p53 higher concentrations 
known to inhibit PP1 (15 nM). The reduction in p53 accumulation with low dose 
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Figure 6.3. The effect of sphingosine-1-phosphate signaling perturbation on p53 
accumulation 
Histogram shows the effect of a panel of sphingosine-1-phosphate receptor 
agonists and antagonists on p53 accumulation across an appropriate concentration 
range. Two vehicle controls were included due to the different drug solubilities; 
however no significant difference on percent p53 positive cells was detected. This 





































































































Figure 6.4. The effect of Myc activation on Protein Phosphatases 
Western blot shows the effect of MYC activation on PP1A and PP2AC following 










Figure 6.5.  Knockdown of protein phosphatases and protein kinase C zeta 
Histogram compares percent p53 positive cells in the non-target pool (siNT) to 
siRNA knockdown of PP1CA, PPP1CC, PPP2CA,  and PRKCZ. Error bars are 
the standard error (n=3). * indicates a significant p-value (≤0.05; T-test). Statistics 





























































Figure 6.6.  Small molecule inhibitors of protein phosphatases and protein kinase 
C zeta 
Histograms shows the dose response effect of protein phosphatase inhibitor 
Okadaic acid (A) and protein kinase C zeta inhibitor PKCζ pseudosubstrate 
compared to control. Okadaic acid was previously shown to inhibit PP1 (IC50 = 3 - 
15 nM) and PP2A (IC50 = 0.1-1 nM). Error bars are the standard error (n=3). * 
indicates a significant p-value (≤0.05; T-test). Statistics were carried out on a 
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okadaic acid was similar to the reduction seen with siPPP2AC (see above), thereby 
validating the siRNA results. PKCζ pseudosubstrate did not affect MYC-driven p53 
accumulation as expected from the siRNA knockdown experiments described above 
(figure 6.6B).  
 
Overall these analyses suggest that PP2A regulates p53 accumulation in response to 
MYC-driven de novo ceramide synthesis; however as the reduction in p53 
accumulation was not as striking as that seen with knockdown of de novo ceramide 
synthesis enzymes, PP2A is unlikely to be the sole regulator of the p53 response to 
increased de novo ceramide synthesis. 
 
6.3 Fatty acids and PPARγ 
 
As knockdown of enzymes involved in FA biosynthesis (particularly arachidonic 
acid synthesis) augmented MYC-driven p53 accumulation, it was hypothesised that 
addition of unsaturated FAs might reduce MYC-driven p53 accumulation. A panel of 
10 unsaturated FAs with a range of chain lengths and levels of desaturation were 
tested, and only arachidonic acid (20:4) significantly reduced p53 accumulation in a 
conecentration-dependent manner (figure 6.7A and B). Linolenic acid (18:3), but not 
linoleic acid (18:2), also showed a trend toward decreased p53 accumulation with 
increasing treatment concentration. Linoleic and linolenic acid are essential FAs in 
mammals due to lack of the desaturase required for their synthesis.  
 
As knockdown of PPARG augmented MYC-driven p53 accumulation it was 
hypothesised that PPARγ negatively regulates p53 (figure 6.1). PPARγ ligand 
Rosiglitazone was shown to significantly reduce MYC-driven p53 accumulation in a 
concentration-dependent manner (figure 6.8A and B). Concomitantly, PPARγ 
antagonist T0070907 significantly increased p53 accumulation in a concentration-
dependent manner (figure 6.8A and B). These experiments demonstrate that PPARγ 
activity regulates p53. Furthermore, deregulation of MYC potently reduced levels of 
PPARγ compared to control cells (figure 6.9A), suggesting that MYC may activate 
p53, at least in part, through depletion of PPARγ and consequent reduction in its 
negative regulation of p53.  
 
Rosiglitazone was also tested alongside knockdown of SPTLC2, CERS4, DEGS2, 
and PPP2CA to investigate whether these pathways were additive in terms of 
regulating p53 accumulation (figure 6.9B). Knockdown of SPTLC2, CERS4, and 
DEGS2 had no additional effect on p53 accumulation following rosiglitazone 
treatment, while knockdown of PPP2CA slightly decreased p53 accumulation. The 
effect of shRNA knockdown of CERS4 on PPARγ was tested by western blot and 		
while shCERS4 reduced p53 levels, this was not accompanied by an increase in 
PPARγ levels (figure 6.10). These results indicate that regulation of p53 by PPARγ 
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Figure 6.7. The effect of fatty acid treatment on p53 accumulation 
(A) Histogram shows dose responsive effects of unsaturated fatty acid (FA) 
treatment on percent p53 positive cells. Cells were treated with vehicle control or 
the indicated FA concentration at the same time as MYC was activated with 4OHT 
for 48 hr. Error bars are the standard error (n=3). * indicates a significant p-value 
(≤0.05; T-test). Statistics were carried out on a single biological replicate. (B) 
Immunofluorescent images show the effect of linolenic acid or arachidonic acid 
treatment on p53 accumulation, as quantified in (A). Immunofluroescence shows 











Figure 6.8.  The effect of PPARγ perturbation on p53 accumulation 
(A) Immunofluorescent images show the effect of PPARγ ligand Rosiglitazone 
(1000 nM) and PPARγ antagonist T0070907 (100 nM) on p53 stablilsation. 
Immunofluroescence shows DAPI (blue) and p53-FITC (green). (B) Histogram 
shows dose responsive effects on percent p53 positive cells of Rosiglitazone and 
T0070907. Drugs were added at the same time as 4OHT treatment for 48 hr. Error 
bars are the standard error (n=3). * indicates a significant p-value (≤0.05; T-test). 


















































Figure 6.9.  The effect of MYC activation on PPARγ 
(A) The western blot shows the effect of MYC activation on PPARγ  and p53 
alone (no drug), as well as with 48 hr Rosiglitazone or T0007907 treatment (100 
nM) (n=3). Drugs were added at the same time as 4OHT treatment for 48 hr. (B) 
The western blot shows the effect of SPTLC2, CERS4, DEGS2, or PPP2CA 
knockdown on p53 accumulation plus/minus 48 hr Rosiglitazone treatment (100 
nM) (n=1). All samples were extracted from MRC5 cells following 48hr MYC 






















































































Figure 6.10.  The effect of CERS4 knockdown on PPARγ and p53 
Western blot shows the effect of CERS4 shRNA knockdown on PPARγ  and p53 



































In summary, data are presented in this chapter that further validate two major clusters 
of siRNA screen hits involved in fatty acid biosynthesis/arachidonate metabolism 
and de novo ceramide synthesis. MYC-driven de novo ceramide synthesis positively 
regulates p53, and whether this was due to a downstream target of ceramide 
signalling or ceramide remodelling was investigated. Analysis of known targets of 
ceramide signalling revealed that PP2A was required for full p53 accumulation in 
response to MYC deregulation; however knockdown or pharmacological inhibition of 
PP2A did not reduce p53 accumulation to the same extent as knockdown to de novo 
ceramide synthesis enzymes. This indicates that PP2A may be one of multiple 
proteins that regulate p53 accumulation in response to MYC-driven de novo 
ceramide synthesis.  
 
The role of ceramides as intermediates in sphingolipid metabolism was analysed 
using pharamacological inhibitors. Of the compounds tested, ceranib 1, which blocks 
the conversion of ceramide to sphingosine, and NVP-231, which blocks the 
conversion of ceramide to ceramide phosphate, potently increased MYC-driven p53 
accumulation. Downstream of sphingosine, sphingosine-1-phosphate receptor 
ligands or antagonists were tested for their effect on p53 accumulation. The 
compounds had no effect on p53 accumulation, indicating that increased p53 
accumulation caused by ceranib 1 was due to increased ceramide levels, not 
inhibition of ceramide conversion into sphingosine-1-phosphate downstream. This 
finding agrees with MYC deregulated cells increasing de novo ceramide synthesis, 
but disagrees with the observation that MYC deregulated cells deplete total ceramide 
levels, indicating that p53 may respond to compartment specific increases in 
ceramide synthesis driven by MYC overexpression.  
 
In keeping with knockdown of PPARγ/arachidonate metabolism increasing MYC-
driven p53 accumulation, PPARγ activity was shown to negatively regulate p53. 
Deregulation of MYC depleted levels of AA, DPA, DHA, and PPARγ, which 
indicates that MYC-driven depletion of PPARγ and its ligands may be sufficient to 
relieve its inhibition of p53 and result in p53 accumulation. As AA, DPA, and DHA 
were previously documented to regulate PPARγ (Kliewer et al. 1997), PPARγ may 
be a key sensor of MYC-driven FA changes. Concomitantly, treatment with AA (but 
not other unsaturated FAs) reduced MYC-driven p53 accumulation. Finally, 
knockdown of de novo ceramide synthesis enzymes did not affect PPARγ levels, 
indicating that these two metabolic pathways independently regulate MYC-driven 








7 Chapter 7- Discussion 
	
Activation of the MYC oncogene drives cell proliferation and cell growth, and these 
attributes lead to its frequent overexpression or amplification in human cancer 
(Koskinen and Alitalo, 1993). In otherwise genetically intact cells, overexpression of 
MYC activates the p53 tumour suppressor pathway, which resists cell cycle 
progression (Finch et al., 2006; Hermeking and Eick, 1994). Despite decades of 
research, no transcriptional target of MYC has been found that mediates p53 
pathway activation. Furthermore, the contrasting effects of MYC and p53 on cell 
metabolism fit with a homeostatic model, whereby p53 responds to MYC-driven 
metabolic changes. Whilst MYC target genes indicate MYC remodels metabolic 
pathways towards anabolism (reviewed in Dang, 2013), p53 has been documented to 
promote catabolic pathways that favour restoration of cellular energy charge and 
redox status (reviewed in Kruiswijk et al. 2015). Loss of p53 is frequently selected 
for in a variety of tumours (Eischen et al. 1999; Hill et al. 2015) and tumour cell 
lines (Farrell et al. 1991; Wiman et al. 1991), and p53-null tumours are characterised 
by increased proliferation with no marked effect on apoptosis (Elson et al. 1995; Hsu 
et al. 1995; Finch et al. 2006). This indicates that loss of p53 may also alleviate 
increased cell stress associated with relief of proliferative inhibition. In addition to 
p53 responding to MYC-driven metabolic changes, we further hypothesised that p53 
loss conferred a metabolic advantage to MYC overexpressing cells. 
 
A large loss-of-function metabolic siRNA screen was carried out to determine 
whether metabolic enzymes, transporters, and transcription factors regulated p53 
accumulation in response to MYC activation. Functional annotation of 36 siRNAs 
revealed two key clusters of hits involved in FA synthesis/arachidonate metabolism 
and sphingolipid synthesis. Importantly, these were very specific areas of 
metabolism relative to the broad range of metabolic pathways targeted by the siRNA 
library. Knockdown of sphingolipid enzymes, particularly those involved in de novo 
ceramide synthesis, prevented p53 accumulation; indicating that ceramide positively 
regulates p53. Knockdown of enzymes involved in long-chain FA elongation and 
arachidonic acid metabolism augmented p53 accumulation, implicating long-chain 
FAs as negative regulators of p53. Knockdown of FA-responsive PPARγ (reviewed 
in Desvergne and Wahli, 1999), a master regulator of lipid homeostasis (reviewed in 
Lehrke and Lazar, 2005), was one of the strongest hits that exacerbated p53 
accumulation, providing further evidence of the importance of fatty acid and lipid 
remodelling in regulating the p53 response to MYC activation.  
 
Targetted metabolomic analysis revealed that loss of p53 increased the biosynthetic 
capacity of MYC deregulated cells. Myc/p53DN cells increased synthesis of pentose 
phosphate pathway intermediates, including pentose 5-phosphate, and intermediates 
of the serine synthesis pathway. These intermediates were used to increase synthesis 
of nucleotides, nucleosides, and nucleobases. Further analysis of the fate of 
nucleotides showed p53 loss increased RNA synthesis, DNA synthesis, and lipid 
precursor synthesis in MYC deregulated cells, supporting the hypothesis that loss of 




7.1 Sphingolipid synthesis 
 
Sphingolipids are a functionally diverse class of lipids that all share a sphingosine 
backbone. Modification of this basic structure gives rise to multiple sphingolipid 
species including ceramides, ceramide phosphates, glycosylsphingolipids, 
sphingosine-1-phosphate, and sphingomyelins (which also contain a 
glycerophospholipid-derived component). Of these species, much research has 
focused on ceramides due to their key role as membrane components, as 
intermediates in the metabolism of more complex sphingolipids, and as signalling 
molecules (reviewed in Goñi and Alonso, 2006). Ceramides are some of the least 
polar and more hydrophobic lipids in membranes and have been shown to increase 
the molecular order, lateral phase separation, and domain formation of phospholipid 
bilayers (Holopainen et al. 1997; Hsueh et al. 2002). Lipid microdomains have been 
shown to act as platforms for membrane trafficking and intracellular signalling 
(reviewed in Simons and Ikonen, 1997), highlighting the importance of sphingolipids 
as membrane components. 
 
In this study, knockdown of de novo ceramide synthesis enzymes SPTLC2, CERS4, 
and DEGS2 were shown to reduce p53 accumulation in response to MYC activation. 
Concomitantly, ORMDL2, which negatively regulates SPT, was identified as a hit 
that increases p53 accumulation. SPTLC2, CERS4, and DEGS2 were validated by 
individual siRNAs targeting each gene, by genetic knockdown experiments, and by 
genetic overexpression experiments. Stable-isotope tracer analysis by LC-MS 
showed that MYC overexpression significantly increased de novo ceramide synthesis, 
demonstrating that this is a relevant pathway for p53 to respond to. Further analysis 
of over 50 sphingolipid species revealed that MYC overexpression increased 
ceramides and lactosylceramides with ≥C24 FA residues, while sphingolipids with 
shorter-chain FA residues decreased. 
 
The ability of ceramides to form lipid rafts is in part due to them comprising a long 
fatty acyl chain that can interdigitate with the cytoplasmic leaflet of the bilayer 
(Ohno et al. 2010). Ceramides and latosylceramides with longer ≥C24 FA residues 
were previously implicated in membrane signaling through their interaction with the 
Src family kinase LYN, demonstrating the role of longer-chain ceramides in 
membrane signalling (Sonnino et al. 2009). Ohno et al. (2010) showed that ELOVL1 
was essential for the production of C24 sphingolipids, and ELOVL1 was identified 
as a gene whose knockdown augmented MYC-driven p53 accumulation in the 
siRNA screen. This suggests that inability to synthesise C24 FAs is metabolically 
stressful following MYC overexpression. Ohno et al. (2010) also showed that 
knockdown of ELOVL1 mRNA caused a reduction in the activity of LYN, linking 
long-chain FA elongation to ceramide-mediated signalling. ELOVL1 deficient mice 
die shortly after birth due to epidermal growth barrier defects (Sassa et al. 2013), 
which may be due to decreased levels of ceramides with ≥C26 FA residues detected 
in the epidermis. Together these studies suggest that MYC overexpression drives 




Whilst promotion of ceramide synthesis by MYC is novel, multiple studies have 
shown that ceramides respond to stress stimuli and promote an appropriate response. 
C16 ceramide has been shown to trigger apoptosis in response to ionising radiation 
through increased de novo ceramide synthesis driven by activation of CERS5 and 
CERS6 (Mesicek et al. 2010). A similar response was observed in C.elegans due to 
DNA double-strand breaks (Deng et al. 2008). ER stress was shown to trigger 
apoptosis by both the de novo synthesis of ceramide and increased acid 
sphingomyelinase activity, which hydrolyses ceramide from sphingomyelin (Sauane 
et al. 2010). Saune et al. showed that ceramide triggers apoptosis by activating PP2A 
to dephosphorylate anti-apoptotic protein Bcl-2. Ceramide also has a structural role 
in apoptosis as cytosolic cytochrome C is released from the mitochondria through 
ceramide channels (Colombini, 2010).  
 
Of closer relevance to this study, ceramide has been shown to respond to moderate 
stress and trigger a non-apoptotic response. In C.elegans, a genome-wide siRNA 
screen revealed several hits in sphingolipid metabolism (including de novo 
synthesis), whose knockdown prevented the induction of mitochondrial repair 
pathways in response to mitochondrial stress (Liu et al. 2014b). Liu et al. 
demonstrated the importance of ceramides as mediators of cellular stress in a 
genome-wide context, and thus provided validation of the metabolism-focused 
siRNA screen described here. MYC deregulation was shown to induce mitochondrial 
chaperone gene GRP75 (the readout of the C.elegans screen), but not ER chaperone 
gene GRP78, indicating that MYC deregulation induces mitochondrial stress.  
 
Several downstream targets of ceramide signalling have been described that may be 
important in regulating p53, including protein phosphatases PP1 and PP2A (Chalfant 
et al. 1999, 2004; Dobrowsky et al. 1993), and PKCζ (Müller et al. 1995). MYC 
overexpression was shown to increase protein levels of PP2A, but not PP1, and 
knockdown of the catalytic subunit of PP2A moderately reduced p53 accumulation. 
This was further validated using Okadaic acid, which was previously described to 
inhibit PP2A at low concentrations and reduced p53 levels to a similar extent as 
PP2A knockdown. However, PP2A knockdown or inhibition did not reduce p53 to 
the same extent as knockdown of de novo ceramide synthesis enzymes, suggesting 
that other proteins are involved in regulating p53 in response to increased ceramide 
synthesis. The role of PP2A in regulating p53 may also be context dependent as Ajay 
et al. (2010) showed that inhibition of PP2A activates p53. More studies are required 
to determine the involvement of PP2A in MYC-driven p53 accumulation, and an 
untargeted approach to identify p53 bound proteins following MYC overexpression 
may identify novel players that regulate this process.  
 
The role of ceramides as intermediates in sphingolipid metabolism was analysed 
using pharmacological inhibitors. Of the compounds tested, ceranib 1, which blocks 
the conversion of ceramide to sphingosine, and NVP-231, which blocks the 
conversion of ceramide to ceramide phosphate, potently increased MYC-driven p53 
accumulation. This indicated that either an inability to synthesise downstream 
sphingolipids, or an accumulation of ceramide, was metabolically stressful in MYC 
deregulated cells. Sphingosine-1-phosphate is synthesised from sphingosine 
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downstream of the ceramidase inhibited by ceranib 1, and was previously described 
to regulate cell growth (Zhang et al 1991) and block programmed cell death 
(Cuvillier et al. 1996). Sphingosine-1-phosphate receptor ligands or antagonists had 
no effect on p53 accumulation, indicating that increased p53 accumulation caused by 
ceranib 1 was due to increased ceramide levels. This is supported by CERS4 
overexpression experiments that showed CERS4 overexpression increased de novo 
ceramide synthesis and p53 accumulation (albeit not to the same extent as the 
downstream inhibitors).  
 
The use of pharmacological inhibitors such as ceranib 1 probably exerts cell-wide 
effects on multiple ceramide species, which may explain why ceranib 1 treatment has 
a much stronger effect on p53 accumulation compared to CERS4 overexpression, 
which was specific to C18-C22 ceramide species. Furthermore, while MYC 
overexpressing cells increased de novo ceramide synthesis, the total levels of most 
ceramide species decreased. This may indicate that, in the case of MYC 
overexpression, p53 responds to compartment-specific changes in ceramide 
synthesis, which may only be visualised using stable heavy-isotope tracer analyses as 
opposed to analysing the total cellular ceramide pool. It is possible that cell-wide 
changes in ceramide levels could induce p53 accumulation; however the mechanism 
of how this occurs may be distinct from how MYC-driven de novo ceramide 
synthesis promotes p53 accumulation.  
 
Overall these data clearly demonstrate that MYC overexpression drives de novo 
ceramide synthesis and remodelling of sphingolipid metabolism to specifically 
accumulate long-chain ceramides and lactosylceramides. p53 responds to increased 
de novo ceramide synthesis driven by MYC overexpression, and the mechanism of  
how ceramide regulates p53, and whether this mechanism is cellular compartment-
specific, is yet to be elucidated.  
   
7.2 Fatty acid and glycerolipid synthesis 
 
FAs are used in the cell for lipid biosynthesis, storage, or they can be catabolised by 
fatty acid oxidation (FAO) to maintain energy homeostasis. Cells can acquire FAs 
through the de novo synthesis pathway, through extracellular uptake, or through the 
breakdown of cellular or membrane lipids (reviewed in Eljamil et al. 2015). Multiple 
enzymes involved in FA synthesis were identified as screen hits whose knockdown 
augmented MYC-driven p53 accumulation. This is in keeping with previous research 
on MYC transcriptional targets, which include several de novo FA synthesis 
enzymes ACLY, ACACA, and FAS (Zeller et al. 2003; Loven et al. 2012).  
 
De novo FA synthesis begins with the conversion of pyruvate into acetyl-CoA in the 
mitochondrial matrix, followed by condensation with oxaloacetate to produce citrate. 
MYC target genes ACLY and ACACA then convert citrate to cytosolic acetyl-CoA, 
and acetyl-CoA to malonoyl-CoA respectively. Malonyl-CoA is the 2-carbon donor 
used to synthesise FAs in each round of the elongation cycle. Three genes involved 
in the direction of carbon into acetyl-CoA synthesis were identified as hits that 
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increased MYC-driven p53 accumulation:  aldolase B (ALDOB), dihydrolipoamide 
S-acetyltransferase (DLAT), and phosphopanthothenate cysteine ligase (PPCS). 
ALDOB catalyses the reversible cleavage of fructose 1,6-bisphosphate to 
glyceraldehyde 3-phosphate in the glycolytic pathway, and was identified as the 
second strongest hit in the siRNA screen. ALDOB was likely particularly important 
in the generation of pyruvate because all experiments in this study (unless otherwise 
stated) were carried out in media lacking pyruvate. DLAT encodes component E2 of 
the multi-enzyme pyruvate dehydrogenase complex (PDC) that converts pyruvate to 
acetyl-CoA.  PDC therefore commits pyruvate-derived carbon to the TCA cycle (for 
FA synthesis) as opposed to lactate or alanine production. PPCS converts 
phosphopanthothenate to phosphopantothenyl cysteine in the CoA synthesis pathway 
(Daugherty et al. 2002), and total levels of phosphopantothenate were increased in 
cells with deregulated MYC. 
 
Experiments utilising stable-isotope labelled glucose revealed that MYC 
significantly increased synthesis of pyruvate through glycolysis, and stable-isotope 
labelled pyruvate showed that MYC significantly increased incorporation of 
pyruvate-derived carbon into citrate. These studies confirmed that MYC drives the 
synthesis of metabolites that may be used for de novo FA synthesis.  
 
Synthesis of FAs up to the length of palmitate (C16) occurs in the cytoplasm and is 
catalysed by the MYC target gene FAS (Zeller et al. 2003). Elongation of long-chain 
FAs is localised to the ER and is catalysed by elongase enzymes, of which ELOVL1 
and ELOVL7 were identified as screen hits (reviewed in Eljamil et al. 2015). Stable-
isotope labelled pyruvate was used to measure the rate of de novo fatty acid 
synthesis, and increased incorporation of label was seen in palmitate and lignocerate 
following MYC activation, supporting the necessity of elongase enzymes in MYC 
activated cells. As mentioned above, ELOVL1 was previously shown to hydrolyse 
C24:0-CoAs, as well as C22:0-CoAs and C26:0-CoAs; however ELOVL7 showed 
strong specificity for C18:3-CoAs (linolenoyl-CoA) (Ohno et al. 2010).  
 
In addition to de novo FA synthesis, multiple siRNA screen hits were identified in 
arachidonate (C20:4) metabolism. Arachidonic acid (AA) may be synthesised from 
the hydrolysis of membrane phospholipids by phospholipase A2 (reviewed in Dennis 
and Norris, 2015). Two genes encoding phospholipase A2s were identified as screen 
hits: PLA2G1B and PLA2G4B, indicating that phospholipase A2s are required for 
freeing esterified arachidonic acid in the context of MYC overexpression. 
Downstream, AA can be used for eicosanoid synthesis, which is catalysed by screen 
hits ALOX15B and ALOX12 (arachidonate lipoxygenases). The identification of 
multiple screen hits in arachidonate metabolism is in keeping with results presented 
by Hall et al. (2016), which showed that MYC overexpression remodelled 
arachidonate metabolism and increased phospholipase A2 activity.  
 
As knockdown of multiple FA enzymes increased p53 accumulation, it was 
hypothesised that FA treatment would rescue MYC-driven p53 accumulation. From 
a panel of ten unsaturated FAs, only AA significantly reduced p53 accumulation in a 
dose-dependent manner. Linolenic acid (LA) also showed a dose-dependent 
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reduction of p53 accumulation, although this was not significant. The high number of 
screen hits in arachidonate metabolism coupled with previous data showing that 
arachidonate metabolites activate screen hit PPARγ (reviewed in Desvergne and 
Wahli, 1999), led us to investigate whether PPARγ responds to MYC-driven FA 
changes and subsequently regulates p53.  
 
PPARγ was identified as the third strongest screen hit whose knockdown increased 
p53 accumulation. A potent, PPARγ-specific ligand Rosiglitazone significantly 
reduced p53 accumulation in a dose-dependent manner, while PPARγ inhibitor 
T0070907 potently increased p53 accumulation in a dose-dependent manner. This 
validated PPARγ as a negative regulator of p53. MYC activation depleted PPARγ 
levels, suggesting that MYC-driven depletion of PPARγ contributes to p53 
accumulation. Analysis of over thirty FAs of varying chain length and desaturation 
level showed that MYC overexpression significantly decreased the majority of FAs, 
including AA and DHA, which were previously shown to activate PPARγ (reviewed 
in Desvergne and Wahli, 1999). This indicates that regulation of p53 by PPARγ is 
affected by MYC in two ways: downregulation of PPARγ itself and reduction in the 
FAs that activate it, leading to relief of inhibition of the pathway. 
 
DHA treatment was previously shown to lead to increased incorporation of DHA in 
plasma membrane (Zerouga et al. 1996) and mitochondrial membrane phospholipid 
species (reviewed in Stanley et al. 2014). To investigate whether MYC deregulation 
drives remodeling of FAs into glycerophospholipid synthesis, changes in PC and PE 
levels following MYC deregulation were analysed. MYC activation potently 
increased levels of PCs with DHA residues, such that these were the only group of 
PCs that significantly increased from >50 PCs analysed. Several PEs with DHA and 
AA residues also increased; however this was not confined to polyunsaturated FA 
residues. These results confirmed that MYC deregulation remodels arachidonate 
metabolites into glycerophospholipid synthesis, particularly PC synthesis.  
 
The results in this study show similarities with data presented by Hall et al. (2016) 
who found that MYC overexpression in KRAS-driven lung adenocarcinoma 
remodeled arachidonate metabolism and increased phospholipase A2 activity. The 
fact that arachidonate metabolism was also identified as a major screen cluster from 
the broad range of metabolic pathways in this study further confirms that MYC 
overexpression remodels arachidonate metabolism. However, whilst Hill et al. show 
that MYC overexpression increases arachidonate metabolites and AA-containing 
phospholipids, we found that arachidonate metabolites decrease and DHA-containing 
phospholipids increase. These differences are likely due to the different contexts in 
which MYC overexpression is analysed in the two studies, for example in an intact 
genetic background versus KRAS deregulation, and in vitro versus in vivo.  
 
Whilst the reason for MYC overexpression driving increased synthesis of 
phospholipids with DHA residues was not addressed in this study, several studies 
have documented that phospholipids with DHA residues display altered membrane 
structure and function (see below). DHA has a high number of double bonds relative 
to chain-length and this attribute increases membrane fluidity, permeability, 
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vesicular fusion, elastic compressibility, and flip-flop rate (reviewed in Stillwell and 
Wassall, 2003). Furthermore, treatment with DHA was shown to improve 
mitochondrial tolerance to Ca2+-induced mitochondrial permeability transport pore 
(MPTP) opening (Khairallah et al. 2010a, 2010b).  
 
Aside from glycerophospholipids, FAs can also be used to synthesise triacylglycerol 
(TG) species, which may either be stored in lipid droplets or catabolised back to free 
fatty acids (reviewed in Currie et al. 2013). MYC deregulation potently increased 
TGs with a variety of chain lengths and desaturation levels. MYC-deregulated cells 
place a high biosynthetic demand on the cell, which may result in increased TG 
turnover to support lipid synthesis even in the presence of exogenous FAs.  
 
Senkal et al. (2017) recently reported coregulation of triglyceride and sphingolipid 
metabolism. Diacylglycerol acyl transferase 2 (DGAT2), which is usually associated 
with the conversion of DG to TG for storage, was shown to associate with CERS and 
convert de novo ceramide into acylceramide for storage. DG and ceramide may 
compete to interact with DGAT2, and knockdown of GPAT2, which converts FA-
CoA into LPA to synthesise DG, reduces MYC-driven p53 accumulation (table 3.2). 
This may indicate that in the absence of DG more ceramide is converted to 
acylceramide, reducing the de novo ceramide pool that is required to positively 
regulate p53. Further research to determine the effect of MYC overexpression on 
acylceramide synthesis may offer mechanistic insight into how de novo ceramide 
synthesis regulates p53.   
 
7.3 Limitations and future research  
 
This study indicated that MYC overexpression increases the synthesis of long-chain 
FAs and sphingolipids. However, interpretation of experimental data is limited by 
not combining information on total pool size with information on incorporation of 
heavy-isotope label into the total lipid pool. Figure 4.3 shows that the percent label 
incorporation from 13C3-pyruvate to palmitate and lignocerate increases in MYC 
overexpressing cells (compared to control cells) over an 8 hr timecourse. Figure 4.3 
also shows that the total levels of palmitate and lignocerate decrease, which could 
indicate that the increase in percent label is caused by a drop in total pool size, not by 
increased synthesis. Plotting the total levels of labelled and unlabelled FAs in a 
single figure could strengthen the conclusions that could be drawn from this data. 
 
Data presented on MYC driving long-chain sphingolipid synthesis is more accurately 
interpreted as MYC overexpressing cells increased total levels of long-chain 
sphingolipids (figure 5.1) and incorporation of carbon derived from 13C2-serine 
(indicating increased de novo ceramide synthesis; figure 5.6). This demonstrates that 
long-chain sphingolipids increase at a high enough rate that the increase in this de 
novo pool is not dampened by the total pool size increase. Nevertheless, it would be 




All lipids were extracted using a chloroform-based protocol due to this method being 
good for analysis of ceramides, phosphatidylcholines and phosphatidylethanolamines 
(Bligh and Dyer, 1959). Further interrogation of the lipidome using other extraction 
methods, such as a butanol-based protocol (Morrison et al. 1980), would allow 
detection of more polar lipids, including lysophospholipids, phosphatidic acid lipids, 
acylcarnitines, and sphingosine phosphates (reviewed in Tumanov and Kamphorst, 
2017). It would be interesting to combine different extraction methods to further 
profile MYC-driven lipid remodelling.  
 
Further research to characterise the functional relevance of MYC-driven lipid 
changes is required. In particular, long-chain ceramides and lactosylceramides, as 
well as glycerophospholipids with DHA residues, were previously implicated in 
remodelling membrane structure (Ohno et al. 2010; Stillwell and Wassall, 2003). 
Characterising whether MYC activated cells have altered plasma membrane and 
mitochondrial membrane composition and function may give key insight into MYC 
biology.  
 
p53 was shown to respond to MYC-driven ceramide synthesis; however mechanistic 
insight into how ceramide activates p53 is yet to be elucidated. No known targets of 
ceramide signalling clearly regulated MYC-driven p53 accumulation, although PP2A 
seemed to be a contributor, and therefore an untargeted approach to identify p53 
binding partners following MYC activation may be the best approach to understand 
underlying mechanisms. p53 also responded to MYC-driven FA remodelling via 
PPARγ, which negatively regulated p53. p53 binding partners may also reveal how 
PPARγ regulates p53. 
 
MRC5 human fibroblasts were used in this study due to their intact genetic 
background meaning tumour suppressor pathways have not been selected against (as 
is the case in many cancer cell lines). However, following the acquisition and 
validation of the primary siRNA screen, this study could be strengthened by testing 
the relevance of MYC-driven lipid remodellng in a Myc overexpressing tumour 
model such as Eµ-Myc transgenic mice.  
 
This study has given key insight into how lipid remodeling in response to oncogene 
activation can regulate tumour suppressor pathways. As our knowledge of the 
lipidome improves, it will be interesting to further characterise lipid remodeling 
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